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Summary
The human CtIP protein promotes error-free repair of DNA double-strand breaks (DSBs)
by the homologous recombination (HR) pathway. Furthermore, CtIP has emerged as
a multivalent adaptor with important implications in a variety of genome stability mainte-
nance pathways such as cell cycle checkpoint control, DNA replication and transcriptional
regulation. Therefore, it is not surprising that haploid insufficiency of CtIP predisposes
mice to multiple types of tumours and CtIP mutations have been linked to several human
cancers. Intriguingly however, many aspects of how CtIP is involved in counteracting tu-
mourigenesis and cancer progression are still poorly understood to date.
In my PhD thesis, I sought to gain insights into the molecular network of factors and
pathways collaborating with CtIP in the surveillance of genome integrity by multiplexed
image-based RNAi screening. Specifically, I developed a high content screening assay
to interrogate a large number of human genes for synthetic genetic interactions with CtIP
in presence or absence of the chemotherapeutic drug camptothecin (CPT). From the
screen data analysis, BARD1, the obligate interaction partner of the well-known BRCA1
tumour suppressor, emerged as a candidate for constituting a synthetic sick gene pair
with CtIP. Indeed, I could demonstrate that simultaneous disruption of BARD1 and CtIP
decreased cell viability to a greater extent than depletion of BARD1 or CtIP alone. More-
v
over, I showed that BARD1 and CtIP physically interact even in absence of an intact
BRCA1/BARD1 heterodimer, indicating that BARD1 and CtIP might have a functional
connection beyond the BRCA1/BARD1 complex. Finally, I determined that concurrent
loss-of-function of CtIP and BARD1 leads to a severe increase of endogenous DNA le-
sions arising in the context of DNA replication and ultimately to chromosomal breakage.
Taken together, I propose that CtIP and BARD1 cooperate to promote faithful replication
thereby contributing to genome stability and counteracting cancer development.
vi
Zusammenfassung
Krebs entsteht, wenn sich die Funktion bestimmter Sequenzen (Gene) des Erbguts (DNA)
durch Mutationen so verändert, dass sich Zellen infolgedessen unkontrolliert teilen. Um
zu verhindern, dass DNA-Schäden zu Mutationen führen, verfügen menschliche Zellen
über eine Vielzahl an Reparatursystemen. Das humane CtIP Protein ist dabei vor allem
für die Reparatur von DNA-Doppelstrangbrüchen essentiell. Neben dieser Funktion ist
CtIP auch an der Regulation einer Reihe weiterer zellulärer Prozesse beteiligt, die Ein-
fluss auf die Stabilität des Genoms haben, darunter an der Kontrolle des Zellzyklus
sowie der DNA-Replikation und -Transkription. Es ist daher nicht erstaunlich, dass die
Lebenserwartung von Mäusen mit einer heterozygoten Deletion des CtIP-Gens durch
die Bildung zahlreicher Tumore stark reduziert ist. Mutationen innerhalb des CtIP-Gens
sind außerdem in Verdacht mit einer Reihe von Krebsarten im Zusammenhang zu ste-
hen. Wie CtIP auf molekularer Ebene der Tumorentstehung entgegenwirkt, ist bisher
allerdings noch weitgehend unbekannt.
Das Ziel meiner Doktorarbeit war es daher, das molekulare Netzwerk, in welchem CtIP
interagiert um die Krebsentstehung zu verhindern, genauer zu untersuchen. Aus diesem
Grund habe ich ein RNA-Interferenz Screening Verfahren entwickelt, mithilfe dessen ich
eine große Anzahl von sogenannten genetischen Interaktionen mit CtIP ermitteln kon-
vii
nten. Diese Analyse habe ich zum einen in unbehandelten Zellen, zum anderen aber
auch nach Behandlung mit dem Chemotherapeutikum Camptothecin (CPT) durchgeführt.
Aus der Datenanalyse des Screens ging hervor, dass CtIP und BARD1, der Interaktion-
spartner des bekannten BRCA1 Tumorsuppressor Proteins, möglicherweise durch eine
negative genetische Interaktion charakterisiert sind. Tatsächlich konnte ich im Folgenden
zeigen, dass der gleichzeitige Verlust von CtIP und BARD1 das Überleben der Zellen
stärker beeinträchtigt als der einzelne Verlust von CtIP oder BARD1. Ich konnte weiterhin
demonstrieren, dass das CtIP und das BARD1-Protein miteinander interagieren können,
ohne dass es dazu des gemeinsamen Interaktionspartners BRCA1 bedarf. Dies deutet
darauf hin, dass CtIP und BARD1 eine funktionelle Rolle erfüllen könnten, die über die
Funktionen des BRCA1/BARD1 Heterodimers hinausgeht. Schlussendlich konnte ich
darlegen, dass der gleichzeitige Verlust von CtIP und BARD1 einen schwerwiegenden
Anstieg von endogenen DNA Schäden bedingt, die durch Fehler während der Replikation
entstehen. Diese führen letztlich zu Brüchen innerhalb der Chromosomen und Schäden
am Genom. Zusammengefasst komme ich in meiner Doktorarbeit zu dem Schluss, dass
CtIP und BARD1 kooperieren um eine fehlerfreie Replikation der DNA zu unterstützen,
und dass dieser Mechanismus entscheidend dazu beitragen könnte der Krebsentstehung
entgegenzuwirken.
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Introduction
1.1 Genome instability, a driving force for cancer develop-
ment
The body of an adult human being is made up of approximately 4 x 1013 cells whose
size, number and type ultimately define not only appearance but also the structure and
functions of this organism [1]. Stored inside the nucleus of almost every cell resides a
helical molecule called deoxyribonucleic acid (DNA). This carries the genetic information
necessary to build and maintain an organism by governing cell division and survival. It is
of utmost importance that these processes are tightly controlled because their deregula-
tion can give rise to cancer, a disease that is characterized by excessive cell proliferation.
Early on it became clear that changes to the DNA, called mutations, are the underlying
cause for most types of cancer. Today it is a widely accepted concept that unrestrained
proliferation and the adaptability associated with cancer development are achieved by a
multistep process involving numerous mutations and clonal expansion [2–4]. In addition,
it was found that almost all human cancers have an unstable genome, which is consid-
ered to play a key role for the accumulation of genetic changes in the form of mutations
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and rearrangements and the transformation of a normal into a malignant cell [5]. Fur-
thermore, through the study of human genetic disorders it was discovered that germline
mutations in genes that are involved in the maintenance of genomic integrity and DNA
repair predispose their carriers to tumour development [5–7]. This has led to the notion
that the acquisition of genomic instability (defined as a mutator phenotype) is a hallmark
of cancer [8, 9].
1.2 The DNA damage response (DDR) counteracts genome in-
stability
The genome is constantly exposed to endogenous and exogenous DNA damage that
may cause mutations leading to carcinogenesis. DNA lesions can be induced by ionizing
radiation as encountered for example during radiography (x-rays), by ultraviolet light from
the sun or by certain chemical agents such as heterocyclic amines in overcooked meat or
chemotherapeutical drugs. Remarkably, spontaneous DNA damage, mostly caused by
DNA replication errors, hydrolytic cytosine deamination and oxidative DNA base damage,
occurs at a rate of up to 105 lesions per cell per day [10–12] (Figure 1).
In order to counteract these insults and preserve genome stability, cells are equipped
with a coordinated signal-transduction network, which is collectively known as the DNA
damage response (DDR). A series of events constitute the DDR, such as detection of
the DNA damage by sensors, accumulation of repair factors by mediators and repair of
the lesion by effectors [12] (Figure 1.1). The DDR also includes signalling mechanisms
mediating cell cycle arrest and regulation of DNA replication to prevent cells from prolif-
2
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Figure 1.1: The DNA damage response (DDR). Exogenous and endogenous DNA damaging agents
generate various types of lesions including DNA single- and double-strand breaks (SSBs and DSBs).
The multifunctional MRN complex detects DSBs, while FA-proteins are required for the DNA interstrand
crosslink (ICL)-induced checkpoint response. PARP predominantly acts as a SSB sensor protein. RPA
binds to regions of ssDNA that are exposed at stalled replication forks or after DSB resection. MRN and
RPA mediate the recruitment of ATM and ATR-ATRIP, respectively, and the subsequent activation of the
corresponding pathways, coordinating cell-cycle checkpoints, DNA repair and apoptotic responses to
DNA damage. The Ku70/Ku80 heterodimer (KU) competes with MRN for binding to DSBs. KU recruits
DNA-PKcs, which is a major component of the canonical NHEJ machinery during DSB repair. MRN
on the other hand initiates HR. Once activated, the DNA damage signalling cascade extends through
multiple phosphorylation events primarily via the cell-cycle checkpoint kinases CHK1 and CHK2. Their
signals converge on downstream effectors such as the tumour suppressor protein p53, the CDC25 pro-
tein phosphatase and the WEE1 tyrosine kinase. As a result, CDK activity is inhibited, delaying cell
cycle progression from G1 to S (the G1/S checkpoint) or from G2 to M phase (the G2/M checkpoint).
The DNA damage response (DDR) thus orchestrates a variety of cellular outcomes: the transcriptional
programme of the damaged cell is altered and the cell cycle is transiently arrested, thereby facilitating
repair of the DNA lesions. In situations where DNA damage is too severe and cannot be repaired,
the DDR triggers apoptosis or senescence. ADP = adenosine diphosphate; ATM = ataxia telangiec-
tasia mutated protein; ATR = ATM- and Rad3-related; ATRIP = ATR-interacting protein; CDK = cyclin-
dependent kinase; DNA-PK = DNA-dependent protein kinase; DNA-PKcs = DNA-PK catalytic subunit;
FA = Fanconi anaemia complementation group proteins; HR = homologous recombination; ICL = inter-
strand crosslink; MRN = MRE11-RAD50-NBS1 complex; NEHJ = nonhomologous end joining; PARP
= poly(ADP)-ribose polymerase; RPA = replication protein A; ssDNA = single-stranded DNA. Adapted
from [13].
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erating as long as DNA integrity is compromised. Should DNA repair not be attainable
leading to a catastrophic level of genomic instability, the DDR can impact on downstream
cell fate decisions, such as programmed cell death or senescence. Upon DNA damage
induction, three members of the phosphatidylinosit-ol-3-kinase (PI3K) related kinases
(PIKKs), namely ATM (ataxia telangiectasia mutated), ATR (ATM- and Rad3-related) and
DNA-PKcs (DNA-dependent protein kinase catalytic subunit), are recruited to damaged
chromatin and trigger the DDR [14]. Downstream of ATM and ATR, phosphorylation
events are initiated to activate multiple transducer and effector proteins, most notably p53
and the downstream checkpoint kinases CHK1 and CHK2, which in turn phosphorylate
WEE1 kinase and CDC25 phosphatases. Consequently, through regulating the activ-
ity of cyclin-dependent kinases (CDKs) and an adjusting of the transcriptional program,
cell cycle arrest is achieved allowing time for repair, thereby preventing replication or cell
division in the presence of damaged DNA (Figure 1.1).
Depending on the nature of the lesion, specific pathways are available for DNA repair. The
base excision repair (BER) pathway removes minor changes to DNA such as oxidised or
alkylated bases, small base adducts and single-strand breaks (SSBs) via incision of the
damaged base [10, 15]. A key player in this process is the poly(ADP-ribose) polymerase
(PARP). Upon detection of SSBs, PARP covalently attaches poly(ADP-ribose) chains to
itself and to acceptor proteins in the vicinity of the lesion, thereby facilitating the repair of
SSBs (Figure 1.1). The nucleotide excision repair (NER) pathway addresses more com-
plex, DNA helix-distorting base lesions, such as pyrimidine dimers that can arise from ex-
posure to UV light, by excision of the damaged oligonucleotide [16]. Errors encountered
during DNA replication such as mis-incorporated nucleotides or insertions and deletions
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are recognized and removed by the mismatch repair (MMR) pathway [17]. Replication-
blocking lesions of various kinds may be bypassed by either DNA template switching
or translesion synthesis (TLS). A special class of DNA polymerases with less stringent
base-pairing properties performs the latter mechanism by temporarily taking over from the
obstructed replicative polymerase to circumvent damage-induced replication blocks [18].
DNA double-strand breaks (DSBs) represent the most dangerous type of lesions since a
single unrepaired DSB can be sufficient to kill a cell, whereas mis-repaired DSBs poten-
tially result in chromosomal re-arrangements, that can directly promote carcinogenesis.
Therefore, cells have evolved four mechanistically distinct DSB repair pathways: homol-
ogous recombination (HR), non-homologous end-joining (NHEJ), alternative NHEJ and
single-strand annealing (SSA). NHEJ and HR denote the two major DSB repair pathways
(see below), with NHEJ operating throughout the cell cycle and HR being most active
during S-phase [19, 20]. Finally, repair of DNA interstrand cross-links (ICL), which repre-
sent highly cytotoxic lesion inhibiting both DNA replication and transcription, is achieved
by a complex mechanism coordinated by the Fanconi Anemia (FA) pathway. It involves
the cooperation of several repair pathways including NER, TLS and HR [21] (Figure 1.1).
Failure of the DDR is often causative for genetic alterations from single point mutations to
gross chromosomal rearrangements thereby giving rise to genome instability. It is widely
accepted that defects in DDR promote cancer development. In fact, tumour genome pro-
filing by deep sequencing has demonstrated that DDR genes are frequently mutated in all
cancer types [22]. However, DDR defects can also provide an inherent weakness of can-
cer cells that can be harnessed for treatment (“Achilles heel of cancer”). Genotoxic radio-
and chemotherapy that cause DNA damage exceeding the repair capacity of the DDR
5
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has been the mainstay of cancer treatment for many decades [22–24]. Moreover, exploit-
ing specific vulnerabilities of DDR pathways in cancer cells directly holds great promise
for targeted cancer therapy and is currently under vigorous investigation [13, 25].
1.3 Homologous recombination (HR) is required for genome
stability and tumour avoidance
The most serious threat to genome integrity and cell survival is posed by simultaneous
breakage of both complementary DNA strands creating a DSB. DSBs are generated upon
exposure to ionizing radiation (IR) or a number of chemotherapeutic drugs such as topoi-
somerase poisons (e.g. camptothecin, CPT) and arise as a consequence of collapsed
replication forks [26, 27]. Moreover, DSBs are produced as intermediates during meiosis,
V(D)J- and class switch recombination, important physiological processes allowing for
slight genetic variability and adaptation [28, 29]. Due to the deleterious consequences
a DSB may entail, all organisms are equipped with two major DSB repair pathways:
NHEJ and HR. NHEJ is initiated by quick association of the Ku heterodimer to DSBs
which triggers religation of the broken DNA ends without the need of extensive process-
ing (Figure 1.2). Even though, NHEJ can in principle function throughout the cell cycle,
it predominates in G1. Importantly, repair by the NHEJ pathway is prone to errors [19].
During S-phase, when an undamaged sister chromatid becomes available as a template,
DSBs are therefore preferentially repaired by the HR pathway.
HR is initiated by recognition of a DSB by the MRE11-RAD50-NBS1 (MRN) complex and
subsequent DNA-end resection, a process that generates tails of 3’ single stranded DNA
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(ssDNA) and thereby commits repair irreversibly to HR [30, 31] (Figure 1.2).
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Figure 1.2: DNA double-strand break (DSB repair). DSBs are predominantly repaired by two dis-
tinct pathways: NHEJ or HR. NHEJ operates throughout the cell cycle, but mainly during the G1 and
G2 phases, whereas HR peaks in S phase. Rapid association of the Ku70/80 heterodimer to DSBs
promotes NHEJ. Alternatively, MRN, which is initially recruited to DSBs in competition with Ku70/80, ini-
tiates HR together with CtIP by performing short-range DNA-end resection to generate short 3’ ssDNA
overhangs. BRCA1/BARD1 antagonises 53BP1 to facilitate DSB resection. Next, long-range resec-
tion is catalysed either by EXO1 or BLM in conjunction with DNA2. Importantly, ssDNA stretches are
immediately coated by RPA and the formation of RPA-coated ssDNA stimulates the activation of ATR.
Displacement of RPA by RAD51 is mediated by BRCA2 and PALB2, resulting in the formation of RAD51
nucleoprotein filaments. Subsequent strand invasion into the homologous DNA template and capturing
of the second DNA end leads to the formation of a double Holliday junction, which is processed by
resolvases. Finally, the DNA is sealed by ligases to accomplish error-free repair of the DSB. 53BP =
p53 binding protein; BRCA1 = Breast cancer type 1 susceptibility protein; BARD1 = BRCA1-associated
ring domain 1; CtBP = C-terminal binding protein; CtIP = CtBP-interacting protein; PALB1/2 = partner
and localiser of BRCA1/2. Adapted from [13].
Due to its significance for DSB repair pathway choice, DNA-end resection has been the
subject of vigorous investigation over the recent years. As a result, a two-step end re-
section mechanism has been proposed for mammalian cells: Upon recognition of the
DSB, the MRN nuclease complex tethers the broken ends and in conjunction with the
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CtBP-interacting protein (CtIP) performs an initial “end-trimming” of 50-100 nucleotides
from the DSB ends [32]. This is followed by a more processive long-range resection step
carried out by either exonuclease 1 (EXO1) or the BLM helicase together with DNA2 cre-
ating long ssDNA stretches of up to several thousand nucleotides [33, 34] (Figure 1.2).
Genetic studies in S. cerevisiae have long implicated the Mre11-Rad50-Xrs2 (MRX) com-
plex, homologue to the human MRN, in the initial processing of DSBs. The MRE11
nuclease subunit exhibits both a DNA endonuclease and a 3’-5’ exonuclease activity,
thus possessing the opposite polarity to generate 3’ ssDNA tails at DSB ends [35]. Re-
cently however, emerging genetic and biochemical evidence has indicated a slightly dif-
ferent mode for the first step of DNA-end resection in yeast: MRX in conjunction with
Sae2, the yeast homologue of human CtIP, introduces an internal incision about 300 bp
proximal to DSB thereby creating an entry point for bidirectional resection catalysed by
the Mre11 exonuclease in 3’–5’ direction, EXO1 in 5’–3’ direction and possibly also by
DNA2 [36, 37]. Besides its crucial role in DNA-end resection, MRN promotes the re-
cruitment of ATM to DSBs via its NBS1 subunit and subsequent ATM activation involving
auto-phosphorylation on serine 1981 [38]. ATM in turn phosphorylates a variety of DDR
factors, including histone H2AX at serine 139 (γH2AX) and CHK2 at threonine 68 to
mediate DNA damage checkpoint signalling and DSB repair [14]. Following resection,
ssDNA stretches are immediately coated by replication protein A (RPA) [39] (Figure 1.2).
RPA is an evolutionarily conserved, heterotrimeric complex consisting of RPA1, RPA2
and RPA3 [40]. Importantly, RPA-coated ssDNA recruits the ATR kinase, which phos-
phorylates RPA2 at serine 33 [32, 41]. This primes RPA2 for further phosphorylation on
residues closer to the N-terminus including serine 4 and serine 8. RPA-Ser4/Ser8 phos-
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phorylation hence marks the mature, hyper-phosphorylated and chromatin-bound form
of RPA2 that serves as an important signalling platform orchestrating the DDR and cell
cycle checkpoint response [19, 41]. Following DNA-end processing and RPA recruitment,
the BRCA2-PALB2 complex promotes RAD51 nucleation onto ssDNA, thereby replacing
RPA [42]. The RAD51 nucleoprotein filament then invades the homologous, intact DNA
template forming a displacement loop. The second end of the broken chromosome is
captured and anneals to the complementary strand of the donor DNA molecule, result-
ing in the formation of two Holliday junctions (HJs). After DNA synthesis and ligation of
both strands, the double HJ is either dissolved or is dismantled by the catalytic action of
resolvases in order to complete repair [13, 43] (Figure 1.2). HR requires a homologous
DNA sequence, which becomes available only through DNA replication. Thus, repair by
HR can only occur during S/G2 phases of the cell cycle but is error-free since it copies
the missing genetic information from the undamaged sister chromatid [20]. It is therefore
important to note, that for example, more than 50% of breast and ovarian cancers har-
bour mutations in genes involved in HR signifying the importance of this repair pathway
for tumour avoidance [22].
1.4 Faithful DNA replication is pivotal for genome stability
Accurate duplication of the genome is a fundamental biological process critical for the
integrity of the genome and the suppression of cancer-causing mutations. To ensure
that genome duplication occurs exactly once during S-phase of the cell cycle, its ini-
tiation is tightly controlled by temporarily separating it into two steps. First, in a pro-
9
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cess called origin licensing, the replicative DNA helicase minichromosome maintenance
complex (MCM) is loaded at replication origins. This happens exclusively during late
mitosis and G1 phase and requires the origin recognition complex (ORC) and the ac-
tivities of the CDC6 (cell division cycle 6) ATPase and CDT1 (chromatin licensing and
DNA replication factor 1) [44, 45]. Only during the subsequent G1-S transition, the
MCM helicase is activated (origin firing) and additional factors are recruited to from
the CMG (Cdc45–MCM–GINS) complex, a prerequisite for replication start [46]. Once
formed, CMG unwinds the origin allowing replisome assembly and genome replication
(Figure 1.3). A central role in this process is held by cyclin-dependent kinases (CDKs)
as they not only trigger origin firing but also inhibit licensing of newly replicated DNA until
the next cycle, which is critical to prevent DNA re-replication [47, 48]. In eukaryotes, DNA
replication is initiated at multiple origins from which replication forks travel outwards in
both directions. Once DNA replication begins, cells fire replication origins not all at once
but in a regulated fashion, dividing them into early- and late-replicating origins. In fact,
most licensed origins do not fire at all in an unperturbed S-phase but stay dormant to be
triggered as a backup in case some replication forks become obstructed [49].
Numerous obstacles of both exogenous and endogenous sources constantly challenge
the fidelity of DNA replication potentially resulting in a phenomenon collectively termed
‘replication stress’, a crucial driving force of genome instability and a feature of pre-
cancerous and cancerous cells [27, 50] (Figure 1.3). Generally, replication stress is
defined as slowing or stalling in replication fork progression [50]. It can be caused by
unrepaired DNA lesions, which form physical barriers to replication fork progression or by
a number of other obstructions such as mis-incorporated ribonucleotides [51] or certain
10
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DNA sequences that are intrinsically challenging to replicate because of their secondary
structures, such as telomeres, trinucleotide repeats or G-quadruplexes [27, 52]. Replica-
tion fork progression may also be slowed down if the availability of essential factors like
nucleotides or replication machinery components is limited [53, 54]. In fact, chemothera-
peutic agents such as hydroxyurea (HU) function by depleting the intracellular nucleotide
pool thus interfering with replication fork progression particularly in highly proliferating
cancer cells [55]. Problems to maintain replication speed may also arise if replication
and transcription complexes, which both act on DNA, collide [56]. Moreover, inappropri-
ate replication initiation can also trigger replication stress. Excess firing of origins may
deplete nucleotide pools and slow replication fork speed, whereas reduced replication ini-
tiation can lead to under-replicated regions and susceptibility to chromosome breakage
[57, 58]. A particular low density of replication initiation is observed at common fragile
sites (CFSs), which represent late-replicating regions of the genome that are especially
vulnerable to replication stress [59, 60]. Finally overexpression or constitutive activation
of oncogenes such as H-Ras, c-Myc or cyclin E is an emerging source of replication
stress. Even though the exact mechanism of their contribution to replication stress has
not been fully understood, it has been proposed that oncogenes promote increased origin
firing, thus exhausting the nucleotide pools and possibly causing an increased incidence
of collisions with the transcription machinery [50, 61–63].
Because of the serious implications of replication stress, cells have evolved a complex
network responding to replication stress (Figure 1.3). Upon replication fork stalling, the
replicative helicase is uncoupled from the DNA polymerase resulting in the formation of
long stretches of single-stranded DNA (ssDNA) that are rapidly coated by the ssDNA-
11
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Figure 1.3: Mechanisms of replication fork stalling and the replication stress response. Parental
DNA is unwound by the MCM complex and replicated by polymerases bound to the processivity factor
PCNA. When replication stalls at a DNA lesion (red star), DNA synthesis can resume downstream,
generating a primer–template junction that can be recognized by ATR and ATRIP. ATR then initiates a
signalling cascade primarily mediated by the effector kinase CHK1. This response promotes fork sta-
bilization and restart, while preventing progression through the cell cycle until replication is completed.
Replication forks stalled at DNA lesions that are stabilized by the ATR pathway can resume replication.
If stalled forks are not stabilized, or if they persist for extended periods of time, replication forks will
collapse, thereby preventing replication restart. The mechanism by which a replication fork collapses is
still ambiguous, and several possibilities are presented here. MCM = Mini-chromosome maintenance;
PCNA = proliferating cell nuclear antigen. Adapted from [27].
binding protein RPA [64]. This in turn acts as a signal to activate the central compo-
nent of the replication stress response, the ATR kinase [65, 66]. ATR gets recruited to
RPA-bound ssDNA by the ATR-interacting protein (ATRIP) or via the recruitment of its
12
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allosteric activator TopBP1 by the concerted action of Rad17 and the Rad9–Hus1–Rad1
(9-1-1) complex [19, 67]. ATR induces gradual phosphorylation of several target proteins,
such as H2AX (serine 139) and RPA2 (serine 33) triggering the DDR [68]. The key con-
sequences of its activation are mediated by phosphorylation of its downstream effector
CHK1 on serine 345 among others, which orchestrates the cellular response to replication
stress by stabilizing stalled replication forks (local effect), inhibiting the firing of alternative
origins and preventing cell cycle progression (global effects). These events provide time
for the resolution of the replication barrier and allow the cell to restart the replication fork
once the stress has been removed [54, 69] (Figure 1.3). Of note, accumulating evidence
suggests that regulated remodelling of replication forks into four-way junctions, known
as fork reversal, can promote fork stability and repair during perturbed replication [70].In
this context, more and more evidence emerged implying that stalled replication forks may
have undergone structural changes and thus depend on DNA helicases for reactivation.
Several non-replicative helicases, including BLM, WRN and SMARCAL1 have been de-
scribed to promote fork restart [71–73]. If stalled forks cannot be recovered, alternative
mechanisms to rescue global replication involve firing of dormant origins, repriming of
replication or activating the DNA damage tolerance pathways such as TLS or template
switching [18, 74, 75] (Figure 1.3).
If forks are not stabilized or persist for extended periods of time they will ultimately col-
lapse leading to the generation of DSBs (Figure 1.3). This process is particularly ac-
celerated if the ATR-CHK1 pathway is abrogated [67]. The resulting DSBs lead to the
activation of the DNA damage kinases ATM and DNA-PK and their respective down-
stream targets [19]. How stalled forks are processed into DSBs remains equivocal. It is
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possible that cells attempt to resolve otherwise irresolvable stalled fork structures using
nucleases like MUS81-EME1 or DNA2 to deliberately generate a DSB in order to facil-
itate HR-mediated repair and restart [76, 77]. However, nucleolytic cleavage of stalled
replication forks into DSBs may also be a symptom of aberrant activation of nucleases in
the absence of appropriate mechanism for fork protection as it was shown for MRE11 [78]
and DNA2 [79]. Secondly, persistent ssDNA found particularly at stalled replication forks
represent a vulnerable structure prone to passive breakage as well as endonucleolytic
cleavage [80]. Besides long stretches of ssDNA, nicks and gaps as naturally occurring
intermediates of several DNA repair and related pathways are intricately susceptible to
replication stress-induced DNA lesions as they could be passively converted into DSBs
upon encounters with the replication machinery [19, 27] (Figure 1.3).
1.5 Consequences of deregulated replication
Obstacles encountered during replication activate the ATR-CHK1-pathway thus triggering
the S and G2/M cell cycle checkpoints [81]. However, not all replication problems suffi-
ciently activate these cell cycle surveillance pathways and hence localized alterations
of fork progression can escape from checkpoint control [82]. Therefore, incompletely
replicated loci or unresolved replication intermediates might not be addressed before the
onset of mitosis and thus can be carried over to the next cell cycle. 53BP1 protein rec-
ognizes such sites of unrepaired DNA damage forming nuclear bodies upon subsequent
entry into G1 in an attempt to shield them against erosion and mark them for repair dur-
ing the next cell cycle [83, 84]. Potential consequences of cells entering mitosis with
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incompletely replicated or damaged chromosomes include chromatid breaks, anaphase
bridges or chromosome mis-segregation. Indeed, recent data suggest that 53BP1 nu-
clear bodies indicate sites of unresolved or broken anaphase bridges [85]. Lagging chro-
mosomes that arise from mitotic errors can promote the formation of micronuclei and
excessive DNA damage in the daughter cells [86]. Thus, undetected replication stress
jeopardizes the completion of chromosome duplication and successful mitotic commit-
ment potentially causing chromosome aberrations and consequently chromosome insta-
bility. Taken together, this underlines the importance of faithful replication as a barrier
against tumourigenesis [57, 87]. Indeed, current models of cancer development would
argue that the onset of replication stress represents an early event promoting subsequent
mutations that confer growth advantages to pre-cancerous cells. It was demonstrated that
DNA damage response markers accumulate in human cancer cells even in the absence
of exogenous genotoxic treatment at early stages of cancer development [88, 89]. DNA
damage could conceivably arise as a result of enhanced replication stress due to uncon-
trolled induction of oncogenes among other reasons, increasing the level of DNA break-
age, mutation and rearrangements. This may fuel mutations targeting DDR pathways,
thereby facilitating persistent genomic instability and hence promoting the progression
from a precancerous condition to malignancy [9, 90].
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1.6 HR proteins function to restart stalled and collapsed repli-
cation forks
Faithful genome duplication requires the precise coordination of DNA replication and re-
pair. Intriguingly, a growing body of evidence suggests that proteins involved in the repair
of DSBs by the HR pathway also perform key functions in preventing and addressing
replication stress-induced lesions [91–95]. Recent reports have provided evidence that
RAD51 for example promotes restart of stalled replication forks in a process that does
not trigger HR [94]. Furthermore, the MRE11 and DNA2 nuclease were implicated in
replication fork recovery [76, 96]. Upon collapse of stalled replication forks and forma-
tion of one-ended DSBs, the HR pathway becomes essential to carry out DSB resection,
strand invasion, and reassembly of a new replication fork at RAD51-generated D-loop
intermediates [19]. Likewise, CtIP and the BRCA1/BARD1 complex have recently been
implicated in supporting faithful DNA replication.
The human CtIP protein
The human CtIP protein was initially identified as an interaction partner of the CtBP tran-
scriptional co-repressor complex that plays important roles in development and cancer
[97]. Moreover, CtIP was found to be associated with two other bona fide tumour suppres-
sor proteins, BRCA1 and retinoblastoma (pRB), from which it was alternatively termed the
retinoblastoma binding protein 8 (RBBP8) [98, 99] (Figure 1.4A). Despite these early re-
ports about its role in gene regulation, CtIP has become extensively recognized for its
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function in initiating the repair of DSBs by HR by carrying out DNA-end-resection in con-
junction with the MRN complex to generate short 3’- ssDNA tails [32]. Its crucial role in
DSB repair as well as the fact that CtIP interacts with a number of proteins related to car-
cinogenesis have led to the notion that CtIP might be a tumour suppressor itself. Support
for the hypothesis came from findings that homozygous deletion of CtIP in mice leads
to early embryonic lethality while heterozygous animals are viable, but develop multiple
tumours, particularly large lymphomas [100]. In colorectal and endometrial cancers, CtIP
frameshift mutations were reported as a result of microsatellite instability [101, 102] and
epigenetic inactivation of CtIP correlates with breast cancer and is associated with resis-
tance to the drug tamoxifen [103, 104] further confirming a significant link between CtIP
and cancer.
At the molecular level, human CtIP is a 125 kDa nuclear protein of 897 amino acids, which
is significantly conserved among mammals [97]. The C-terminus of CtIP is evolutionarily
highly conserved and shares significant sequence homology with Saccharomyces cere-
visiae Sae2, an orthologue protein required for both meiotic and mitotic DSB repair in
yeast [32, 107] (Figure 1.4A). Cells expressing a mutant lacking the C-terminal part of
CtIP are deficient in DNA-end resection further emphasizing the importance of this do-
main for proper DSB repair function [32]. Remarkably, rare hypomorphic mutations in the
CtIP gene resulting in expression of a C-terminal truncated protein have been identified
to cause severe microcephaly, growth retardation and skeletal abnormalities as well as
impaired DSB resection and ATR activation in patients with Seckel and Jawad syndromes
[108, 109]. The N-terminal domain of CtIP forms a coiled-coil motif that is essential for
oligomerization [110–113] (Figure 1.4A). Furthermore, it was found that CtIP tetramer-
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Figure 1.4: Schematic overviews of CtIP and BRCA1/BARD1 proteins. (A) CtIP protein architec-
ture. The N-terminus of CtIP contains themultimerization regions within a coiled-coil domain and a
consensus motif for pRb-binding (LECEE). The middle region consists of a FANCD2-binding motif, the
nuclease domain that includes residues from approximately 180 to 350, the DNA- and CtBP-binding
sites and a PIP-box mediating interaction with PCNA. CDK phosphorylation at S327 mediates BRCA1
interaction and ATM phosphorylates S664, S745 and T859 in response to DNA damage. The C-terminal
part of CtIP is evolutionary most conserved and contains the CDK phosphorylation site T847 essential
for DNA-end resection. MRN-binding regions are located in both N- and C- terminal regions of CtIP.
Adapted from [105]. (B) The BARD1 protein architecture is compared to that of BRCA1. The N-terminal
regions of both proteins contain a conserved RING finger domain required for heterodimer formation
(dashed box) and E3 ubiquitin ligase activity. At the C-terminus, BRCA1 and BARD1 each possess two
conserved BRCT domains for phosphor-epitope binding. BARD1 additionally harbours three ankyrin
repeats that facilitate protein–protein interaction. The BARD1 N-terminus interacts with NPM/B23, a
chaperon protein involved in centrosome duplication and cell proliferation. The region between the
ANK and BRCT domains was shown to bind to either CSTF1 or the tumour suppressor p53 in a com-
petitive manner thus regulating cell cycle progression and apoptosis. No phospho-proteins interacting
specifically with the BARD1-BRCT domain have been discovered to date but a recent report reveals
that they may bind to negatively charged PARylated substrates. The BRCT repeats at the BRCA1 C-
terminus recognize phosphorylated S(p)XF motifs on the direct binding partners CtIP, CCDC98/Abraxas
or BACH1. The central region of BRCA1 contains phosphorylation substrate residues for the ATM and
ATR kinases (S1387A, S1423A and S1524A) and Chk2 (S988A) and a coiled-coil domain that asso-
ciates with PALB2/BRCA2 during HR. Hotspots for common clinical mutations in BRCA1 are highlighted
(red dashed line). Adapted from [106]. BACH1 = BTB and CNC homolog 1; BRCT = BRCA1 carboxy-
terminal (domain); CCDC98 (Abraxas) = coiled-coil domain containing protein 98; CSTF1 = cleavage
stimulation factor subunit 1 50kDa; CtBP = C-terminal binding protein; FANCD2 = Fanconi anemia
complementation group protein D2; NPM = Nucleophosmin/B23; PAR = poly(ADP-ribose); PIP box =
PCNA-interacting peptide box; pRB = Retinoblastoma protein; RING = Really interesting new gene.
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ization is required for effective accumulation at DSBs and its function in HR [112, 113].
Nevertheless, it remains possible that CtIP can also function in its dimeric form in some
aspects of DNA repair [111, 112]. Both, CtIP N- and C-terminal regions are involved in
mediating the interaction between CtIP and the MRN complex [114]. Additionally, this in-
teraction is strongly regulated by CtIP phosophorylation. Twelve potential CDK phospho-
rylation sites can be found in CtIP and phosphorylation of at least five of them facilitates
the interaction with the FHA and BRCT phospho-peptide binding domains of Nbs1 and
furthermore primes CtIP for modification by the ATM kinase [114]. Upon DNA damage,
ATM phosphorylates CtIP on at least three residues (serine 664 and 745 and threonine
859) thereby enabling HR [114] (Figure 1.4A). Remarkably, it has been found that muta-
tion of a critical CDK site at threonine 847 (T847) renders CtIP incapable of performing
its functions to support HR [32, 114, 115]. Yet, the precise mechanism of how T847
phosphorylation activates CtIP is still unclear as CtIP-T847A mutants remain nuclease
proficient in vitro, and are capable of binding to Nbs1 [114, 116]. Along that line, an en-
donuclease activity has been recently assigned to CtIP residing in the middle part of the
protein (Figure 1.4A). However, this activity seems to be dispensable for DNA-end resec-
tion of “clean” DSB ends, but important for the processing of ends containing secondary
structures such as DNA hairpins or protein–DNA adducts stemming from lesions induced
by topoisomerase poisons and ionizing radiation or at inverted repeats or CFS [116–118].
In this model, the essential role for the CtIP protein in DSB repair would likely involve a
non-catalytic role through CtIP-dependent recruitment of other DNA damage repair fac-
tors underlining the fact some known modifications affect a general CtIP-dependent re-
section function independent of its nuclease activity [116].
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Since the discovery of the role of CtIP in HR-directed repair of DSBs, it has emerged as
a key concept that CtIP-dependent resection of the DNA ends plays a key role in acti-
vation of ATR and CHK1 kinases to induce the cell cycle checkpoint [32, 67]. Recently
however, a study by Koushoult et al. established that CtIP was dispensable for initial
ATR–CHK1 activation after DNA damage but DNA-end resection was critically required
for sustained ATR–CHK1 checkpoint signalling and for maintaining both the intra-S and
G2/M checkpoints in the face of persisting DNA damage [119].
The role of CtIP in genome stability maintenance beyond its role in HR and cell cycle
checkpoints is furthermore emphasized by recent findings implicating it in additional path-
ways addressing different kinds of DNA lesions. CtIP was shown to remove DNA inter-
strand crosslinks through interaction with the FA-protein FANCD2 [120] (Figure 1.4A) as
well as DNA intermediates that form secondary structures or replication blocks [117]. Im-
portantly, it has been suggested that CtIP belongs to the key HR proteins mediating faith-
ful DNA replication as it was shown to be associated with unperturbed replication forks
and act on stalled as well as on collapsed forks [95, 121]. CtIP is thought to ensure repli-
cation fork progression and to prevent the formation of under-replicated regions especially
in the context of common fragile sites [117, 121]. It is also important to note, that even
before these roles of CtIP were uncovered, a minimal region of the CtIP protein (residues
515 to 537) was described comprising a consensus PCNA-interacting motif (PIP-box) that
mediates the assembly of CtIP into replication foci during S-phase [122] (Figure 1.4A).
Although the function of this PIP-box remained enigmatic, it was proposed that PCNA
facilitates CtIP localization to sites of on-going replication. This concept gained new im-
petus when an iPond-SILAC-MS screen identified CtIP in the vicinity of active replication
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forks [95].
The BRCA1/BARD1 tumour suppressor complex
The breast cancer early onset gene 1 (BRCA1) is involved in a network of several DNA
repair protein complexes performing fundamental roles in genome stability maintenance
and the suppression of cancer [123]. The landmark discoveries describing that germline
mutations in the BRCA1 gene confer a lifetime risk of up to 90% for developing breast can-
cer and the strong evidence implying that BRCA1 may also be mutated in many sporadic
cancers [124–126] (Figure 1.4B) has sparked intensive investigations about the physio-
logical roles of this factor in tumour suppression. Key studies following the initial molecu-
lar cloning of BRCA1 strongly implied that the protein possesses central functions in the
DDR and thus in preserving chromosomal integrity [127]. It was found that homozygous
disruption of BRCA1 in the mouse germline causes early embryonic lethality and impedes
cell proliferation [128, 129]. Cells defective for BRCA1 exhibit elevated levels of chromo-
some aberrations, such as DNA breaks and chromatid exchanges, enhanced sensitivity
to DNA-damaging agents and defects in cell-cycle checkpoint function [130–135]. Con-
sistently, BRCA1 relocates to nuclear foci upon DNA damage induction [135–137] and
cells lacking functional BRCA1 are highly impaired in performing HR at endonuclease-
induced DSBs [138]. Taken together, these findings firmly established BRCA1 as a cus-
todian of chromosome integrity with an important role in homology-directed DNA repair.
A comprehensive understanding of how BRCA1 contributes to the aforementioned func-
tions on the molecular level is however still incomplete and many important questions
remain unresolved. Further progress in defining how BRCA1 promotes HR was made by
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demonstrating that loss of 53BP1 (TP53BP1, tumour suppressor p53 binding protein 1)
rescues the lethality, tumourigenesis, and genome instability of BRCA1-deficient mice
[139–141]. It was shown that 53BP1 inhibits DNA-end resection in BRCA1 deficient cells
and promotes error-prone NHEJ in S-phase. BRCA1, on the other hand, facilitates the
removal of 53BP1 in S phase to allow resection of DSBs generating the initial substrate
of RAD51-dependent HR [30, 140]. Thus, it was proposed that BRCA1 as well as 53BP1
possess the ability to associate with DSBs, but BRCA1 channels repair into HR, whereas
53BP1 favours NHEJ by antagonizing DNA-end resection. Cells lacking BRCA1 therefore
fail to prevent NHEJ in S phase, and chromosomal aberrations arise from inappropriate
joining of replication-associated DSBs [142].
In vivo, BRCA1 forms an obligate heterodimer with the structurally related BRCA1-
associated ring domain 1 (BARD1) and it has been suggested that BRCA1 requires the
interaction with BARD1 to maintain chromosome integrity and HR function [143–145]
(Figure 1.4B). It has been described that both proteins exhibit close homology within
their conserved amino-terminal RING finger domains and between the C-terminal tan-
dem BRCA1 carboxy-terminal (BRCT) domains [143]. Moreover, BARD1 harbors three
ankyrin (ANK) repeats located upstream of the BRCT domains with an essential function
in chromosome stability and HR [144]. The interaction between BRCA1 and BARD1 is
mediated by the flanking regions of the RING finger motif of the two molecules and con-
fers E3 ubiquitin ligase activity to the RING domains of the heterodimer [146, 147]. Con-
sequently, BRCA1/BARD1 directs its auto-ubiquitylation as well as ligation of K6-linked
ubiquitin structures occurring during S-phase and in response to replication stress and
DNA damage [148]. For instance, it was reported that CtIP is a substrate for K6-ubiquitin
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chains catalysed by BRCA1/BARD1 triggering the association of CtIP with chromatin fol-
lowing DNA damage [149]. Furthermore, the BRCA1/BARD1 E3 ligase has functions
in the regulation of transcription in response to DNA damage by ubiquitination of phos-
phorylated RNA Pol II and by mono-ubiquitination of H2A/H2AX to modulate chromatin
structure [150, 151]. Besides, the BRCA1/BARD1 E3 ligase activity has been implicated
in cell cycle control, particularly in mitotic progression, as it was shown to regulate several
targets involved in centrosome amplification and spindle formation such as the nucleolar
protein nucleophosmin (NPM), γ-Tubulin and Aurora B [152–154]. Importantly, the E3
ubiquitin ligase activity of BRCA1/BARD1 is thought to contribute to genome stability by
facilitating HR [144, 145] but the precise mechanism remains elusive [123].
Further light was shed on the significance of the BRCA1/BARD1 interaction by a recent
study indicating that BRCA1/BARD1 is assembled at the site of DNA damage in a bipha-
sic pattern. Thus, BRCA1 recruitment involves a novel interaction between its partner
protein BARD1 and poly(ADP-ribose) chains at the DSB, which mediates the rapid re-
cruitment of the heterodimer [155] (Figure 1.4B). Similarly, the BARD1-BRCT domain
has been shown to specifically recognize histone H3 dimethylated at lysine 9 through its
interaction with HP1 proteins thus anchoring BRCA1/BARD1 at sited of DNA damage
[156]. Genetically, the significance of the BRCA1/BARD1 interaction is underscored by
the necessity of BARD1 for the majority of BRCA1 in vivo functions. Specifically, it was
described that BARD1 deficiency fully recapitulates BRCA1 nullizygosity, with BARD1
knockouts displaying embryonic lethality, genomic instability, and cancer susceptibility
[157, 158]. However, given the critical interaction, it is surprising that BRCA1 is fre-
quently mutated whereas BARD1 mutations in both hereditary and sporadic breast can-
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cer are relatively rare [159–162]. New insights into the tumourigenic potential of BARD1
loss-of-function came from studies revealing that BARD1 spliced isoforms are often more
abundant than the full-length product in cervical, breast, ovarian and endometrial cancer
cell lines [163] thus implying that aberrant BARD1 splicing may confer oncogenic proper-
ties. Further evidence for this mechanism came from findings that in cancer cells BARD1
spliced isoforms frequently harbour opposing functions compared to the full-length pro-
tein [154, 163, 164]. It remains unclear why BARD1 loss-of-function in cancer proceeds
predominantly through alternative splicing as opposed to mutation. BARD1 deletion may
be too deleterious for cancerous cells to overcome and alternative splicing could provide
a mechanism in which activity is finely modulated, rather than abolished [161]. Alter-
natively, essential functions of BARD1 extending beyond its BRCA1-related roles may
contribute to its cellular indispensability. In fact, several BRCA1-independent roles of
BARD1 have been suggested. BARD1 was for example found to bind and stabilize p53
thus inducing apoptosis in a manner that is antagonized by BRCA1 [165, 166]. Further-
more, BARD1 is considered to play a role in the inhibition of mRNA maturation upon DNA
damage by binding to the mRNA poly-adenylation factor CSTF1 (cleavage stimulation
factor, subunit 1), a mechanism likely involved in cell cycle regulation [167, 168].
Besides the interaction with its key binding partner BARD1 through their N-terminal RING
domains, BRCA1 forms complexes with numerous other factors and hence it is reason-
able to propose that the tumour suppressive roles of BRCA1 are manifested through its
interactions (Figure 1.4B). With regard to the DNA repair function, the tumour suppres-
sor properties of BRCA1 are predominantly mediated by the BRCT domain, that binds
phosphorylated serine motifs [169]. Remarkably, already in early studies, an interaction
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between CtIP and the BRCA1-BRCT motif was uncovered [98, 170] and it was shown
that this is mediated by CDK phosphorylation of CtIP at serine 327 (S327) during G2
phase of the cell cycle [171]. Later, evidence emerged that BRCA1 interacts with CtIP
and MRN in the S/G2 phases to favour DNA-end resection and thus HR [32, 172, 173].
Indeed, it was found that DNA-end resection and HR are impaired in BRCA1-deficient
cells [138, 174] and that chicken DT40 cells expressing human CtIP defective in interact-
ing with BRCA1 (S327A) is incapable to perform HR [173]. However, subsequent studies
have come to challenge the significance of the CtIP-BRCA1 interaction by presenting
several lines of evidence implying that complex formation with BRCA1 is not essential for
CtIP-mediated DNA end-resection and HR [175–177], and possibly only fine-tunes resec-
tion speed [178]. However, if BRCA1 is dispensable for DNA-end resection, the question
remained how it promotes HR. It has been suggested that the CtIP–BRCA1 complex for-
mation in mammalian cells involves the removal of the 53BP1 effector protein RIF1 from
DSB regions, which otherwise blocks DNA-end resection [179]. Thus the principle role
of BRCA1 in DSB repair may involve its function in antagonizing 53BP1 in S-phase thus
facilitating CtIP-mediated DNA-end resection and subsequent HR [177].
Further insights in the tumour suppressive activities of BRCA1 have emerged from stud-
ies which have uncovered a role of BRCA1 activity at the replication fork as being cen-
tral to its DNA repair function. Previous studies already indicated that upon replication
stalling, BRCA1 rapidly relocalizes to replication foci containing PCNA [180]. Recently, it
was found that BRCA1 participates in replication fork protection as it was demonstrated
that BRCA1 prevents degradation of nascent strands at stalled replication forks [92].
BRCA1 also regulates multiple aspects of replication to promote DNA ICL repair. It was
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shown for instance, that BRCA1 is required to unload the CMG helicase complex from
chromatin after replication forks collide with an ICL [181]. Moreover, BRCA1 is involved in
the recruitment of FANCD2 and subsequent processing of ICLs independently of its HR
activity [182]. By adapting the bacterial replication terminator Tus/Ter complex to induce
site-specific replication fork stalling in mouse cells, it became apparent that BRCA1 is
required for HR at stalled replication forks and that in this incidence HR is regulated dif-
ferently than at endonuclease-mediated chromosomal DSBs [183]. Furthermore, BRCA1
was shown to control the step-wise recruitment of MRE11, FANCD2 and finally CtIP to
stalled replication forks, followed by their concerted actions to promote fork recovery [121]
thus raising the question of whether the CtIP–BRCA1 interaction may function to allevi-
ate blocked replication forks [118]. Consistent with those novel roles ascribed to BRCA1,
it was described that primary mammary epithelial cells from patients with heterozygous
BRCA1 mutations experience higher loads of replication stress while other BRCA1 func-
tions remained unaltered indicating that the proficiency in responding to replication fork
stalling might be the limiting factor in BRCA1 genome integrity control [184].
1.7 Synthetic genetic interactions provide a rational to har-
ness specific DNA repair defects of cancer cells for tar-
geted therapies
To protect the genome, cells have evolved a diverse set of pathways designed to sense,
signal, and repair multiple types of DNA damage. Recently the interconnectedness of
DDR mechanisms has become more and more appreciated as it was discovered that
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partial redundancy of different DDR pathways can coordinate with one another and act
compensatory in the absence of the optimal response [19, 185, 186]. Moreover, it has
been considerably recognized that genetic interactions (GIs), which describe the extent to
which the phenotype of a first gene mutation is modified by the presence of a second one,
can provide detailed information regarding functional relationships between genes and
the structure of their underlying biological pathways. Thus, determining GI profiles within
a cells presents an exciting possibility to understand the buffering relationships between
DNA repair mechanisms in more detail [186–188]. Formally, GIs can be defined as the
deviation from the expectation that the combined effect on the fitness of an organism
of two mutations will be the product of their individual effects [189]. In this context, two
classes of GIs have been described: negative or alternatively termed aggravating or
synthetic sick/lethal (SSL) GIs, whereby the resulting phenotype is more severe than is
expected from the phenotypes associated with the single mutants (Figure 1.5) or positive
(alleviating) GIs, where the combined phenotype is less severe than anticipated [190,
191].
However, in the last decade the analysis of GIs has not only proven to constitute a criti-
cal tool for systems biology to decipher molecular pathways. Particularly SSL interactions
have been intensively investigated in order to identify drugs that will cause lethality to can-
cer cells that harbour inherent defects without harming normal cells (Figure 1.5). More
precisely, during their pathogenesis, many cancer cells acquire mutations in DSB repair
genes and become dependent on a compensatory mechanism in order to survive. Thus,
for example compromised abilities to repair DNA damage confers a weakness that can be
therapeutically exploited on the basis of the concept of synthetic lethality, whereby phar-
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Figure 1.5: Synthetic lethality can be harnessed for cancer therapy. Synthetic lethality is defined
as a combination of mutations or perturbations in two or more genes that leads to cell death, whereas
inactivation of any one of the genes alone does not. Perturbation of genes can occur through genetic
mutation or silencing, depletion by RNAi or chemical inhibition and is depicted by a red cross. Please re-
fer to the main text for details about the example given for synthetic lethality between BRCA1/2 mutation
and PARP inhibition. ADP = adenosine diphosphate; BER = base excision repair; DDR = DNA damage
response; DNA = deoxyribonucleic acid; RNAi = RNA interference; SMI = small molecule inhibitor.
macological inhibition of the “back-up” pathway induces greater toxicity in DNA repair-
deficient cancer cells as compared with normal cells [13, 23, 24, 192] (Figure 1.5). The
first “proof-of-principle” study verifying synthetic lethality as a suitable approach for tar-
geted cancer therapy was published in 2005, after it had been demonstrated that HR-
defective BRCA1- or BRCA2-deficient cell lines display dramatically increased sensitivity
to inhibition of the SSB repair enzyme PARP [193, 194]. The current understanding sug-
gests that inhibition of PARP leads to the accumulation of SSBs which are converted into
DSBs upon encountering DNA replication forks during S-phase when HR is most active
[185]. Consequently, in the absence of functional HR, such as in cancer cells lacking
BRCA1 or BRCA2, PARP inhibition results in the accumulation of DSBs and, ultimately,
in apoptosis or mitotic catastrophe (Figure 1.5). Importantly, normal cells survive the
treatment owing to functional HR, providing the kind of selectivity that is considered the
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ultimate goal of cancer therapy. Following the initial description of the mechanism, clin-
ical development of potent small molecule PARP inhibitors (PARPis) rapidly advanced,
and the first Phase II results in 2009 showed that monotherapy with the PARPi olaparib
(AZD-2281; AstraZeneca) achieved encouraging response rates of 41% and 33% in pa-
tients with BRCA1- or BRCA2-mutated advanced breast and ovarian cancers, respec-
tively [195, 196]. As the concept of personalised medicine emerged, tumour-specific de-
fects represent a promising therapeutic target to be exploited for the selective elimination
of cancer cells. Particularly recent advances in ribonucleic acid interference (RNAi) tech-
nologies and the development of sophisticated screening platforms for SSL interactions
holds great potential to achieve a better understanding of cellular functions and their un-
derlying genetic networks, thus more and more genetic interactions may be uncovered as
potential targets for synthetic lethality in cancer therapy [188, 191, 197]. Recently, a num-
ber of candidate synthetic lethal interactions targeting for instance p53-mutant tumour
cells have been proposed [198, 199], including inhibition of the DNA damage kinases
ATR and CHK1 [200, 201]. Likewise, oncogenic K-Ras mutations have been found to be
synthetically lethal with ATR inhibition [202]. In this context, the recently discovered small
molecule inhibitors of the HR proteins RPA and RAD51 represent promising candidates
to harness defective DDR pathways in cancer cells in the near future [203, 204].
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Aims
The cellular response to DNA damage is essential to safeguard genome integrity and to
prevent malignant transformation. Human CtIP (RBBP8) was originally discovered as an
interacting partner of the three tumour suppressor proteins; CtBP, BRCA1 and retinoblas-
toma (pRB) that are significantly involved in controlling cell cycle progression and prolif-
eration. Nowadays, CtIP is most considerably recognized for its key role in the repair of
DNA double-strand breaks (DSBs) by the homologous recombination (HR) pathway. As
critical functions of CtIP in other DNA repair pathways as well as in cell cycle checkpoint
control and DNA replication are emerging, CtIP is more and more considered to be a
core factor for genome stability maintenance. Accordingly, haploid insufficiency of CtIP
has been shown to predispose mice to multiple types of tumours and CtIP mutations have
been linked to several human cancers. Many aspects of CtIP functions in counteracting
genome instability and cancer development are however still poorly understood.
In my PhD thesis work, I took an unbiased approach to examine CtIP genetic interac-
tions in unperturbed human cells and in response to DNA damage in order to explore the
molecular network of CtIP involved in the maintenance of genome stability.
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Aim 1: Develop a platform to determine genetic interaction profiles of CtIP in hu-
man cells.
Large-scale mapping of genetic interactions provides a powerful tool to dissect the func-
tional organisation of cellular networks that govern processes such as genome stability
maintenance and tumour suppression. Therefore, the major aim of my PhD project was
to develop a platform to systematically survey genetic interactions of CtIP in human cells
in the absence or presence of DNA damage by employing high-content RNA interfer-
ence (RNAi)-based screening. In the first part of my thesis, I describe the approach we
employed to uncover genetic interactions with CtIP in detail.
Aim 2: Elucidate the molecular mechanism underlying the SSL interaction between
CtIP and BARD1.
From the analysis of the RNAi screen, the BRCA1-associated RING domain protein 1
(BARD1) emerged as a strong candidate for synthetic sick/lethal (SSL) interactions with
CtIP. Following up on my screen results, I focussed on investigating the molecular mech-
anism underlying the SSL relationship between CtIP and BARD1. At the same time, I
sought to shed new light on the significance of the CtIP-BRCA1/BARD1 interaction and
its role in genome integrity maintenance. Thus, in the second part of my thesis, my cen-
tral aim was to elucidate how CtIP and BARD1 promote faithful DNA replication, thereby
contributing to genome stability and cell survival.
Taken together, the findings from the two sections described above have constituted a sci-
entific manuscript that will be submitted for publication in a peer-reviewed journal shortly.
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Aim 3: Investigate CtIP functions in DNA interstrand crosslink repair.
Recently, CtIP has been implicated the cellular response to DNA interstrand crosslinks
(ICLs). Distinct DNA repair activities are required for the resolution of ICLs, including
recognition of the lesion and signalling by FANCD2, nucleolytic incision of the crosslink,
and repair of the DSB intermediate through HR. During this process, FANCD2 interacts
with CtIP, thereby tethering CtIP to the site of the ICL in order to ensure proper coordina-
tion of DNA-end resection and subsequent HR. Importantly, FANCD2 mono-ubiquitination
was found to be critical for the accumulation of CtIP at ICL-damaged chromatin, presum-
ably by facilitating the FANCD2-CtIP interaction. Thus, my aim in this project was to
address the question whether CtIP can bind to ubiquitin. The data I have contributed
were included in a publication by Murina et al. in the peer-reviewed journal Cell Reports
in 2014. The scientific manuscript and an indication of my contribution are included in the
Appendix.
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Material and Methods
Cells
U2OS, HEK293T, and HEK293 cells were grown in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin, and
100 mg/ml streptomycin.
The generation of a stable MRC5 cell line with inducible shRNA-expression was de-
scribed previously [120]. MRC5shCtIP and MRC5shLacZ cells were grown in DMEM supple-
mented with 10% Tet system approved FCS, 100 U/ml penicillin, 100 mg/ml streptomycin,
Blasticidin (5 mg/ml), and Zeocin (250 mg/ml). To induce shRNA expression, cells were
treated with 1 µg/ml doxycycline (Dox) as indicated.
The Flp-In T-REx system (Invitrogen, Life Technologies) was used to generate cell lines
stably expressing siRNA-resistant GFP-BARD1. A pEGFP-C1 plasmid comprising hu-
man BARD1 was kindly provided by Prof. Xiaochun Yun (University of Michigan). The
sequence was altered to be resistant to siBARD1 #1 by site-directed mutagenesis us-
ing Expand Long Template PCR System (Roche). The resulting BARD1 sequence was
subcloned to obtain siRNA-resistant GFP-BARD1-containing pcDNA5/FRT/TO vectors
carrying different point mutations. U2OS/Flp-In cells stably expressing GFP-BARD1
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constructs were generated as described previously [205]. Single clones resistant to
250 µg/ml hygromycin B and 12.5 µg/ml blasticidin S were selected and screened for
inducible GFP-BARD1 expression by both immunofluorescence microscopy and immuno-
blotting. To induce expression of GFP-BARD1, cells were treated with 1 µg/ml doxycycline
(Dox) as indicated.
U2OSCas9WT and U2OSCas9∆CtIP cell lines were generated as described previously [206].
In brief, U2OS-Flp-In cells inducibly expressing Cas9-FLAG (U2OSCas9) were transfected
with a plasmid (DU46129, U6_gRNA) encoding a short guide RNA (sgRNA) target-
ing CtIP or the empty vector as control. 8 h after transfection, Cas9-FLAG expres-
sion was induced with Dox (1 µg/ml). Two days later, cells were replated at high di-
lutions to obtain single-cell derived colonies. These were expanded and screened for
sgRNA incision by PCR and restriction digest as well as for loss of CtIP by immunoblot-
ting. Since this procedure yielded only a clonal population of cells showing a reduc-
tion of CtIP protein levels of approximately 30%, these cells were subjected to another
round of sgRNA transfection, Cas9 expression and clonal selection finally establish-
ing the cell lines used here. Ultimately, the targeted genomic region was amplified by
PCR using the following primers (forward 5’-AGCAAGTAGAAGTGTGGAGCA-3’; reverse
5’-ACAAAGCCACTACAGTCTCAAC-3’) and analysed for the presence of insertion and
deletion mutations by deep sequencing.
Combinatorial RNAi image-based screening and data analysis.
MRC5shCtIP cells were treated with 1 µg/ml Dox or left untreated (control) for 48 h prior
to reverse transfection with a custom Silencer® Select siRNA library (Ambion) targeting
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207 human genes. The library comprised of three independent siRNA oligonucleotides
per target arrayed alongside controls in 384-well plates (Greiner bio-one). All liquid han-
dling was completed using an EL406 microplate washer and dispenser (BioTek). RNAi
screens were performed in three biological replicates, each consisting of two technical
replicates. In brief, 0.8 pmol siRNA (Ambion Silencer® Select) dissolved in 5 µl nuclease-
free water were pre-spotted in each well of an assay plate. To this 25 µl DMEM (without
supplements) containing 0.05 µl Lipofectamin RNAiMax (Invitrogen) was added. The mix
was incubated for 1 h at RT before dispensing 180 cells resuspended in 50 µl DMEM sup-
plemented with 10% FCS, 100 U/ml penicillin, and 100 mg/ml streptomycin leading to a
final concentration of 10 nM siRNA per well. For MRC5shCtIP cells that had been exposed
to Dox before, the cell culture media was kept supplemented with 0.1 µg/ml Dox through-
out the screen. Upon reverse transfection, cells were incubated for 6 days followed by
formaldehyde fixation and Hoechst staining (bisBenzimide H 33342; Sigma-Aldrich). The
cells were imaged on two coupled ImageXpress micro (IXM) HCS microscopes (Molecu-
lar Devices) acquiring 9 images per well with a Nikon CFI S Fluor 10X objective. Finally,
quantitative image analysis was carried out using CellProfiler (Broad Institute [207]) and
Matlab (The MathWorks) to assess the number of nuclei per well.
As numbers of nuclei per well represent discrete data, square root transformation was
applied and within-plate normalization was performed to median values of negative con-
trol conditions (percentage of control), i.e. mock transfected cells or cells treated with
non-targeting siRNAs. The strictly standardized mean difference (SSMD) was used to
measure the magnitude of difference in cell viability between the cytotoxic positive con-
trol (siRNA against kinesin family member 11) and the negative controls as a means for
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quality control [208]. Target genes whose depletion induced cytotoxicity reducing cell
numbers to more than 20% of the overall median cell number were excluded from fur-
ther analysis. To identify negative synthetic genetic interactions with CtIP, a multiplicative
model was applied and an interaction score, termed the ()-score, was computed. Based
on the assumption that the combined effect of two individual perturbations (Vab) will be
the product of their individual effects (Va and Vb), the  score determined the difference
between the observed phenotype and the effect that would be expected if the two genes
do not interact [189]. Theses  scores were used as a basis of hit ranking applying the
Redundant siRNA Activity (RSA) algorithm. First, siRNAs were ranked according to their
 score after which the RSA method was used to assign P-values to each target gene in-
dicating the statistical significance of all siRNAs targeting a single gene being distributed
significantly higher in the ranking than would be expected by chance, calculated based
on an iterative hypergeometric distribution formula [209]. A P-value cut-off of p<0.05 was
chosen to determine a set of candidate hits. Those were further analysed for known as-
sociations with the CtIP protein and grouped according to their molecular functions using
the STRING database and DAVID functional annotation clustering [210, 211].
Transfection
Plasmids were transfected either by using the standard calcium phosphate method or by
FuGENE 6 (Roche) according to manufacturer’s instructions. The FLAG-tagged expres-
sion construct for human BARD1 was a kind gift of Prof. Xiaochun Yun (University of
Michigan). All point mutations were introduced by site-directed mutagenesis using Ex-
pand Long Template PCR System (Roche) and confirmed by sequencing.
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siRNA oligos were transfected at a final concentration of 10 nM using Lipofectamine
RNAiMAX (Invitrogen). For co-depletion experiments, the respective siRNAs were trans-
fected at a final concentration of 10 nM + 10 nM of each oligonucleotide and the total
amount of oligonucleotides was kept equal by transfecting a non-targeting siRNA (Ctrl)
in the single depletion samples. All siRNAs used in this study were purchased from Am-
bion (Silencer® Select siRNAs). The following oligonucleotides (sequences in 5’ to 3’
direction or Ambion siRNA ID are given) were used: Ctrl (Ambion Negative Control #2),
CtIP (GCUAAAACAGGAACGAAUC) [32], CtIP #2 (s11849), BARD1 #1 (s1885), BARD1
#2 (s1886), BARD1 #3 (s1887), BARD1 #4 (CTGAATATTATACCAGATGAA), BRCA1 #2
(s458), BRCA1 #4 (GGAACCUGUCUCCACAAAG). If not indicated, siBARD1 denotes
the use of siBARD1 #1 and siBRCA1 denotes siBRCA1 #2.
Antibodies
A complete list of all primary used in this study can be found in table 3.1. Secondary HRP-
conjugated anti-mouse and anti-rabbit antibodies were form GE-Healthcare. AlexaFluor-
488, -594 and -647-conjugated secondary antibodies were from Invitrogen.
Drugs and cell culture supplements.
Hydroxyurea (HU, Sigma-Aldrich), aphidicolin (Aph, a kind gift of Prof. Massimo Lopes)
and camptothecin (CPT, Sigma-Aldrich) were used as indicated in Figure legends. ATR
inhibitor (VE-821) was provided by Vertex Pharmaceuticals (Abingdon, UK). dNTP analogs
BrdU, CldU, IdU (Sigma-Aldrich), and EdU (Life Technologies) were used as indicated.
For native BrdU labeling, cells were grown with BrdU (30 µM) for 24 h.
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Antibody target Species Supplier/Reference Applicationa
53BP1 rabbit ab-21083 (abcam) IF
pATM S1981 rabbit ab-81292 (abcam) IB
ATM mouse GTX70103 (GeneTex) IB
BARD1 rabbit Gift from R. Baer IB and IF
BRCA1 (D-9) mouse sc-6954 (Santa Cruz) IB
BrdU mouse RPN202 (GE Healthcare) IF
pCHK1 S345 rabbit 2341(Cell Signaling) IB
CHK1 (G-4) mouse sc-8408 (Santa Cruz) IB
CtIP (D-4) mouse sc-271339 (Santa Cruz) IB
DNA2 rabbit Gift from P. Cejka IB
EXO1 rabbit A302-640A (Bethyl) IB
FLAG mouse F3165 (Sigma) IB
GAPDH mouse MAB374 (millipore) IB
γH2AX (20E3) rabbit 9718 (Cell Signaling) IF and FACS
MRE11 (12D7) mouse GTX70212 (GeneTex) IB
ORC2 rabbit 559266 (BD PharMingen) IB
pRPA S4/S8 rabbit A300-245A (Bethyl) IB and IF
RPA2 (Ab-3) mouse NA19L (Calbiochem) IB and FACS
pHistone3 S10 rabbit 06-570 (millipore) FACS
α-Tubulin mouse T-9026 (Sigma Aldrich) IB
TetR rabbit 631110 (Clontech) IB
a IB: Immunoblot, IF: Immunofluorescence, IP: Immunoprecipitation
Table 3.1: Primary antibodies
Immunoblotting and Immunoprecipitation.
If not specified otherwise, cell extracts were prepared in Laemmli buffer (4% SDS, 20%
glycerol, 120 mM Tris-HCl pH 6.8). Proteins were resolved by SDS–PAGE and trans-
ferred to nitrocellulose. Immunoblots were performed by using the appropriate antibodies
and proteins visualized using the ECL detection system (Western BrightTM, Advansta)
imaging on a FusionSolo (Witec AG).
When indicated, a Triton X-100-insoluble (chromatin-enriched) fraction was isolated as
described in Peña-Diaz et al. [212]. Briefly, cells were rinsed twice in cold PBS and in-
cubated for 5 min on ice in pre-extraction buffer (25 mM HEPES (pH 7.4), 50 mM NaCl,
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1 mM EDTA, 3 mM MgCl2, 300 mM sucrose, 0.5% Triton X-100, and protease inhibitors).
After buffer removal and rinsing in PBS, adherent cellular material was harvested by
scraping it into Laemmli buffer. The chromatin-enriched fraction was then heat dena-
tured, sonicated, and analysed by immunoblotting.
Flag-BARD1 wild-type or L44P mutant transiently expressed in HEK293T cells were
lysed in RIPA buffer (50 mM Tris-HCl (pH 7.5), 1% NP-40, 0.25% Sodium-deoxycholate,
150 mM NaCl, 1 mM EDTA, 0.1% SDS, protease inhibitors (1 mM benzamidine and
0.1 mM PMSF)), subjected to benzonase treatment (10 U Benzonase® (Roche)) for
30 min at 4 °C, cleared by centrifugation (14000 rpm) and immunoprecipitated using the
M2-agarose anti-FLAG resin (Sigma-Aldrich) overnight at 4 °C. Immunocomplexes were
stringently washed four times with RIPA buffer followed by one wash with TEN100 buffer
(0.1 mM EDTA, 20 mM Tris-HCl, pH 7.4, 100 mM NaCl), boiled in SDS-sample buffer and
analysed by SDS-PAGE followed by immunoblotting.
Immunofluorescence Microscopy
U2OS cells grown on coverslips were either fixed directly in 4% formaldehyde in PBS
(w/v) and permeabilized or pre-extracted for 5-10 min on ice before fixation in formalde-
hyde for 15 min as described previously [32]. After incubation with the indicated primary
antibodies and appropriate AlexaFluor-488, -594 and -647-conjugated secondary anti-
bodies (1:1’000) (Life Technologies), coverslips were mounted with Vectrashield® (Vector
Laboratories) containing DAPI and sealed. Images were acquired on a Leica DMI 6000
fluorescence microscope. Laser microirradiation was performed as described previously
[213].
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Images were analysed using a customized CellProfiler [207] pipeline to identify nuclei
(DAPI channel) and the number of 53BP1 bodies. For complementation experiments, nu-
clei were identified and classified according to intensities measured in the green channel
(expression of GFP-tagged fusion proteins). The number of 53BP1 bodies in these was
determined.
Colony formation assay
MRC5shCtIP cells were transfected with the indicated siRNA using Lipofectamine RNAiMax
(Invitrogen). On the next day, cells were re-plated into two sets of 6-well plates at low cell
dilutions (triplicates). 48 h post transfection one set of 6-well plates was exposed to
1µg/ml Dox to induce shCtIP while the other one was kept untreated as a control. Cells
were cultured for 10 days to allow formation of colonies. Subsequently, these were fixed
in methanol and stained in crystal violet/ethanol (0.5/20%) solution. Colonies reaching a
minimum of 50 cells were counted and the number of colonies without Dox was set to be
100% for each siRNA transfection in order to determine the effect of CtIP co-depletion.
CellTiter-Blue® Cell Viability assay.
For drug hypersensitivity assays, cells transfected with siRNA where indicated were
seeded in triplicates at a density of 500 or 1000 cells/well in 96 well plate 24 h post-
transfection or after administration of 1 µg/ml Dox (MRC5shRNA). Cells were exposed
to the indicated doses of drugs at 24 h after plating and grown for 4 days at 37° C. To
measure cell viability, CellTiter-Blue® reagent (Promega) was added on the last day, cells
were incubated at 37 °C for 4-24 h, and then fluorescence was measured at 560/590 nm.
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For screen validation, 500 or 1000 U2OS cells were reverse transfected with 10 nM +
10 nM of the indicated siRNAs in a 96-well plate in triplicates. Cell proliferation was
allowed for 6 days before addition of CellTiter-Blue® reagent (Promega).
Metaphase spreads
HEK293 cells were transfected with the indicated siRNAs for 48 h, subsequently treated
with HU for 4 h and allowed to recover for 48 h. Metaphase spreads were prepared
as described in Murina et al. [120]. In brief, cells were treated with colcemid (Gibco)
for 3 h prior to harvesting by trypsinization. The cell pellet was resuspended in 5 ml of
a 0.075 M hypotonic potassium chloride (KCL, PanReac AppliChem) solution and incu-
bated for 30 min. at 37 °C for swelling. For fixation, cells were incubated in 5% acetic
acid (PanReac AppliChem) in ddH2O for 3 min. followed by two rounds of fixation by
ethanol (EtOH, Merck) and acetic acid in a 3:1 ratio for 10 min.. Fixed cells were resus-
pended in fixative to the appropriate cell density, spread on glass slides (Menzel-Gläser,
ThermoFisher) and stained with Giemsa (GIBCO). Phase contrast images were acquired
using an Olympus IX83 inverted at 100x magnification.
DNA fiber analysis.
DNA fiber analysis was carried out as described previously [78]. In brief, asynchronous
U2OS cells were labeled with 33 µM CldU for 30 min followed by exposure to 2 mM HU
for 2 h and chased with 340 µM IdU for 40 min before collection and resuspension in
PBS. Cells were lysed (lysis buffer: 200 mM Tris-HCl (pH 7.4), 50 mM EDTA, 0.5% SDS)
and DNA fibers were stretched onto glass slides and fixed in Methanol:Acetic acid (3:1,
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Merck). After rehydration in PBS, these were denatured with 2.5 M HCl for 1 h, washed
with PBS and blocked with 2% BSA in PBS containing 0.1% Tween 20 for 30 min. The
newly replicated CldU and IdU tracks were stained by standard immunofluorescence us-
ing anti-BrdU antibodies (primarys: α-IdU, α-BrdU from BD Biosciences; α-CldU, α-BrdU
from Abcam and secondarys: α-mouse Alexa Fluor 488 from Invitrogen and α-rat Cy3
from Immuno Research). Coverslips were mounted using Antifade Gold (Invitrogen). Im-
ages were acquired on a Leica DMI 6000 fluorescence microscope and analysed using
Fiji software [214]. Statistics were calculated in Graph Pad Prism (GraphPad Software
Inc.).
Flow Cytometry Analysis
Where indicated, cells were transfected with siRNA as described above and the knock-
down was allowed to persist for 48 h. Analysis of cell cycle, RPA, γH2AX and pS10-H3
was carried out as previously described [215]. Shortly, cells were treated as described in
the Figure legends, harvested by trypsinization and fixed using 4% formaldehyde/PBS.
For RPA staining, cells were pre-extracted in 0.3% Triton X-100/PBS on ice for 10 min
prior to fixation. For assessment of pS10-H3, cells were permeabelized after fixation.
EdU incorporation was analysed using the Click-iT EdU technology (ThermoFisher) ac-
cording to manufacturer’s instructions. For RPA/γH2AX and pS10-H3 analyses, cells
were incubated in 0.5% saponin/1% BSA/PBS containing the primary antibodies for 2 h
at RT, followed by incubation with a secondary antibody and staining of the DNA with
DAPI (DNA content). Fluorescence was measured on a LSR II Fortessa (BD Bioscience)
and analysed with FlowJo X (Tree Star).
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To assess apoptosis, U2OS were transfected with siRNA as described above and re-
plated into gelatin-coated (0.1% in PBS) 6-well tissue culture plates. On the indicated
days cells were harvested by trypsinization. Cells were collected in polysterene FACS
tubes and washed with annexin binding buffer (10 mM HEPES/NaOH, 140 mM NaCl,
2.5 mM CaCl2 (pH 7.4)). After washing, cells were stained in 50 µl annexin binding
buffer including 5 µl annexin V-FITC (eBioscience) and propidium iodide (1ug/ml; Ther-
moFisher) for 20 min at RT. Cells were then washed with annexin binding buffer before
analysis by flow cytometry with a LSRII Fortessa (BD Bioscience) and analysed with
FlowJo X (Tree Star).
Statistical analysis
Statistical differences were determined by unpaired t test except for fork asymmetry,
which was analysed by Mann-Whitney U test and quantification of 53BP1 nuclear bod-
ies, which was analysed by Kolmogorov-Smirnov test. In all cases: ns – not significant
(P > 0.05); * – P ≤ 0.05; ** – P ≤ 0.01; *** – P ≤ 0.001; **** – P ≤ 0.0001.
HR reporter assay
U2OS-TLR cells were transfected with siRNA as described above. After 6 h, cells were
transfected with the I-SceI-expression plasmid and the exogenous donor template con-
taining the missing part of eGFP. 72 h after siRNA transfection, cells were collected by
trypsinization, and analysed by flow cytometry using a LSRII Fortessa (BD Bioscience)
as described previously [112]. Data analysis was performed using FlowJo X (Tree Star)
to assess the percentages of eGFP-positive cells depicting the efficiency of homologous
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recombination.
Pulsed field gel electrophoresis (PFGE)
U2OS cells were transfected with siRNA as described above and pulse labelling of the
replication forks with [14C]thymidine was performed before and during HU treatment.
Cells were harvested and PFGE was performed as described in [216].
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4.1 Multiplexed RNAi and drug-sensitivity screen to investi-
gate synthetic genetic interactions of CtIP in the presence
or absence of DNA damage.
In order to expand our understanding of CtIP gene functions and their impact on the cellu-
lar homeostasis in response to DNA damage, we performed multiplexed high-throughput
RNA interference (RNAi) screens with isogenic cell lines differing only in their CtIP ex-
pression status in the presence or absence of the DNA damaging agent camptothecin
(CPT). To assess synthetic genetic interactions in these cells by combinatorial RNAi, we
manually curated an arrayed siRNA library targeting 207 human genes. About 40% of
those target genes are implicated in the DNA repair processes and cell cycle checkpoint
control. Among them, we selected key players from a wide range of DDR pathways,
which might function in either distinct or partly compensatory pathways with respect to
HR. Furthermore, we included target genes involved in other cellular pathways like DNA
replication and transcription, as well as protein modifiers such as kinases, phosphatases
and ubiquitin ligases (Figure 4.1A).
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Figure 4.1: Multiplexed RNAi and drug-sensitivity screen to investigate synthetic genetic inter-
actions of CtIP in the presence or absence of DNA damage. (A) Classification of genes targeted by
oligonucleotides of the custom-designed siRNA library. (B) Schematic overview of experimental setup
and data analysis of the RNAi screen.
To minimize the potential risk of seed sequence-driven off-target effects [217], we em-
ployed a Silencer® Select siRNA library (Ambion) consisting of three siRNAs targeting
distinct regions of each gene, singly arrayed in 384-well plates alongside controls. As
Silencer® Select siRNA oligonucleotides are designed to enhance target specificity and
potency by harbouring chemical modifications, we used them at a minimum effective
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amount of 8 pmol siRNA per well further reducing the risk of off-target effects [218].
To monitor various biological and technical parameters of the screening procedure, we
dedicated 24 wells per assay plate to internal controls. This included three different non-
targeting siRNAs (siNegCtrl #1, siNegCtrl #2, siLuciferase) as well as mock-transfected
cells. An siRNA targeting CtIP was used as a positive control for CPT hypersensitiv-
ity [32]. To assess the efficiency of siRNA transfection, a cytotoxic positive control was
included, which silences kinesin family member 11 (siKif11), a gene critical for cell vi-
ability [219]. To perform the combinatorial RNAi screen, we used MRC5shCtIP cells, in
which we conditionally downregulated CtIP for 48 h prior to reverse transfection of the
arrayed siRNA library (Figure 4.1B). Two days post siRNA transfection, cells were either
mock-treated or incubated with 10 nM CPT to induce DNA damage. Six days after siRNA
transfection, cells were fixed and the nuclei were stained with Hoechst. Consequently,
microscopic images of each well were acquired and image analysis was performed using
CellProfiler [207], an open-source software tool for quantitative analysis of biological im-
ages, to extract the number of cells per well as a read-out for cell viability (Figure 4.1B).
RNAi screens were conducted in biological triplicates, each replicate screen consisting
of technical duplicates.
Our experimental set up led to four different conditions in which genetic perturbations
were conducted: 1) Cells with normal CtIP expression that had not been exposed to DNA
damage (–Dox, untreated), 2) Cells with normal CtIP expression exposed to DNA dam-
age (–Dox, CPT), 3) Cells depleted of CtIP that had not been exposed to DNA damage
(+Dox, untreated) and 4) Cells depleted of CtIP exposed to DNA damage (+Dox, CPT).
In total, our screening approaches generated about 15000 data points for subsequent
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analysis. After image segmentation and feature extraction, we first visualized our data
output in order to monitor the overall screen performance. Raw data was displayed as
plate-well series plot, a scatter plot that summarizes the data points across the plates
from all replicates of the screen. This representation indicated the absence of cross-
plate systematic errors such as spatial effects or batch-to-batch variations (Figure 4.2A).
Moreover, within-plate experimental artefacts (edge effects or drift) were examined by
plotting the median cell numbers of each row or column across all screening plates (Fig-
ure 4.2B). A small, but expected, decrease of median cell numbers in column eight and
fourteen depicted the presence of two wells containing siKif11 in that column. Overall,
no potential systematic problems or plate effects caused by the experimental procedure
itself were evident from raw data display.
For the screen data analysis, we first square-root transformed the raw data to render its
distribution closely symmetric and approximately normal making it more suitable for sta-
tistical analysis. This was followed by normalization of each data point to the median of
negative controls per plate (percentage of control, POC) to adjust for variation between
plates. For quality control, we subsequently monitored the correlation of normalized cell
numbers between the three biological replicates. Pearson correlation coefficients rang-
ing between 0.69 and 0.81 revealed good data reproducibility (Figure 4.2C). The strictly
standardized mean difference (SSMD) was used to measure the magnitude of difference
in cell viability between the cytotoxic positive control (siKif11) and the negative reference
(Ctrl) as a second mean for quality control. Adopting the criterion for a very strong pos-
itive control, SSMD values of approximately 3.0 for each assay plate, suggested good
differentiation between positive and negative controls and indicated high quality data
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Figure 4.2: Visualizing data outputs of the screen for quality control and data analysis. (A)
Plate-well series plot to display the raw cell numbers measured in each well from all replicates of the
screen. (B) Median values of raw cell numbers per row or column across all plates from the screen
reveal the absence of row or column artefacts like edge effect or drift. (C) Replicate correlation plots to
visualize overall reproducibility. The x- and y-axis represent two biological replicates and each data point
represents data obtained from one well. Pearson correlation coefficients between the three biological
replicates are displayed. (D) Representative images of Hoechst-stained nuclei from cells transfected
with a non-targeting siRNA (Ctrl) or the cytotoxic siKif11, respectively. To measure the magnitude of
difference between these two populations as a indication for efficient siRNA transfection, the strictly
standardized means difference (SSMD) was computed for each assay plate. Results for one replicate
screen are shown. By adopting the criterion for a very strong positive control, SSMD values indicate
good data quality
(Figure 4.2D) [208]. This confirmed what had been anticipated in the plate-well series
plot, where the values for siKif11-transfected cells clustered at the low end of cell number
values for each plate (Figure 4.2A). Moreover, this plot indicated the expected CPT hyper-
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sensitivity of cells expressing reduced CtIP levels [32]. Transient transfection of an siRNA
targeting CtIP (data points depicted in orange in data sets -Dox) as well as Dox-mediated
induction of shCtIP on the batch level resulted in a reduction of cell viability upon exposure
to CPT (compare –Dox +CPT and +Dox +CPT). Taken together, our quality assessment
indicated that our control measures met our expectations and therefore no screening data
needed to be excluded from the analysis due to poor data quality. To eliminate bias re-
sulting from the ratio between small numbers, we next removed siRNA mediating high
cytotoxicity from further analysis. We thus excluded 29 target genes whose depletion
reduced cell viability to less than 20% of the overall median cell number per well.
To identify negative synthetic genetic interactions with CtIP in the absence of DNA dam-
age, we applied a multiplicative model and computed an interaction score, termed the
epsilon () score. Based on the assumption that the combined effect of two individual
perturbations will be the product of their individual effects, the  score determined the
difference between the observed phenotype and the effect that would be expected if the
two genes do not interact [189]. Theses  scores were then used to compute a hit rank-
ing based on the Redundant siRNA Activity (RSA) algorithm. First, siRNAs were ranked
according to their  scores. Consequently, the RSA method was used to assign p-values
to each target gene. The RSA p-values were calculated based on an iterative hyperge-
ometric distribution formula developed by König et al.[209]. They indicated the statistical
significance of all siRNAs targeting a single gene being distributed significantly higher in
the ranking than would be expected by chance. A p-value cut-off of p<0.05 was chosen
to determine a set of high-confidence candidate hits depicting putative SSL interactions
with CtIP loss of function (Figure 4.3A). SSL genetic interactions with CtIP occurring in
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the absence of CPT treatment were further analysed for known associations with the CtIP
protein and grouped according to their molecular functions using the STRING database
and DAVID functional annotation clustering [210, 211]. Not surprisingly, our candidate
hits clustered in three different cellular pathways: DNA repair, cell cycle control and tran-
scription (Figure 4.3B).
Another class of synthetic interactions is represented by the so-called ‘synthetic rescue’,
whereby the combined phenotype of two gene disruptions is less severe than anticipated
from the single perturbations as it enhances cell proliferation. Such positive genetic in-
teractions could potentially also be identified from our screening data. To this end, we
reinterpreted the  scores in order to determine which target gene depletion conferred
a growth advantage to cells lacking CtIP. Interestingly, the top scoring candidates identi-
fied as synthetic rescue gene pairs with CtIP were the PIKK member and histone acetyl
transferase scaffold protein TRRAP (TRansformation/tRanscription domain-Associated
Protein) [220] and the DNA replication processivity factor PCNA (Proliferating cell nu-
clear antigen) [221]. However, these results need to be interpreted with caution as the
well dimensions in a 384-well plate limits cell proliferation considerably and might there-
fore restrict the discovery of growth-enhancing phenotypes.
As a second aim of our screen, we sought to identify proteins, which would confer hy-
persensitivity to the DNA damaging agent CPT upon depletion in a CtIP-proficient back-
ground. For this analysis, we calculated the fold-change in cell viability between untreated
cells and those that had been exposed to CPT for each siRNA [222]. Subsequently, we
used the RSA algorithm for a target gene ranking according to the increase in CPT hyper-
sensitivity. As expected, cells depleted of known DDR genes such as CtIP (alternative
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name RBBP8), BRCA1, BARD1, RAD51, ATR and RPA2 were hypersensitive to CPT
(Figure 4.3C). Remarkably, CtIP, BRCA1 and BARD1 were identified as top scoring can-
didates emphasising the importance of these DDR factors in the cellular response to
DSBs. Of note, a large number of the factors identified were in concordance with pro-
teins already identified to mediate resistance to CPT, including NFKBIL2, SMC3, EXO1,
RAD18 and SMC6 [213, 223–226]. Since we failed to uncover genes that had not previ-
ously been linked with the DDR, we decided not to follow up on any of these hits. Never-
theless, these findings served as a validation for the success of our screening and data
analysis strategies. SSL hits that also conferred CPT hypersensitivity upon disruption are
indicated in Figure 4.3B.
A third possible application of our screen would have been the investigation of so called
‘differential genetic interactions’ [186]. These describe how functional interconnections
between pathways are altered in response to DNA damage by comparing the genetic
interactome with and without perturbation by a DNA-damaging agent. However, as ex-
pected, CtIP-depleted MRC5shCtIP cells were highly sensitive to CPT per se, thus the
number of cells assayed per double perturbation decreased dramatically in this condition.
Acquiring data from a sufficient number of cells is a critical parameter for the sensitivity
of the detection of genetic interactions [197]. Hence, the data we acquired in the +Dox
+CPT condition was not suitable for the identification of differential genetic interactions.
Adjustments in experimental design would be necessary in order to mitigate this problem.
Thus, we refrained from further analysis of our existing data sets.
Taken together, our focused screen uncovered a set of potential SSL interactions with
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the CtIP gene. Moreover, we identified a number of proteins that mediated resistance to
CPT-induced DNA damage. In my doctoral thesis, I have subsequently focused on the
validation and functional characterization of SSL interactions with CtIP in the absence of
DNA damage. Among the high-confidence candidates, we selected four genes (ESCO1,
DDB, BARD1, and SLX4) for further retesting and validation of the genetic interaction
with CtIP by complementary assays (data not shown). During this extensive and time-
consuming period, we obtained the most promising and reproducible results for the SSL
interaction between CtIP and BARD1. Therefore, we decided to further investigate the
functional interconnection between these two proteins. In the second part of my PhD
thesis I hence sought to determine how CtIP and BARD1 collaboratively contribute to cell
survival.
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4.2 RNAi screening reveals a negative synthetic genetic inter-
action between CtIP and BARD1
In order to investigate functional relationships of the CtIP gene, we analysed synthetic
genetic interactions of CtIP by RNA interference (RNAi)-based screening, which was de-
scribed in detail in the previous section. Subsequently, we primarily focussed on aggra-
vating, or, alternatively termed, synthetic sick/lethal genetic interactions (SSL). SSL inter-
actions occur if two otherwise viable single gene disruptions lead to lethality or severely
impaired cell growth (synthetic sickness) when combined [190]. In order to carry out
systematic perturbation screens, we generated and characterised MRC5shCtIP human fe-
tal lung fibroblast cells in which we can conditionally downregulate CtIP protein levels
through the expressing of a short hairpin RNA (shRNA) against CtIP under the control
of a doxycycline (Dox)-inducible promoter (Figure 4.4A) [120]. Importantly, the extent of
CtIP disruption after Dox-induction and siRNA transfection are comparable and both re-
sult in CPT hypersensitivity, a well established phenotype of CtIP-deficiency (Figure 4.4A
and Supplementary Figure 4.4A) [32]. Using MRC5shCtIP cells, we conducted a multi-
plexed image-based RNAi screen interrogating 207 human genes for synthetic growth
defects with CtIP (Figure 4.4B). Our image and data analysis pipeline revealed eighteen
SSL candidate genes scoring below our cut-off (RSA p-value < 0.05) to potentially exhibit
a negative genetic interaction with CtIP (Figure 4.4C). Among the strongest candidates,
we found the BRCA1-associated RING domain protein 1 (BARD1) (Figure 4.4D). Re-
markably, in our screen data analysis, BRCA1, the obligate interaction partner of BARD1,
scored just above the p-value cut-off suggesting that co-depletion of BARD1 and CtIP
might cause a more severe growth defect than the co-depletion of BARD1 and CtIP (Fig-
ure 4.4D).
Subsequently, we confirmed the negative synthetic genetic interaction between CtIP and
either BARD1 or BRCA1 in MRC5shCtIP cells by colony formation assays using identical
as well as different siRNAs as in the screen (Figure 4.4E). Consistent with our screening
data, co-depletion of CtIP and BARD1 significantly decreased cell viability compared to
depletion of CtIP alone, whereas co-depletion of CtIP and BRCA1 only partially replicated
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Figure 4.4: Identification of a synthetic sick genetic interaction between CtIP and BARD1 by
RNAi image-based screening. (A) SV40-transformed MRC5 cells were transfected with the indi-
cated siRNAs for 48 h. MRC5 cells stably expressing doxycycline (Dox)-inducible shRNA against CtIP
(MRC5shCtIP) or LacZ (MRC5shLacZ, control) were cultivated in the absence or presence of Dox (1 µg/ml)
for 48 h. Whole cell lysates were prepared and subjected to immunoblotting to indicate the extent of
CtIP depletion. (B) Schematic outline of the RNAi screen to investigate synthetic genetic interactions
of CtIP. (C) Candidate genes for SSL interactions with CtIP were ranked by redundant siRNA activity
(RSA) analysis. A RSA p-value cut-off of p < 0.05 was defined to determine a hit list. (D) Genetic
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before (input) and after immunoprecipitation (IP) using anti-Flag antibody coupled to agarose beads.
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this phenotype. These findings were further corroborated by combinatorial siRNA deple-
tion studies in U2OS cells (Supplementary Figure 4.4B). In line with previous findings, we
also observed a notable interdependency of BRCA1 and BARD1 protein stability in cells
depleted for either protein respectively [143, 157].
The most accepted mechanistic explanation of negative synthetic genetic interactions
comprises two genes functioning in parallel, mutually compensatory pathways, known as
between-pathway SSL. Physical interaction, on the other hand, is often interpreted to de-
note gene products functioning within the same pathway or protein complex [227, 228].
However, recent findings revealed that multiple negative interactions occur between fac-
tors implicated in the same molecular pathway or even within one complex [191, 229].
Since protein-protein interactions between BARD1 and BRCA1 and between BRCA1 and
CtIP are well established, this prompted us to carry out co-immunoprecipitations using
Flag-tagged BARD1 expression constructs. As expected, CtIP efficiently co-precipitated
with Flag-BARD1 wild type (WT) indicating that CtIP and BRCA1/BARD1 exist in a trimeric
complex (Figure 4.4F). Interestingly, we observed that a significant fraction of CtIP retains
the ability to form a complex with BARD1-L44P, a mutation that disrupts the BRCA1-
BARD1 dimer [230]. Thus, we concluded that BARD1 and CtIP interact, at least in part,
independently of their common interaction partner BRCA1.
Taken together, our results unveiled the presence of a negative genetic interaction be-
tween BARD1 and CtIP, two DDR factors residing within the same multi-protein complex.
We failed to detect a comparable SSL interaction between CtIP and BRCA1 implying
that BARD1 and CtIP might have a functional connection beyond the BRCA1/BARD1
heterodimer.
4.3 Prolonged downregulation of CtIP and BARD1 triggers a
cell stress response associated with hallmarks of endoge-
nous DNA damage.
To investigate the underlying mechanisms for the synthetic sick relationship between CtIP
and BARD1, we depleted the respective proteins alone or in combination in U2OS cells.
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After four days, downregulation of BARD1, but not CtIP, resulted in a marked increase of
apoptosis (Figure 4.5A and B). Intriguingly, co-depletion of both proteins further elevated
the fraction of apoptotic cells compared to knockdown of BARD1 alone. Conversely,
downregulation of CtIP and BARD1 for only two days was not sufficient to induce apop-
tosis above basal levels (Supplementary Figure 4.5A). Co-depletion of BRCA1 and CtIP
resulted in a similar trend of increased apoptosis; albeit to a lesser extent as the com-
bined disruption of BARD1 and CtIP (Figure 4.5B) reminiscent of the results of the RNAi
screen (Figure 4.4). Additionally, we also observed that prolonged abrogation of CtIP or
BARD1 expression delayed cell proliferation and compromised replication as indicated
by a reduction of S-phase cells and slower incorporation of nucleotides (Supplementary
Figure 4.5B). Comparable to the increase of apoptosis, the delay in S-phase became
apparent only several cell divisions after depletion of the respective proteins. We there-
fore hypothesize that cells deficient for CtIP and BARD1 encounter problems during each
round of DNA replication.
To address whether cells depleted of CtIP and/or BARD1/BRCA1 accumulate DNA le-
sions, we analysed the levels of the histone variant H2AX phosphorylated on serine
139 (γH2AX) by flow cytometry at two days after siRNA transfection (Figure 4.5C). Even
though apoptosis was not effectively induced at this early time point, we found a marked
increase of γH2AX-positive nuclei in CtIP/BARD1-deficient cells (Figure 4.5C). This was
accompanied by an increase of cells arrested in G2/M phase, which became evident
already upon single depletion of the respective proteins, but was further elevated after si-
multaneous disruption of BARD1 and CtIP. Conversely, co-depletion of CtIP and BRCA1
was not able to fully emulate these phenotypes (Figure 4.5C). Therefore, we concluded
that the concurrent loss of CtIP and BARD1 leads to DNA damage predominantly mani-
festing in G2/M cells, ultimately slowing down cell proliferation and inducing cell death. We
next investigated the role of CtIP, BARD1 and BRCA1 in the G2/M cell cycle checkpoint
using phosphorylated serine 10 at histone 3 (pS10-H3) as a mitotic marker. We found
that CtIP-depleted cells could enter mitosis without impediments (Figure 4.5D). Surpris-
ingly, mitotic cells were decreased about two-fold upon BARD1 but not BRCA1 disruption
suggesting a previously uncharacterized role for BARD1 in the G2/M cell cycle transition.
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Figure 4.5: Simultaneous disruption of BARD1 and CtIP provokes apoptosis and is associated
with accumulation of γH2AX. (A) U2OS cells were transfected with the indicated siRNA, and the
knockdown was allowed to persist for 48 h. Whole-cell extracts were analysed by western blotting
with the indicated antibodies. (B) Cells were transfected with the indicated siRNA as in (A) and were
harvested at four days post transfection. Induction of apoptosis was determined by flow cytometric
analysis. Annexin VFITC-positive staining indicates early apoptotic cells, whereas Annexin V-positive/PI-
positive staining indicates late apoptotic cells. (C) and (D) U2OS cells were treated as in (A). 48 h after
siRNA transfection, cells were harvested and were fixed, permeabilized and immunostained with anti-
γH2AX or anti-phospho-histone H3 along with DAPI before analysis by flow cytometry. Quantification
gates were established in samples transfected with siCtrl. (C) Representative cell cycle distributions and
representative dot plots depicting the intensity of the γH2AX signal (y axis) against the DNA content
(x axis) for each knockdown condition are shown. Percentages indicate mean ± s.e.m. of γH2AX-
positive cells (n ≥ 3). (D) Percentages indicate mean ± s.e.m. of phospho-histone H3-positive cells (n
= 2). a. u. = arbitrary units.
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This finding implies that cellular stress experienced by cells lacking BARD1 during S/G2
phase is sufficient to trigger cell cycle arrest and possibly apoptosis as a secondary event
in a subset of cells.
Combined, these results suggest a scenario in which endogenous DNA lesions accu-
mulate during each cell cycle in cells co-depleted of CtIP and BARD1. This results in
BARD1-dependent partial G2/M arrest, impaired proliferation and apoptotic cell death
upon sustained disruption of both factors.
4.4 Loss-of-function of CtIP and BARD1 causes signs of ele-
vated replication stress.
It has been recently proposed that unresolved replication intermediates can get converted
into DNA lesions upon entry of a cell into mitosis. 53BP1 protein was shown to recognizes
such sites of unrepaired DNA damage forming nuclear bodies (NBs) upon subsequent
entry into G1 to shield them against erosion [83, 84]. To address, whether BARD1 and
CtIP counteract replication stress-induced DNA damage, we determined the prevalence
of 53BP1 NBs in cells depleted of CtIP and/or BARD1 or BRCA1 by immunofluorescence
microscopy (Figure 4.6A and Supplementary Figure 4.6A)). Remarkably, downregulation
of CtIP or BARD1 respectively increased the average number of 53BP1 NBs per nucleus
significantly. Concurrent disruption of CtIP and BARD1 further amplified the number of
nuclei with supernumerary 53BP1 NBs. In line with previous reports, we find that the
average increase of 53BP1 NBs in CtIP/BARD1-depleted cells was caused by a marked
shift towards few nuclei with a much higher prevalence of 53BP1 NBs, which is illustrated
by their elevated incidence in the 90th percentile of cells analysed [83]. Knockdown of
BRCA1 induced a similar phenotype like knockdown of BARD1 implying a role for the
BRCA1/BARD1 heterodimer in counteracting accumulation of 53BP1 NBs (Supplemen-
tary Figure 4.6A). From these results we inferred that depletion of CtIP and/or BARD1 is
sufficient to elicit endogenous chromosomal stress that manifests as 53BP1 nuclear bod-
ies in a subset of cells. Likely, 53BP1 NBs, once formed, can persist in case HR-mediated
repair fails to address these DNA lesions during subsequent G2/S phases. Alternatively,
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53BP1 might accumulate upon induction of DSBs for example at a collapsed replication
fork during S phase.
Importantly, 53BP1 NBs could be fully restored to basal levels by the stable expression
of siRNA-resistant GFP-BARD1 wildtype (WT) ruling out off-target effects of the siRNA-
mediated knockdown (Figure 4.6B and Supplementary Figure Figure 4.6B). Expression
of the GFP-BARD1 L44P mutant [230] on the other hand, was not able to reduce 53BP1
NBs to normal levels corroborating previous findings that the BRCA1/BARD1 complex is
necessary to counteract the impediments leading to formation of 53BP1 NBs.
To further substantiate our findings beyond relying solely on RNAi-mediated protein de-
pletion, we attempted generating stable U2OS CtIP knockout cells using the
CRISPR/Cas9 technology as described by Munoz et al. [206]. However, CtIP demon-
strated to be essential for long-term cell survival, hence we were unable to produce
a full knockout. Nevertheless, we succeeded in targeting several of the CtIP alleles
present in U2OS cells to generate a cell line with markedly reduced CtIP expression
(U2OSCas9∆CtIP) (Supplementary Figure 4.6C). Consistently, we observed increased for-
mation of 53BP1 NBs in U2OSCas9∆CtIP cells upon treatment with low doses of the DNA
polymerases inhibitor aphidicolin (Aph) that selectively impair progression of replication
forks through physiological barriers [231] (Supplementary Figure 4.6C). Besides 53BP1
NBs, micronuclei (MN) formation is considered another marker of chromosome breakage
stemming from replication stress-induced DNA lesions [79]. Accordingly, we detected a
two-fold increase in the number of micronuclei upon disruption of CtIP and BARD1 (Fig-
ure 4.6C). Collectively, these data strongly implies crucial roles of CtIP and BARD1 in
counteracting endogenous replication stress.
Next, we sought to directly analyse replication fork progression in cells devoid of CtIP
and/or BARD1 that are experiencing mild replication stress induced by hydroxyurea (HU)
treatment. By conducting a dual-labelling DNA fiber assay, we compared the tract lengths
of sister replication forks. Sister forks depict two replisomes that have originated from the
same origin of replication but travel in opposite directions. If replication progresses with-
out perturbations, sister forks are characterized by similar replication rates resulting in
symmetrical patterns of CldU/IdU incorporation [232]. However, our analysis revealed
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Figure 4.6: CtIP- and BARD1-deficiency induces 53BP1 nuclear bodies and replication fork
stalling. (A) U2OS cells were transfected with the indicated siRNA. After 48 h of knockdown, cells
were fixed and immunofluorescence was performed with anti-53BP1 antibody (red) along with DAPI
staining. Upper left panel: Box plots represent quantification of 53BP1 nuclear bodies per nucleus.
Black bars denote mean ± 95 % confidence interval, red circles denote the 90th percentile assessed
in at least 900 nuclei (n ≥ 3). Right panel: Frequency distributions indicate the percentage of cells
displaying a certain range of 53BP1 nuclear bodies for each knockdown condition. Bottom panel: Rep-
resentative images are shown. Whole-cell extracts of the corresponding samples analysed by western
blotting are shown in Supplementary Figure 4.6A.
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Figure 4.6: (B) Parental U2OS cells and U2OS cells stably expressing siRNA-resistant GFP-tagged
wildtype (WT) or mutant (L44P) human BARD1 were transfected with siCtIP for 48 h, and immuno-
fluorescence was performed with anti-53BP1 antibodies. Box plots represent quantification of 53BP1
nuclear bodies from at least 600 nuclei (n = 3). Black bars denote mean ± 95 % confidence interval.
Whole-cell extracts of corresponding samples were analysed by immunoblotting. Representative im-
ages are shown in Supplementary Figure 4.6B. (C) The number of micronuclei (MN) in cells treated
as in (A) was quantified by immunofluorescence microscopy in DAPI-stained cells. Data represent the
mean ± s.e.m. (n = 5). (D) DNA fiber analysis of U2OS cells treated as in (A). Cells were pulsed with
CldU, exposed to 2 mM HU for 2 h, and pulsed with IdU. Box plots indicate the ratios of left/right fork
lengths of bidirectional replication forks traveling from a single origin. The lines denote mean ratios ±
95 % confidence interval (n = 2). Representative images are shown in Supplementary Figure 4.6D.
marked fork asymmetry in HU-treated cells lacking CtIP or BARD1 that was increased in
a additive manner upon co-depletion of both factors (Figure 4.6D and Supplementary Fig-
ure 4.6D). These results indicate that individual forks are more susceptible to persistent
stalling in CtIP/BARD1-deficient cells. Thus, we not only provide evidence that simultane-
ous loss of CtIP and BARD1 leads to a synergistic increase of endogenous DNA damage
but also to prolonged fork stalling suggesting that CtIP and BARD1 play important but
non-overlapping roles to ensure faithful DNA replication.
4.5 DNA double-strand breaks (DSBs) arising in the absence
of CtIP and BARD1 cannot be resolved and causes chro-
mosomal aberrations.
Upon infliction of DNA lesions, the DDR signalling network is elicited to coordinate the
DNA damage response. A key feature of the DDR is the activation of the apical kinases
ATM (ataxia telangiectasia mutated) and ATR (ATM-and Rad3-related). According to
current understanding, formation of DSBs leads to the initial recruitment and activation
of ATM mediating the phosphorylation of its downstream target CHK2, among others.
ATR, on the other hand, is activated by RPA binding to regions of single-stranded DNA
(ssDNA) that are exposed at stalled replication forks or after DSB resection inducing a
signalling cascade that involves the effector kinase CHK1 [13, 19]. To assess in more
detail what kind of DNA lesions are induced in the absence of CtIP and BARD1, we
monitored DNA damage signalling by ATM- and ATR-pathway activation (Figure 4.7A).
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Control cells that had been treated with HU to induce replication stress demonstrate the
characteristic activation of the ATR-CHK1 pathway upon fork stalling. However, CHK1
phosphorylation was largely unaltered upon CtIP, BARD1 or BRCA1 depletion and co-
depletions in the absence of exogenous treatments. Conversely, the ATM-dependent
arm of the DDR was initiated readily when CtIP or BARD1 were disrupted, displaying
an additive increase upon ablation of both proteins (Figure 4.7A). Knockdown of BRCA1
alone or concurrently with CtIP did not cause ATM auto-phosphorylation of the same
magnitude as CtIP/BARD1 depletion. From this data we hypothesized that persisting
DNA lesions occurring upon CtIP/BARD1 disruption might partially represent replication-
associated DNA DSBs. Therefore, we wanted to address the possibility that DSBs might
arise concurrently with DNA replication, for example as a consequence of replication
fork collapse. We treated [14C]thymidine-pulse labelled cells with HU and performed
pulsed field gel electrophoresis (PFGE) to analyse the DNA fragments generated during
replication (Figure 4.7B). Interestingly, knockdown of CtIP, BARD1 or both barely induced
damage at sites of newly replicating DNA. Chemical inhibition of Wee1 on the other hand
caused a clear elevation of DNA breaks in newly replicated areas thereby confirming
previous findings [216]. From our analysis we thus inferred, that in cells lacking CtIP and
BARD1, formation of DSBs happens most likely not concomitantly to DNA replication and
is therefore not the result of enhanced collapse of stalled replication forks.
Since persisting DSBs can potentially cause chromosomal rearrangements, we next
analysed metaphase spreads from cells lacking CtIP and/or BARD1, which had been
exposed to mild HU-treatment followed by a release from the replication stress to al-
low cell cycle progression (Figure 4.7C). Intriguingly, depletion of either CtIP or BARD1
alone elevated the prevalence of chromosomal aberrations per metaphase significantly
while co-depletion of both proteins led to a further increase of chromosomal abnormal-
ities. Most notably, we predominantly observed chromosomal fragments and deletions
that can be the result of chromosome or chromatid breakage [233]. To complement our
data, we investigated whether CtIP/BARD1 downregulation was associated with changes
in the sensitivity of cells to HU-induced replication stress (Supplementary Figure 4.7A).
In line with previous reports, we show that ATR inhibition impairs cell survival in cells
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Figure 4.7: Cells experience elevated levels of DSB formation and chromosomal aberrations in
the absence of CtIP and BARD1. (A) U2OS cells were transfected with the indicated siRNA for 48 h.
One sample transfected with a non-targeting siRNA (siCtrl) was treated with 2 mM HU for 2 h prior to
harvest. Whole-cell extracts were analysed by immunoblotting with the indicated antibodies. (B) U2OS
cells treated as in (A) and U2OS cells treated with a chemical inhibitor of Wee1 (Wee1i) were pulse-
labelled with methyl-[14C]thymidine 48 h after siRNA transfection and concomitantly treated with 2 mM
HU for 4 h. Cells were harvested and DNA fragments were separated by pulsed field gel electrophoresis
(PFGE). (C) HEK293 cells were transfected with the indicated siRNAs for 48 h, treated with 2 mM HU
for 4 h, and released from HU for 48 h. Prior to harvest, cells were arrested in metaphase with 0.1 µg/ml
colcemid for 3 h. Metaphase spreads were prepared according to standard protocols and stained with
Giemsa stain. Representative images are shown and specific chromosomal aberrations are magnified
as insets (right panel). Lower left panel: Aberrations from 30 metaphase spreads were analysed. Box
plots indicate aberrations per metaphase, black lines denote the mean ± 95 % confidence interval
(n = 3). Whole-cell lysates of the same samples were subjected to immunoblotting (upper left panel)
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upon HU-treatment [54, 234]. Knockdown of BARD1 conferred slight hypersensitivity
to chronic exposure to HU-induced replication stress compared to control cells. How-
ever, cells were not sensitized to HU-treatment by downregulation of CtIP indicating that
its loss-of-function is compliant with cell survival despite inducing considerable levels of
DNA lesions and chromosomal aberrations (Figures 4.5B, 4.6A and 4.7C).
CtIP as well as BARD1 play essential roles in HR-mediated DSB repair [32, 145]. In
line with previous reports, we found that CtIP depletion strongly interfered with HR at
I-SceI-induced DSBs measured in an HR reporter assay (Supplementary Figure 4.7B)
[205, 235]. Likewise, HR was almost completely blocked by depletion of BARD1 or
co-depletion of BARD1 and CtIP. Since defective HR should result in hypersensitivity
towards DSB-inducing agents, we additionally assessed cell survival upon chronic ex-
posure to CPT. Elevated sensitivity towards this drug was evident in CtIP- as well as in
BARD1-depleted cells, while co-depleted cells showed epistatic sensitivity towards CPT
(Supplementary Figure 4.7C) Consequently, these results support a critical role for both,
CtIP and BARD1 in facilitating DSB repair by HR. Since it was shown that BRCA1 can
recruit CtIP to chromatin and into nuclear DNA repair foci following DSB formation [149],
we also tested whether the HR deficiency was due to impaired CtIP recruitment subse-
quent to knockdown of BARD1 or BRCA1. However, in cells that had not been exposed
to genotoxic stress, neither BARD1 nor BRCA1 downregulation affected the recruitment
of CtIP to chromatin considerably (Supplementary Figure 4.7D). Correspondingly, CtIP
could readily accumulate at sites of laser-induced DNA damage in the absence of BARD1
(Supplementary Figure 4.7E), contradicting the notion that CtIP recruitment is compro-
mised by BARD1 disruption in this setting. Collectively our findings imply that the simulta-
neous absence of BARD1 and CtIP causes DSB formation and can result in chromosomal
aberrations. In addition, we determine that CtIP/BARD1-deficient cells are dysfunctional
in HR, which would be the preferable pathway to address DSBs. Moreover, our data sug-
gests that DNA lesions induced by loss of CtIP alone do not impair cell survival upon mild
induction of replications stress.
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4.6 CtIP prevents excessive ssDNA formation in response to
fork stalling
To substantiate the concept that CtIP plays a major role in supporting correct DNA replica-
tion, we sought to examine the molecular consequences of replication stress in cells de-
void of CtIP. To this end, we assessed DNA damage signalling in cells lacking CtIP expres-
sion following acute exposure to HU or to the topoisomerase I-inhibitor CPT. A common
feature of stalled forks, but also of resected DSBs, is the presence of single-stranded DNA
(ssDNA) and the subsequent recruitment of RPA followed by hyper-phosphorylation of the
RPA2 subunit on several residues, among them serine 4 and serine 8 [32, 65, 119, 236].
Intriguingly, upon mild HU treatment, we found RPA2 hyper-phosphorylation to be in-
creased in CtIP-depleted cells when compared to control cells (Figure 4.8A). CHK1 phos-
phorylation on serine 345 was however largely unaffected by the knockdown of CtIP. In
contrast, and consistent with the literature, when DSBs were induced by treating cells
with CPT, RPA2 and CHK1 phosphorylations were decreased upon depletion of CtIP
confirming that the absence of CtIP impairs DNA-end resection of CPT-induced DSBs
[32]. By using a flow cytometry-based method to detect RPA retention on damaged chro-
matin [237], we further corroborated our previous finding, observing that the percent-
age of HU-induced RPA-positive cells was increased upon CtIP disruption (Figure 4.8B).
Correspondingly, the percentage of HU-induced γH2AX-positive cells was slightly but
reproducibly elevated in this assay. To more directly evaluate whether RPA2 hyper-
phosphorylation corresponded to the formation of ssDNA we immuno-stained bromod-
eoxyuridine (BrdU)-labeled cells with an anti-BrdU antibody. Consistently, the BrdU signal
was strikingly increased in response to HU following the knockdown of CtIP (Figure 4.8C).
Remarkably, U2OSCas9∆CtIP cells expressing only residual levels of CtIP displayed a sim-
ilar increase of RPA-coated ssDNA upon exposure to HU (Supplementary Figures 4.8A
and B). Consistent with our previous findings in HeLa cells transfected with siRNA tar-
geting CtIP, U2OSCas9∆CtIP cells exhibited no hypersensitivity towards HU-induced repli-
cation stress in terms of cell survival (Supplementary Figure 4.8C). However, in marked
contrast to cells transfected with siRNA against CtIP, we neither detected a substantial
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Figure 4.8: CtIP counteracts the formation of excess RPA-coated ssDNA in response to replica-
tion stress. (A) U2OS cells were transfected with the indicated siRNA for 48 h and were left untreated
or were incubated with either HU (2 mM) for 2 h or CPT (1 µM) for 1 h prior to harvest. Whole-cell
extracts were analysed by western blotting with the indicated antibodies. (B) Cells treated as in (A)
were harvested, permeabilized, fixed, immunostained with anti-RPA2 and anti-γH2AX antibodies and
analysed by FACS. Bottom panel: Dot plots represent the intensity of the signals for RPA2 or γH2AX
staining (y axis) against the DNA content (x axis). Quantification gates were established in untreated
samples transfected with siCtrl. The square marks the gate and shown are the percentages of HU
treated-cells contained in them. Upper panel: Percentages indicate mean ± s.e.m. of RPA2-positive
cells (n = 3). a. u. = arbitrary units. (C) Cells treated as in (A) were immunostained for BrdU to visu-
alize single-stranded DNA under non-denaturing conditions. (D) U2OS cells were transfected with the
indicated siRNAs for 48 h and were treated with HU (2 mM) for 2 h prior to harvest. Whole-cell extracts
were analysed by western blotting with the indicated antibodies. (E) DNA fiber analysis of U2OS cells
as in Figure 4.6D. DNA fibers were enumerated and the percentage of new origins (IdU-labeled only)
was quantified. Box plots indicate mean ± s.e.m. (n = 2).
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reduction in the levels of phosphorylated RPA2 nor significant hypersensitivity upon CPT-
treatment in U2OSCas9∆CtIP cells (Supplementary Figures 4.8A, B and C). These findings
suggest that even though low levels of CtIP are sufficient to maintain DNA-end resection
at CPT-induced DSBs, they are inadequate to perform CtIP functions during the response
to replication stress. Collectively, these data reveal that DNA damage in cells lacking CtIP
challenged by replication stress is characterized by increased ssDNA formation, a com-
mon intermediate at replication-associated DNA lesions. However, the question remained
how CtIP counteracts the generation of surplus levels of ssDNA in the face of replica-
tion stress. Excessive fork degradation by promiscuous nucleases such as MRE11 and
DNA2 that perform uncontrolled resection of stalled replication forks has recently been
described [78, 238]. Since several HR proteins, like Rad51 and BRCA1/2, have been
implicated in preventing uncontrolled nucleolytic resection of stalled forks [92, 94], it was
conceivable that CtIP might restrain the activity of a nuclease that, upon loss of CtIP
functions, unleashes its potent activity to excessively resect DNA in the vicinity of stalled
replication forks. However, neither co-depletion of MRE11, DNA2 nor EXO1 repressed
the HU-induced increase of phosphorylated RPA2 in cells lacking CtIP (Figure 4.8D).
Thus, we concluded that CtIP is not implicated in protecting stalled replication forks from
nucleolytic degradation. However, by conducting a DNA fiber assay, we determined that
CtIP-depleted cells showed a considerable increase in new origin firing in response to
HU-treatment (Figure 4.8E). This might indicate that the increase of ssDNA formation in
CtIP-deficient cells that are experiencing replication stress is likely caused by activating
of alternative origin firing.
In summary, we showed that CtIP functions to prevent the excessive generation of ss-
DNA, a toxic intermediate induced by replication stress. We furthermore found that the
negative effects of CtIP disruption on DNA replication are enhanced by simultaneous loss
of the BRCA1/BARD1 complex. We describe the identification of a SSL genetic interac-
tion between CtIP and BARD1 that is however not fully recapitulated by CtIP and BRCA1.
As an underlying cause for the synthetic sick phenotype, we propose the profound inabil-
ity to efficiently prevent and resolve replication stress in the absence of CtIP and BARD1.
From our analysis we concluded, that ablation of both proteins led to a severe increase
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of endogenous DNA lesions arising in the context of replication and ultimately to the
generation of DNA DSBs. Moreover, without BARD1 and CtIP, the HR pathway, address-
ing these lesions, was drastically impaired and consequently chromosomal aberrations
arose. Since an elevated incidence of chromosomal abnormalities would likely induce
programmed cell death, we inferred that this mechanism might contribute to the synthetic
sick phenotype of CtIP and BARD1 depletion.
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Supplementary Figure 4.4. (A) MRC5 cells were transfected with the indicated siRNAs for 48 h.
MRC5shCtIP cells were cultivated in the absence or presence of Dox (1 µg/ml) for 48 h. Cells were then
treated with the indicated doses of CPT. Cell survival was determined after 4 days using the CellTiter-
Blue® cell viability assay. Data represents the mean ± s.e.m. (n = 5). Whole-cell extracts of the
corresponding samples were analysed by western blotting. (B) U2OS cells were reverse transfected
with combinations of the indicated siRNAs in 96-well plates. The knockdown was allowed to persist for
6 days upon which survival was determined using the CellTiter-Blue® cell viability assay (Promega).
Data are presented as mean ± s.e.m. (n ≥ 2). Whole-cell extracts of the corresponding samples were
analysed by western blotting.
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Supplementary Figure 4.5. (A) U2OS cells were transfected with siRNA as in Figure 4.5A, and the
knockdown was allowed to persist for 48 h. Cells were then harvested and the induction of apoptosis
was determined by flow cytometric analysis. Annexin VFITC-positive staining indicates early apoptotic
cells whereas Annexin V-positive/PI-positive staining indicates late apoptotic cells. (B) U2OS cells were
transfected with the indicated siRNAs for five days, pulse-labelled with EdU and analysed by FACS.
Left panel: Dot plots represent the intensity of the signals for EdU (y axis) against the DNA content
(x axis). Quantification gates were established in samples transfected with siCtrl. Dashed line denotes
the threshold for EdU incorporation and percentage of cells with EdU intensities above the threshold
are indicated. Right panel: Representation of EdU intensities from 10 000 EdU-positive cells (n = 2).
Black bar indicates mean value. a. u. = arbitrary units.
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Supplementary Figure 4.6. (A) U2OS cells were transfected with the indicated siRNA as in Fig-
ure 4.6A. After 48 h of knockdown, cells were fixed, and immunofluorescence was performed with
anti-53BP1 along with DAPI staining. Box plots represent quantification of 53BP1 nuclear bodies per
nucleus. Black bars denote mean ± 95 % confidence interval, red circles the 90th percentile assessed
in at least 900 nuclei (n ≥ 3). Right panel: Whole-cell extracts of the corresponding samples from
this figure and Figure 4.6A were analysed by western blotting. (B) Representative images from cells
described in Figure 4.6B. (C) U2OSCas9WT and U2OSCas9∆CtIP cells were treated with 0.2 µM aphidicolin
(Aph) for 24 h, fixed and immunostained for 53BP1. Box plots represent quantification of 53BP1 nuclear
bodies per nucleus. Black bars denote mean ± 95 % confidence interval, red circles the 90th percentile
assessed in at least 600 nuclei (n = 2). Bottom panel: Frequency distribution of 53BP1 nuclear bodies
for each cell line. Upper left panel: Whole-cell extracts of the corresponding cell lines were analysed by
western blotting. (D) Representative images from DNA fibers described in Figure 4.6D.
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Supplementary Figure 4.7. (A) HeLa cells were transfected with the indicated siRNA. 48 h post-
transfection, cells were pre-treated for 15 min with 10 µM ATRi (where indicated) and then treated
with the indicated doses of HU. Survival was determined after 4 days using the CellTiter-Blue® cell
viability assay. Data are presented as mean ± s.e.m. (n ≥ 3). Whole-cell extracts of the corresponding
samples were analysed by western blotting. (B) U2OS cell lines containing a classical DNA repair
GFP-based reporter for HR were transfected with the indicated siRNAs and six hours later transfected
with the I-SceI expression plasmid and the exogenous GFP donor template. Cells were harvested
72 h after siRNA transfection and GFP-positive cells indicating HR repair activity were assessed by flow
cytometry. Data are presented as mean ± s.e.m. (n = 2). (C) Same cells as in (A) were treated with
the indicated doses of CPT. Survival was determined after 4 days using the CellTiter-Blue® cell viability
assay. Data are presented as mean± s.e.m. (n = 4). (D) U2OS cells were transfected with the indicated
siRNA. After 48 h of knockdown, total cell extracts (WCE) and chromatin-enriched fractions (Chromatin)
were prepared and analysed by immunoblotting using the indicated antibodies. (E) U2OS cells stably
expressing GFP-tagged CtIP were grown on coverslips and transfected with BARD1 siRNA for 48 h. For
the last 24 h cells were cultivated in the presence BrdU (10 µM) prior to laser micro-irradiation. 15 min
post irradiation, cells were fixed, immunostained for BARD1 and γH2AX and analysed by fluorescence
microscopy.
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Supplementary Figure 4.8. (A) U2OSCas9WT or U2OSCas9∆CtIP cells were either mock-treated, treated
with CPT (1 µM) for 1 h or with HU (2 mM) for 2 h prior to harvest. Whole-cell extracts were analysed
by western blotting. (B) Cells treated as in (A) were harvested, permeabilized, fixed, immunostained
with anti-RPA2 or anti-γH2AX antibodies and analysed by FACS. Dot plots represent the intensity of the
signals for RPA2 or γH2AX staining (y axis) against the DNA content (x axis). Quantification gates were
established in untreated samples of U2OSCas9WT. The square marks the gate and shows the percentage
of drug-treated cells contained in it. a. u. = arbitrary units. (C) U2OSCas9WT or U2OSCas9∆CtIP cells were
transfected with the indicated siRNA. 48 h post-transfection, cells were pre-treated for 15 min with 10 µM
ATRi (where indicated) and then treated with the indicated doses of HU or CPT. Survival was determined
after 4 days using the CellTiter-Blue® cell viability assay. Data are presented as mean ± s.e.m. (n ≥
3).
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The DDR is essential to safeguard genome integrity and to prevent malignant transfor-
mation. Human CtIP is most considerably recognized for its key role in the repair of DNA
DSBs by the HR pathway yet more recently, it has emerged as an important player in
genome stability maintenance beyond its role in DSB processing. In order to explore the
molecular network of CtIP and to provide insights into the organization of biological path-
ways which CtIP participates in, I investigated synthetic genetic interactions with CtIP.
Through multiplexed RNAi-based screening in the absence or presence of the DNA-
damaging agent CPT, I assessed genetic interactions with CtIP on the one hand and
genes conferring CPT hypersensitivity on the other hand. Analysis of the latter confirmed
a number of factors that had already been shown to mediate resistance towards CPT.
Unfortunately, we failed to uncover genes that had not previously been linked with the
DDR in this part of the screen and therefore refrained from further investigation.
However, our screen analysis revealed a number of interesting candidate genes for syn-
thetic sick/synthetic lethal (SSL) interactions with CtIP. One of our SSL candidate hits
was for example DNA polymerase θ (encoded by the POLQ gene), a protein implicated
in the error-prone microhomology-mediated end-joining (MMEJ) pathway of DSB repair.
Intriguingly, the absence of DNA polymerase θ was shown to enhance cell death in HR-
deficient cells in a publication that was issued after we had completed our screen [239],
thus confirming one of the SSL interactions we identified. In addition, our RNAi screen
uncovered a novel SSL genetic interaction between CtIP and BARD1. As part of my
PhD thesis, I demonstrate the importance for this interconnection during DNA replication
and the replication stress response. Remarkably, the negative genetic interaction be-
tween CtIP and BARD1 affects two components residing in a single protein complex. It
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has been previously reported that DDR pathways represent a hotspot for within-pathway
SSL interactions and that negative genetic interactions frequently connect components
of the same essential protein complex [228, 229]. Indeed, CtIP as well as BARD1 have
described to be essential for cell survival and their knockout in mice caused embryonic
lethality at day E4 and E7.5, respectively [100, 240]. Consistently, human cell lines lacking
CtIP or BARD1 have not been established to date. Subsequently, we sought to elucidate
the molecular mechanism underlying the SSL relationship between CtIP and BARD1.
From our analysis we propose that CtIP and BARD1 are involved in different aspects
of preventing and addressing endogenous DNA lesions arising in the context of DNA
replication stress.
CtIP has previously been proposed to associate with unperturbed replication forks to en-
sure replication fork progression and to prevent the formation of under-replicated regions
especially in the context of common fragile sites [95, 117, 121, 122]. CtIP was further-
more shown to act upon replication fork stalling by suppressing new origin firing and pro-
moting fork restart [121]. Here we find, that siRNA-mediated silencing of CtIP expression
causes accumulation of RPA-coated ssDNA in cells experiencing mild replication stress
induced by acute HU treatment. Importantly, ssDNA formation is a common intermediate
at replication-associated lesions [79, 216]. It may be caused by helicase and polymerase
uncoupling, by unscheduled origin firing or by uncontrolled fork resection by promiscu-
ous nucleases [54, 64, 78, 92]. RPA-coating shields stalled replication forks against fatal
breakage at regions of unprotected ssDNA and it was perceived that excessive ssDNA
generation may lead to exhaustion of cellular pools of RPA thus promoting irreversible
fork collapse [54]. However, here we show that RPA2 hyper-phosphorylation was rather
modest following HU treatment compared to its potent induction in response to the DSB-
inducing agent CPT. Thus, we assume that the amount of ssDNA generated after acute
exposure to mild doses of HU, though markedly increased upon CtIP depletion, is not suf-
ficient to exhaust the cellular RPA pool. In addition, we found that the ATR-CHK1 pathway
is functional in CtIP-deficient cells following replication stress. We furthermore sought to
determine the molecular mechanism responsible for the surplus formation of RPA-coated
ssDNA in CtIP-deficient cells treated with HU. Upon fork stalling, limited nucleolytic re-
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section allows RAD51-dependent HR to facilitate repair and restart of the blocked fork
[94]. However, promiscuous nucleases, such as MRE11 and DNA2 and possibly also
EXO1, have been described to perform uncontrolled resection of stalled replication forks
in the absence of proper control mechanisms [92, 238]. From our analysis, we could
not provide compelling evidence indicating that the increase in ssDNA in cells devoid of
CtIP was mediated by any of the three nucleases implicated in DNA resection, MRE11,
DNA2 or EXO1. Consistently, Yeo et al. [121] suggested that CtIP is dispensable for
protecting stalled replication forks from nucleolytic degradation. In line with this study, we
observed a substantial increase of new origin firing in the absence of CtIP representing
an alternative explanation for the increased generation of ssDNA in CtIP-deficient cells
encountering HU-induced replication stress. Interestingly, CtIP deficiency was not asso-
ciated with hypersensitivity to HU treatment. Hence, we concluded that RPA shielding
stabilizes and protects the ssDNA intermediates formed as a consequence of perturbed
DNA replication in cells lacking CtIP. We furthermore inferred that interference with repli-
cation fork progression may render CtIP-deficient cells susceptible to accumulating low
amounts of DNA lesions but their prevalence is not sufficient to impair cell survival. Con-
sistently, downregulation of CtIP in the absence of any exogenous treatments provoked
mild replication-associated DNA damage determined by a slight increase of γH2AX, an
elevated incidence of 53BP1 nuclear bodies and chromosomal aberrations. Conversely,
CtIP disruption was insufficient to affect G2/M checkpoint activation or apoptosis induction
significantly. Therefore, we assume that cells lacking CtIP can survive in the presence of
mild replication stress associated with few DNA lesions.
BARD1, on the other hand, had not been studied yet in the context of DNA replication or
in the response to replication stress. However, evidence for the presence of BARD1 at
the replication fork was recently presented in a study by Dungrawala et al. which identi-
fied BARD1 alongside its heterodimeric partner BRCA1 at HU-stalled forks by using an
iPond-SILAC-approach coupled with mass spectrometry [95]. For the first time, here,
we investigated the functional consequences of BARD1 disruption on DNA replication.
Intriguingly, we observed an unexpected cell cycle response indicating that BARD1 is re-
quired for G2/M transition in otherwise unperturbed cells. Moreover, siRNA-mediated de-
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pletion of BARD1 alone activated the DDR involving elevated levels of γH2AX and 53BP1
nuclear bodies, and the generation of chromosomal aberrations. Furthermore, cells lack-
ing BARD1 displayed modest but significant hypersensitivity towards HU, indicating that
BARD1 counteracts replication-associated DNA damage. Thus, we propose that not
only BRCA1 but also its obligate binding partner BARD1 possesses important functions
in safeguarding genome integrity by promoting faithful DNA replication. It is, however,
important to note, that siRNA-mediated knockdown of BARD1 destabilized BRCA1 con-
siderably. Thus, we cannot rule out that the phenotypes described here are in fact me-
diated at least in part by a function associated with BRCA1/BARD1 heterodimerization.
To dissect the details of individual contributions of either BARD1 or BRCA1 on promoting
faithful DNA replication would be very challenging and was therefore beyond the scope
of this work.
Remarkably, we found that co-depletion of BARD1 and CtIP did not only cause a syn-
thetic sick growth defect but was also accompanied by a synergistic increase of endoge-
nous DDR activation at early time points. Even though the induction of apoptotic cell
death as well as of H2AX phosphorylation was already notable upon downregulation of
BARD1 alone, both phenotypes were significantly augmented upon simultaneous disrup-
tion of CtIP. As the increase in γH2AX occurred predominantly in the G2/M population of
cells co-depleted for CtIP and BARD1 and was accompanied by an accumulation of cells
arresting in the G2/M phase of the cell cycle, we reasoned that cells lacking CtIP and
BARD1 might have problems to accurately complete replication during S phase. In sup-
port of this notion, CtIP/BARD1-deficient cells displayed an additive increase in sister fork
asymmetry during recovery from exposure to HU, implying that CtIP and BARD1 might
cooperate to counteract replication fork stalling. To further investigate the hypothesis that
CtIP and BARD1 promote faithful DNA replication, we monitored the prevalence of 53BP1
nuclear bodies, which have recently been shown to form in regions of under-replicated
DNA and are primarily observed in cells that have experienced replication stress in the
previous S phase [83, 84]. Intriguingly, upon co-depletion of CtIP/BARD1 we observed
a striking synergistic increase in 53BP1 nuclear bodies potentially marking chromosomal
loci with unresolved replication stress. Even though the type of DNA lesion accountable
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for 53BP1 accumulation on chromatin following replication stress has not been deter-
mined to date, it is worth noting that DSBs were suggested to contribute to their genesis
[83]. In support of this hypothesis, we demonstrated that simultaneous downregulation of
CtIP and BARD1 induced the activation of ATM in an additive manner. Thus, we postu-
lated that 53BP1 nuclear bodies stemming originally from replication impediments could
partly denote sites of DNA DSBs. Interestingly, in this context 53BP1 has been shown
to associate in nuclear foci at DSBs upon induction of severe DNA damage [142]. Thus,
53BP1 bodies might also indicate sites of DNA rupture and persisting DSBs. This notion
was further strengthened by the finding that CtIP and BARD1 deficiency caused an addi-
tive increase in chromosomal aberrations, particularly chromatid breaks, fragments and
a few chromosome fusions [233], which can form upon mitotic chromosome breakage
or if DSBs are not faithfully repaired [19, 241]. Taken together, we concluded that CtIP
and BARD1 cooperate to counteract the formation of DSBs stemming from aberrantly
resolved replication-associated DNA lesions.
Nevertheless, it remained possible that a higher frequency of fork collapse might be the
source for the elevated incidence of DSBs in cells lacking CtIP and/or BARD1. We specif-
ically addressed this question and found that depletion of neither CtIP nor BARD1 alone
or in combination caused the formation of DSBs in newly replicated DNA following HU-
treatment. Thus, DSBs are likely generated by other mechanisms than fork collapse. No-
tably, a previous study suggested that constitutive activation of the ATM-CHK2 pathway
can occur in a DSB-independent manner in cells displaying elevated rates of endoge-
nous replication fork stalling due to the absence of the BLM helicase [242]. However, we
reasoned that DSB induction should be a prerequisite for the chromosomal aberrations
observed upon CtIP/BARD1 co-depletion. Interestingly, recent data specified that 53BP1
nuclear bodies predominantly indicate sites of unresolved or broken anaphase bridges
[85] supporting the notion that DSBs might rather arise from persisting, toxic replication
intermediates. Following this rationale, we determined that DSBs, once formed, could not
be addressed by the HR pathway due to its impairment in the absence of BARD1 and
CtIP. We thus inferred that error-free, HR-mediated dissolution of 53BP1 nuclear bodies
during subsequent S and G2 phases of the cell cycle was compromised in cells lacking
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CtIP and BARD1 and as a consequence, deleterious DNA lesions such as DSBs might
therefore persist.
In this context it is important to note, that 53BP1 might shield damaged chromatin from
deleterious consequences of un- or mis-repaired DNA breaks in a mechanism analo-
gous to the one proposed by Toledo et al. [54]. In case DNA lesions accumulate and
sequester all available 53BP1, every new round of replication would potentially gener-
ate additional regions of under-replicated DNA and might ensue further DNA breakage.
Moreover, it is tempting to speculate that in cells devoid of CtIP and BARD1, DNA breaks
could become an inappropriate substrate for error-prone repair mechanisms like NHEJ
due to the impairment of HR. In fact, it is well established that association of 53BP1
with DSBs promotes NHEJ [30, 243]. Hence, the resulting incidence of chromosomal
breaks and rearrangements could hardly be compatible with cell survival and might serve
as an explanation for the synthetic sick phenotype observed between CtIP and BARD1.
Moreover, unresolved replication intermediates can occasionally manifest in anaphase
bridges, chromosome breakage and mis-segregation giving rise to cell division defects
such as micronuclei [241, 244]. Consistently, we also noticed a considerable increase
of micronuclei formation upon either CtIP or BARD1 disruption and upon co-depletion of
both factors.
Collectively, in my PhD thesis I propose that CtIP and BARD1 functions are intercon-
nected through a synthetic sick genetic interaction. In the absence of BARD1 and CtIP,
disproportionate levels of endogenous DNA lesions arise in the context of replication and
cannot be appropriately addressed due to simultaneous dysfunction of the HR pathway.
Our data is consistent with the hypothesis that endogenous DNA damage can conceiv-
ably arise as a result of enhanced replication stress increasing the level of DNA breakage
and chromosomal aberrations [87]. Importantly, if DNA damage exceeds the repair ca-
pacity, programmed cell death would be initiated. In rare cases however, such aberrations
may escape from cell surveillance pathways and contribute to mutagenesis and malignant
transformation.
The evidence presented here underlines the essential role of HR for counteracting en-
dogenous DNA damage in order to protect cells against spontaneous chromosome in-
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stability. A critical function in mediating HR has been ascribed to the BRCA1/BARD1
heterodimer [138, 144]. Subsequently, it was established that CtIP interacts with BRCA1
and initially this interactions was implicated in facilitating DNA-end resection [172, 173].
However, recent findings have challenged the significance of the CtIP-BRCA1 interac-
tion as it was demonstrated that complex formation with BRCA1 is dispensable for CtIP-
mediated DNA end-resection and HR [175–177]. Furthermore, several studies have un-
covered novel roles in preserving the integrity of DNA replication forks particularly for
BRCA1 [92, 181, 183], whereas the significance of its obligate interaction partner BARD1
in these processes was often overlooked. Here, we reveal that CtIP genetically and phys-
ically interacts with BARD1 to cooperate in promoting faithful DNA replication. Thus, we
uncovered a previously uncharacterized role of the CtIP–BARD1/BRCA1 protein network
for combating replication stress, genome instability and hence the development of cancer.
Moreover, important implications for the tumour suppressive role of CtIP emerge from our
study. It was already proposed by Bartek et al. in 2007, that dosage insufficiencies of
DNA repair genes might only be unmasked once a cell is challenged with an increased
load of DNA damage such as replicative stress induced by pre-cancerous lesions [245].
Further support for this important concept emerged when it was discovered that primary
mammary epithelial cells from patients with heterozygous BRCA1 mutations experience
higher loads of replication stress while other BRCA1 functions, such as promoting HR, re-
mained unaltered [184]. Hence, the authors of this study concluded that the proficiency to
respond to replication fork stalling might be the limiting factor in BRCA1 genome integrity
control. Similar results were obtained in cells lacking the BLM helicase and it was found
that the deficiency of BLM likely generates enhanced replication stress similar to the sit-
uation in pre-cancerous tissues [242]. By using the CRISPR/Cas9 technology, here, we
demonstrate that expression of diminished levels of CtIP also contributes to a phenotype
of mild but persistent replication stress that may dampen cell surveillance mechanisms
but can ultimately cause increased chromosomal aberrations. Hence, consequences of
reduced CtIP expression might potentially provoke genomic instability and tumour sus-
ceptibility. Our novel findings therefore underscore the importance of CtIP as one of the
HR proteins with a crucial role in combating situations of elevated endogenous replication
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stress thus elucidating further details of the significance of CtIP for tumour suppression.
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Abstract
Genomic instability, a hallmark of almost all human can-
cers, drives both carcinogenesis and resistance to thera-
peutic interventions. Pivotal to the ability of a cell to main-
tain genome integrity are mechanisms that signal and repair
deoxyribonucleic acid (DNA) double-strand breaks
(DSBs), one of the most deleterious lesions induced by ion-
ising radiation and various DNA-damaging chemicals. On
the other hand, many current therapeutic regimens that ef-
fectively kill cancer cells are based on the induction of ex-
cessive DSBs. However, these drugs often lack selectivity
for tumour cells, which results in severe side effects for
the patients, thus compromising their therapeutic potential.
Therefore, the development of novel tumour-specific treat-
ment strategies is required.
Unlike normal cells, however, cancer cells are often char-
acterised by abnormalities in the DNA damage response in-
cluding defects in cell cycle checkpoints and/or DNA re-
pair, rendering them particularly sensitive to the induction
of DSBs. Therefore, new anticancer agents designed to ex-
ploit these vulnerabilities are becoming promising drugs
for enhancing the specificity and efficacy of future cancer
therapies. Here, we summarise the latest preclinical and
clinical developments in cancer therapy based on the cur-
rent knowledge of DSB signalling and repair, with a special
focus on the combination of small molecule inhibitors with
synthetic lethality approaches.
Key words: genomic instability; DNA damage response;
DNA repair; cancer therapy; small molecule inhibitors;
synthetic lethality
Introduction
Cancer is the major cause of death in Switzerland among
people aged 45–84 years [1]. The latest Swiss cancer stat-
istics indicate that prostate cancer in men and breast cancer
in women are the most common types, with 6,000 and
5,500 incidences per year, respectively. Notably, lung can-
cer is still the leading cause of cancer-related death in
the Swiss population, accounting for approximately 3,000
deaths each year [2].
Almost all human cancers are characterised by genomic
instability, which is considered to play a key role in the
conversion of a normal cell into a premalignant cell [3].
Mechanisms contributing to genomic instability include
aberrant repair of deoxyribonucleic acid (DNA) lesions as
well as defective signalling to cell-cycle checkpoints and
induction of apoptosis. Damaging agents, emanating from
endogenous and environmental sources such as oxidative
stress and ultraviolet (UV) radiation, constantly challenge
the integrity of DNA. Remarkably, spontaneous DNA dam-
age, mostly hydrolytic cytosine deamination and oxidative
DNA base damage, occurs at a rate of up to 105 lesions per
cell per day [4, 5].
In order to counteract these insults and preserve genome
stability, cells activate a coordinated signal-transduction
network, which is collectively known as the DNA damage
response (DDR). Generally, this response consists of a
series of events such as detection of the DNA damage by
sensors, accumulation of repair factors by mediators and
repair of the lesion by effectors [6]. Cells are equipped with
a variety of distinct, but partially compensatory, DNA re-
pair mechanisms, each addressing a specific type of lesion
[5]. DNA double-strand breaks (DSBs) are considered to
be the most hazardous lesions, since a single unrepaired
DSB may trigger cell death whereas a misrepaired DSB
potentially results in mutations such as chromosomal re-
arrangements, which can promote carcinogenesis. There-
fore, activation of cell-cycle checkpoints and faithful repair
in response to DSBs are a primary barrier to malignant
transformation.
The fact that DSBs are highly cytotoxic is exploited in
conventional cancer treatment with radiation therapy and
certain chemotherapeutic drugs such as DNA crosslinkers
and topoisomerase inhibitors. Although those agents in-
duce DSBs in all cells, hyperproliferating cancer cells are
much more susceptible to killing than normal cells.
However, most of these well-established treatments cause
a number of adverse effects, mainly by affecting the fast-
dividing cells of the patient, such as haematopoietic stem
cells, hair follicles and cells lining the stomach and intest-
ines. Therefore, novel strategies to treat cancer are eagerly
anticipated and the subject of extensive research.
In this review, we summarise how DSB repair and its ge-
netic interactions have emerged as targets for improved
cancer treatment strategies in the recent past. We also high-
light the current knowledge of small molecule inhibitors
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(SMIs) of DSB signalling and repair factors, which are
promising candidates for clinical use. For a comprehensive
overview of targeting DDR pathways for cancer therapy,
we direct the reader to recently published reviews [7–9].
DNA damage response
The DDR is a multifaceted signalling network, which is eli-
cited upon detection of DNA lesions in order to coordinate
the cell cycle, DNA repair and possibly senescence or ap-
optosis (fig. 1). Three members of the phosphatidylinosit-
ol-3-kinase (PI3K) related kinases (PIKKs) ‒ ATM (ataxia
telangiectasia mutated), ATR (ATM- and Rad3-related) and
DNA-PKcs (DNA-dependent protein kinase catalytic sub-
unit) ‒ become activated upon DNA damage to trigger the
DDR [10]. Through a cascade of phosphorylation events,
ATM and ATR activate multiple proteins, most notably p53
and the downstream checkpoint kinases CHK1 and CHK2,
which in turn phosphorylate WEE1 kinase and CDC25
phosphatases. Consequently, through regulating the activ-
ity of cyclin-dependent kinases (CDKs), the progression
from one cell cycle phase to another is delayed [11].
Depending on which CDK is inhibited; the cell cycle is ar-
rested either at the G1/S or the G2/M transition. The res-
ulting cell-cycle arrest allows time for repair, thereby pre-
venting genome duplication or cell division in the presence
of damaged DNA. Thus, cells with an abrogated DDR gen-
erally display an increased sensitivity towards DNA-dam-
aging agents.
DNA repair pathways
Depending on the type of DNA damage, cells invoke spe-
cific DNA repair pathways in order to restore the genetic
information (see fig. 1). Briefly, minor changes to DNA
such as oxidised or alkylated bases, small base adducts
and single-strand breaks (SSBs) are restored by the base
excision repair (BER) pathway [4]. A key player in this
process is poly-adenosine-diphosphate-ribose (PAR) poly-
merase (PARP). Upon detection of SSBs, PARP covalently
transfers PAR chains to itself and to acceptor proteins in
the vicinity of the lesion, thereby facilitating the repair of
SSBs. More complex, DNA helix-distorting base lesions,
such as those induced by UV light, are repaired by nuc-
leotide excision repair (NER) [5]. Another kind of dam-
age disturbing the helical structure of DNA is represented
by base mismatches. Mismatch repair factors recognise and
process misincorporated nucleotides as well as insertion or
deletion loops that arise during recombination or from er-
rors of DNA polymerases [12]. Covalent links between the
two strands of the double helix represent a type of DNA
damage referred to as interstrand crosslinks (ICLs). ICLs
represent the most deleterious lesions produced by chemo-
therapeutic agents such as mitomycin C (MMC), cisplat-
in and cyclophosphamide. ICL repair is complex and in-
volves the collaboration of several repair pathways, namely
Fanconi anaemia, NER, translesion synthesis and homo-
logous recombination (HR) [13].
DNA double-strand break repair
Thus far, four mechanistically distinct DSB repair mechan-
isms in mammalian cells have been described: nonhomo-
logous end joining (NHEJ), alternative-NHEJ, single-
strand annealing and HR [14]. NHEJ and HR represent
the two major DSB repair pathways, with NHEJ operating
throughout the cell cycle and HR being most active during
S-phase (fig. 2) [15]. NHEJ starts with the binding of the
Ku70/80 heterodimer to both ends of the break, followed
by the recruitment of the catalytic subunit of DNA-depend-
ent protein kinase (DNA-PKcs). Subsequent phosphoryla-
tion events mediated by the DNA-PK holoenzyme lead to
appropriate DNA end processing by the Artemis nuclease.
DSB repair by NHEJ is completed by rejoining of the ends
Figure 1
The DNA damage response.
Exogenous and endogenous DNA damaging agents generate various types of lesions
including DNA single- and double-strand breaks (SSBs and DSBs). The multifunctional
MRN complex detects DSBs, while FANCM is required for the DNA interstrand crosslink
(ICL)-induced checkpoint response. PARP predominantly acts as a SSB sensor protein.
RPA binds to regions of single-stranded DNA (ssDNA) that are exposed at stalled
replication forks or after DSB resection. MRN and RPA mediate the recruitment of ATM
and ATR-ATRIP, respectively, and the subsequent activation of the respective pathways,
coordinating cell-cycle checkpoints, DNA repair and apoptotic responses to DNA damage.
The Ku70/Ku80 heterodimer (KU) competes with MRN for binding to DSBs. KU recruits
DNA-PKcs to form the catalytically active DNA-PK holoenzyme which is a major
component of the canonical NHEJ machinery during DSB repair. MRN on the other hand
initiates HR (see also fig. 2). Once activated, the DNA damage signalling cascade
extends through multiple phosphorylation events primarily via the cell-cycle checkpoint
kinases CHK1 and CHK2. Their signals converge on downstream effectors such as the
tumour suppressor protein p53 or the CDC25 protein phosphatase and WEE1 tyrosine
kinase. As a result, CDK activity is inhibited, delaying cell cycle progression from G1 to S
(the G1/S checkpoint) or from G2 to M phase (the G2/M checkpoint). The DNA damage
response (DDR) thus orchestrates a variety of cellular outcomes: the transcriptional programme of the damaged cell is altered and the cell
cycle is transiently arrested, thereby facilitating repair of the DNA lesions. In situations where DNA damage is too severe and cannot be
repaired, the DDR triggers apoptosis or senescence.
ADP = adenosine diphosphate; ATM = ataxia telangiectasia mutated protein; ATR = ATM- and Rad3-related; ATRIP = ATR-interacting protein;
CDK = cyclin-dependeant kinase; DNA = deoxyribonucleic acid; DNA-PK = DNA-dependeant protein kinase; DNA-PKcs = DNA-PK catalytic
subunit; FANCM = Fanconi anaemia complementation group M; HR = homologous recombination; ICL = interstrand crosslink; MRN =
MRE11-RAD50-NBS1 complex; NEHJ = nonhomologous end joining; PARP = poly(ADP-ribose) polymerase; RPA = replication protein A
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catalysed by a complex consisting of X-ray repair cross-
complementing protein 4 (XRCC4), XRCC4-like factor
(XLF) and DNA ligase IV. HR takes over if NHEJ is
unsuccessful in ligating the broken DNA ends or when
the DSB is first recognised by the MRE11-RAD50-NBS1
(MRN) complex rather than by Ku70/80 [16]. Together
with CtBP-interacting protein (CtIP; CtBP = C-terminal
binding protein), MRN resects DSBs to generate short 3'-
single-stranded-DNA (ssDNA) tails that get immediately
coated with replication protein A (RPA) [17]. The
BRCA2-PALB2 complex promotes RAD51 nucleation
onto ssDNA, thereby replacing RPA. The RAD51 nucleo-
protein filament then invades the homologous, intact DNA
template forming a displacement loop. The second end of
the broken chromosome is captured and anneals to the
complementary strand of the donor DNA molecule, result-
ing in the formation of two Holliday junctions (HJs). After
DNA synthesis and ligation of both strands, the double HJ
is either dissolved or is dismantled by the catalytic action
of resolvases in order to complete repair [18]. Thus, re-
pair by HR is error-free since it copies the missing genetic
information from the undamaged sister chromatid, where-
as NHEJ is error-prone since DNA ends without sequence
homology are religated with the risk of causing mutations
[19]. Given that a single unrepaired DSB has the potential
to kill a cell, inhibition of repair by compounds that target
factors involved in NHEJ or HR will increase the sensitiv-
ity of cancer cells to DSB-inducing anticancer agents.
Harnessing DNA damage signalling
and repair for cancer therapy
The fact that cells with a compromised DDR are hypersens-
itive to DNA damage-inducing agents is currently under
vigorous investigation for use in targeted cancer therapy.
More precisely, during their pathogenesis, many cancer
cells acquire defects in a certain DNA repair pathway and
become dependent on a compensatory mechanism in or-
der to survive. Hence, pharmacological inhibition of the
“backup” pathway in combination with DNA damage will
selectively kill cancer cells but spare their normal counter-
parts. Furthermore, highly proliferative cancer cells are in-
herently hypersensitive to DNA damage because S-phase,
in which DNA replication takes place, is the most vulner-
able period of the cell cycle.
Targeting DSB signalling pathways
As previously mentioned, cell-cycle checkpoint activation
in response to DSBs gives a cell time for DNA repair be-
fore entry into S-phase or mitosis. Consequently, cell-cycle
checkpoints reduce the efficacy of DNA-damaging agents
used in cancer therapy. Therefore, selective abrogation of
checkpoint signalling sensitises cancer cells to chemo- and
radio-therapy, potentiating cancer treatment [20]. Import-
antly, more than 50% of human tumours are defective in
p53 tumour suppressor function and cell-cycle checkpoint
inhibitors have been demonstrated particularly to sensitise
p53-deficient cancer cells to various anticancer agents in
clinical use [21].
In the late 1960s, long before the discovery of cell-cycle
checkpoints, the first attempts to sensitise cancer cells to
standard cytotoxic therapy were made using ordinary com-
pounds such as caffeine [22]. Later it was found that caf-
feine directly binds to and inhibits ATM and ATR in vitro
and thus interferes with initiation of the DDR [23, 24].
However, since caffeine is a relatively nonselective agent,
efforts have been made to develop more potent and se-
lective inhibitors of the PIKK family members ATM, ATR
and DNA-PKcs (table 1). In 2004, KuDOS Pharmaceut-
icals (now AstraZeneca) reported the identification of
KU-55933, a specific SMI of ATM [25]. On the molecular
level, KU-55933, like most kinase inhibitors, competes
with the ATP-binding site of the enzyme, thereby inhibiting
the catalytic activity of ATM [26]. Based on the promising
preclinical results, KU-60019, a KU-55933 analogue with
Figure 2
DNA double-strand break (DSB) repair.
DSBs are predominantly repaired by two distinct pathways: NHEJ
or HR. NHEJ operates throughout the cell cycle, but mainly during
the G1 and G2 phases, whereas HR peaks in S phase. Rapid
association of the Ku70/80 heterodimer to DSBs promotes NHEJ
by recruiting DNA-PKcs. DNA ends are processed by the
nucleolytic activity of Artemis, followed by religation catalysed by a
complex of XLF, Ligase IV (Lig4) and XRCC4. Alternatively, MRN,
which is initially recruited to DSBs in competition with Ku70/80,
initiates DSB resection together with CtIP thereby promoting HR.
53BP1 antagonises BRCA1 in DSB resection. Extensive DSB
resection by other nucleases and formation of RPA-coated ssDNA
stimulates the activation of ATR. Displacement of RPA by RAD51 is
mediated by BRCA2 and PALB2, resulting in the formation of
RAD51 nucleoprotein filaments. Subsequent strand invasion into
the homologous DNA template and capturing of the second DNA
end leads to the formation of a double Holliday junction, which is
processed by resolvases. Finally, the DNA is sealed by ligases to
accomplish error-free repair of the DSB.
53BP = p53 binding protein; ATM = ataxia telangiectasia mutated
protein; CtBP = C-terminal binding protein; CtIP = CtBP-interacting
protein; DNA = deoxyribonucleic acid; DNA-PK = DNA-dependent
protein kinase; DNA-PKcs = DNA-PK catalytic subunit; HR =
homologous recombination; MRN = MRE11-RAD50-NBS1
complex; NHEJ = nonhomologous end joining; PALB1/2 = partner
and localiser of BRCA1/2; RPA = replication protein A; ssDNA =
single-stranded DNA; XLF = XRCC4-like factor; XRCC4 = X-ray
repair cross-complementing protein 4
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improved pharmacokinetics and bioavailability, was syn-
thesised and shown to radiosensitise glioma cells approx-
imately 10 times more efficiently than KU-55933 [27].
Compounds selectively targeting ATR have long been
awaited, particularly when inhibitors of CHK1, a direct
downstream target of ATR, had proven to be clinically
effective [28]. Finally, in 2011, three ATR inhibitors,
NU-6027, VE-821 and ETP-46464 were described.
NU-6027 is a pyrimidine analogue originally discovered
as an adenosine triphosphate (ATP) competitive inhibitor
of CDKs, but recently reported also to inhibit ATR at low
micromolar concentrations and to confer cisplatin cytotox-
icity independently of CDK inhibition [29, 30]. The ATR
inhibitor VE-821 (Vertex Pharmaceuticals) was identified
using a high-throughput screen against full-length recom-
binant ATR [31]. Preclinical testing of VE-821 using pan-
creatic cancer cells demonstrated its chemo- and radio-
sensitisation properties [32]. ETP-46464 was discovered
by screening compounds with a previously reported activ-
ity against the related PI3Ks using a cell-based system as-
saying for ATR activity [33]. In the same study, NVP-
BEZ235, a recognised dual PI3K/mTOR inhibitor (mTOR
= mammalian target of rapamycin), was also reported to
block efficiently ATM, ATR and DNA-PK activity. Fur-
thermore, NVP-BEZ235 was found to act as a radio- and
chemo-sensitiser in various cancer cell lines and is cur-
rently being tested as a single agent in various Phase I/II
clinical trials [34, 35]. Importantly, most, if not all, of the
aforementioned compounds are likely to inhibit additional
protein kinases, especially when used at concentrations in
the high micromolar range, thus potentially exhibiting “off-
target” effects.
Downstream of ATM and ATR act the two transducer
kinases CHK1 and CHK2, against which several inhibitors
have emerged during recent years. One of the first SMIs,
UCN-01, a derivative of staurosporine, was originally isol-
ated from a Streptomyces strain as a protein kinase antag-
onist with cytotoxic effects [36]. UCN-01 was later shown
to be a potent inhibitor of CHK1 and to block its kinase
activity by interacting with the ATP-binding pocket [37,
38]. Six Phase II clinical trials of UCN-01, either as a
single agent or in combination with other drugs, in patients
with different types of advanced cancer have already been
completed. Recently, three novel CHK1 inhibitors,
GDC-0425 (Genentech Inc.), SCH900776 (now renamed
MK-8776, Merck) and LY-2606368 (Eli Lilly), have
entered Phase I clinical trials either as single agents or in
combination with gemcitabine, a nucleoside analogue [39].
Another promising drug that interferes with checkpoint ac-
tivation is the WEE1 tyrosine kinase inhibitor MK-1775
(Merck), which was discovered by screening a chemical
library [40]. MK-1775 is already under investigation in a
Phase II trial combined with carboplatin in order to assess
the benefit for patients with p53-mutated epithelial ovarian
cancer. Last but not least, efforts to target CDC25 phos-
phatases, which also represent key molecules in checkpoint
regulation, led to the discovery of several CDC25 inhib-
itors, amongst which the most potent are quinonoid-based
derivatives such as the bis-quinone compound IRC-08386
[41, 42].
In summary, several SMIs that interfere with checkpoint
activation show great promise of advancing in clinical
studies and eventually being used as chemo- or radio-sens-
itisers as well as monotherapeutic agents in cancer treat-
ment. Nevertheless, since many of the SMIs have only very
recently been discovered, their safety, tolerability and ef-
ficacy when used alone or in combination has to be further
investigated.
Targeting DSB repair
Impairing the repair of DSBs using drugs that either inhibit
the enzymatic activity or interfere with protein-protein in-
teractions of repair factors provides another approach to
sensitising cancer cells for chemo- and radio-therapy. A
key player in DSB repair by NHEJ is DNA-PK (see fig. 1),
which, like ATM and ATR, belongs to the PIKK family of
protein kinases. In 2003, two DNA-PKcs-specific inhibit-
ors, NU-7026 and NU-7441, were reported, both of which
are practically inactive against ATM and ATR [43, 44]. Un-
fortunately, neither of them has progressed into clinical de-
velopment. However, Celgene Corporation is currently re-
cruiting patients with advanced tumours unresponsive to
standard therapies in order to test the pharmacokinetics and
preliminary efficacy of the dual DNA-PK/mTOR inhibit-
or, CC-115, in a Phase I trial. Moreover, a very recent
preclinical study reported that KU-60648 (AstraZeneca),
a dual inhibitor of DNA-PK and PI3K, acts as a chemo-
sensitiser in cell-based assays and in mice xenografts [45].
More recent attempts to find novel DSB repair inhibitors
led to the identification of mirin, the first inhibitor of the
MRN complex that acts by blocking the nuclease activity
of MRE11 [46]. Interestingly, mirin was shown to kill
BRCA2-deficient cells, an effect that was even more pro-
nounced when combined with a PARP inhibitor [47].
However, since mirin has to be applied at high micromolar
concentrations to inhibit MRN, such treatment is prone to
increase the risks of undesired “off-target” effects and the
generation of more selective derivatives is eagerly anticip-
ated.
During the course of DSB repair by HR, ssDNA is gen-
erated and immediately coated by RPA, which later on is
replaced by the RAD51 recombinase (see fig. 2). Inhibit-
ing the DNA-binding activity of RPA by the SMI MCI13E
yielded encouraging preclinical results in combination with
cisplatin [48]. Moreover, several means to prevent RAD51
action have been reported, including SMIs (B02, RI-1) as
well as inhibitory peptides that interfere with the binding
of BRCA2 to RAD51 [49–52]. Although peptides blocking
protein-protein interactions represent an interesting
concept for inhibiting DSB repair, their potential applica-
tion in the clinics has yet to be established.
In summary, safety, tolerability, pharmacokinetics and ef-
ficacy of most of the aforementioned SMIs have still to be
carefully validated before they may enter clinical trials to
examine their benefit for cancer therapy.
Synthetic lethality approaches to
target DSB repair-deficient cancers
Mutations in DSB repair genes render cancer cells depend-
ent on alternative DNA repair pathways. Thus, comprom-
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ised abilities to repair DSBs confer a weakness that can be
therapeutically exploited on the basis of the concept of syn-
thetic lethality, whereby inhibition of the “back-up” path-
way induces greater toxicity in DSB repair-deficient cancer
cells as compared with normal cells (fig. 3).
PARP inhibitors
The first “proof-of-principle” study verifying synthetic
lethality as a suitable approach for targeted cancer therapy
was published in 2005, after it had been demonstrated that
HR-defective BRCA1- or BRCA2-deficient cell lines dis-
play dramatically increased sensitivity to inhibition of the
SSB repair enzyme PARP [53, 54]. Subsequently, clinical
development of potent small molecule PARP inhibitors
(PARPis) rapidly advanced, and the first Phase II results
in 2009 showed that monotherapy with the PARPi olaparib
(AZD-2281; AstraZeneca) achieved encouraging response
rates of 41% and 33% in patients with BRCA1- or
BRCA2-mutated advanced breast and ovarian cancers, re-
spectively [55, 56]. Furthermore, preclinical studies sug-
gested the potential use of PARPi also in sporadic cancers
that share phenotypical features with cancers arising from
hereditary BRCA mutations, a phenomenon that is referred
to as “BRCAness” [57]. Reasons for “BRCAness” can be
the inactivation of BRCA1 or BRCA2 function caused by
aberrant epigenetic or posttranslational modifications, or a
wider range of mutations in other genes resulting in de-
fective DSB signalling and HR. For example, it was repor-
ted that depletion of factors such as ATR, ATM, CHK1,
CHK2, NBS1, CtIP and RAD51 in cultured cells syner-
gistically increases PARPi cytotoxicity to an extent similar
to mutations in BRCA1/2. This indicates that BRCA-defi-
cient cells are, at least in part, sensitive to PARP inhibi-
tion because of a defect in HR [58, 59]. The current un-
derstanding suggests that inhibition of PARP leads to the
accumulation of SSBs which are converted into DSBs upon
encountering DNA replication forks during S-phase when
HR is most active [60]. Consequently, in the absence of
functional HR, such as in cancer cells lacking BRCA1 or
BRCA2, PARP inhibition results in the accumulation of
DSBs and, ultimately, in apoptosis or mitotic catastrophe.
Importantly, normal cells survive the treatment owing to
functional HR, providing the kind of selectivity that is con-
sidered the ultimate goal of cancer therapy. Nowadays,
most PARPi in preclinical and clinical trials belong to the
third generation of SMIs designed to compete with the
substrate nicotine adenine dinucleotide (NAD+) resulting
in reversible inhibition of PARP. Recent reports indicate
that in addition to catalytic inhibition, some PARPi induce
cytotoxic PARP–DNA complexes, trapping PARP proteins
on damaged DNA. Currently, PARPi are divided into two
classes: catalytic inhibitors and dual inhibitors that not only
block the enzymatic activity but also act as so-called PARP
“poisons” [61, 62].
Today, 7 years after PARPi were first established for cancer
therapy and despite some quite promising clinical studies,
none of them has gained official approval for the treatment
of cancer patients. In 2011, encouraging results from a
Table 1: Small molecule inhibitors of DNA damage response factors in preclinical or clinical development for cancer therapy.
Target Inhibitor Mono- or combination therapy / clinical study stage Clinical trial identifier/
reference
KU-55933 IR, etoposide, doxorubicin, camptothecin, in preclinical testing [25, 95]ATM
KU-60019 IR in preclinical testing using glioma cells [27]
NU-6027 Hydroxyurea, cisplatin, temozolomide, rucaparib in preclinical testing [29]
VE-821 Cisplatin in breast and ovarian cell lines
IR, gemcitabine in pancreatic cancer cells in preclinical testing
[31, 96]
[32]
ATR
ETP-46464 Single agent in p53-deficient cancer cells in preclinical testing [33]
NU-7441 IR, etoposide in preclinical testing of cancer cell lines and tumour xenografts [44, 97]DNA-PKcs
NU-7026 IR and combined with AG14361 (PARPi) in preclinical testing
Anthracyclines, mitoxantrone, etoposide in preclinical testing using leukaemia cells
[43]
[98]
DNA-PKcs/PI3K KU-60648 Etoposide, doxorubicin in preclinical testing [45]
DNA-PKcs/mTOR CC-115 Single agent in Phase I safety and tolerability study (recruiting) NCT01353625
PI3K/mTOR/PIKK NVP-BEZ235 Single agent in several clinical trials
IR, cisplatin in preclinical testing
www.clinicaltrials.gov
[34, 35]
UCN-01 Single agent in Phase II for relapsed T-cell lymphoma (completed)
Single agent in Phase II for metastatic melanoma (completed)
Five-fluorouracil in Phase II for metastatic pancreatic cancer (completed)
Topotecan in Phase II for various forms of ovarian cancer (completed)
Topotecan in Phase II for small cell lung cancer (completed)
Olaparib in pre-clinical testing for multiple mammary tumour types
NCT00082017
NCT00072189
NCT00045747
NCT00072267
NCT00098956
[99]
GDC-0425 Single agent or with gemcitabine in Phase I dose-escalation study (recruiting) NCT01359696
MK-8776 Single agent or with gemcitabine in Phase I dose-escalation study (completed) NCT00779584
CHK1/(CHK2)
LY-2606368 Single agent in Phase I study in patients with advanced cancer (recruiting) NCT01115790
WEE1 MK-1775 Carboplatin in Phase II for epithelial ovarian cancer NCT01164995
CDC25 IRC-083864 Single agent in preclinical testing using pancreatic and prostate cancer cells [42]
MRE11 mirin Single agent or with olaparib (PARPi) in preclinical testing using BRCA2-deficient cells [47]
RPA MCl13E Single agent or with cisplatin in preclinical testing [48]
B02 IR, mitomycin C, cisplatin in preclinical testing [100]RAD51
RI-1 Mitomyin C in preclinical testing [50]
ADP = adenosine diphosphate; ATM = ataxia telangiectasia mutated protein; ATR = ATM- and Rad3-related; CHK = checkpoint kinase; DNA = deoxyribonucleic acid;
DNA-PK = DNA-dependent protein kinase; DNA-PKcs = DNA-PK catalytic subunit; IR = ionising radiation; mTOR = mammalian target of rapamycin; PAR = poly(ADP-
ribose); PARP = PAR polymerase; PARPi = PARP inhibitor; PI3K = phosphatidylinositol-3-kinase; PIKK = PI3K-related kinase; RPA = replication protein A
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Phase II trial with iniparib (BSI-201, Sanofi-Aventis) in
patients with triple negative breast cancer, which shares
many features with BRCA-associated breast cancer, failed
to translate into overall patient survival in a Phase III trial
[63]. Later that year, AstraZeneca announced that olaparib
would not progress into Phase III for hereditary BRCA
mutation-associated breast cancer. This decision was pos-
sibly driven by economic concerns rather than by clinical
issues [64]. Notwithstanding all setbacks, clinical develop-
ment and research on the mechanism of action of PARPi is
still ongoing (table 2). Despite controversies about its ef-
fectiveness as a PARPi, Sanofi's iniparib is under clinical
investigation as a single agent and in combination with
chemotherapeutic regimens in patients with recurrent solid
tumours (NCT01455532), nonsmall-cell lung cancer
(NCT01082549) and ovarian cancer (NCT01033292) [65,
66]. Likewise, AstraZeneca is continuing Phase II trials
with olaparib to treat serous ovarian cancer, since it shares
many features with BRCA1/2-mutated cancers. Indeed,
activity of olaparib as a monotherapy was evident in wo-
men with pretreated high-grade serous ovarian cancer
without germline BRCA1/2 mutations [67]. This finding
clearly demonstrates positive responses of a subpopulation
of sporadic cancers to PARPi therapy and also underlines
the importance of classifying patients according to bio-
markers in order to predict the efficacy of PARPi. Such
potential biomarkers also include deficiency of the phos-
phatase and tensin homologue (PTEN) tumour suppressor.
Interestingly, due to its role in the regulation of RAD51
Figure 3
Synthetic lethality.
Synthetic lethality is defined as a combination of mutations or
perturbations in two or more genes that leads to cell death,
whereas inactivation of any one of the genes alone does not.
Perturbation of genes can occur through genetic mutation or
silencing, depletion by RNAi or inhibition by SMIs and is depicted
by a red cross. If genes that are essential for a certain DNA repair
pathway (e.g. gene A) are inactivated in normal cells, alternative
pathways with functional genes (e.g. gene B) are utilised to
respond to DNA damage. Conversely, cancer cells mutated or
silenced for a component of a DDR pathway are compromised in
their ability to process DSBs. These cells then rely on alternative
DNA repair pathways to repair the breaks. Therefore, inhibition of
the alternative pathway will cause cell death due to persisting
DSBs. Please refer to main text for details about the example given
for synthetic lethality between BRCA1/2 mutation and PARP
inhibition.
ADP = adenosine diphosphate; BER = base excision repair; DDR =
DNA damage response; DNA = deoxyribonucleic acid; DSB =
double-strand break; HR = homologous recombination; PARP =
poly(ADP-ribose) polymerase; RNA = ribonucleic acid; RNAi = RNA
interference; SMI = small molecule inhibitor
transcription, loss of PTEN is associated with defective
HR [68, 69]. In general, detection of compromised HR
provides a rationale to stratify patients for PARPi treat-
ment. Several ways of identifying HR defects are under in-
vestigation, including gene expression profiling and gene
copy number analysis of DNA repair factors [70, 71]. Fur-
ther approaches assess the DSB repair capacity of tumours
by measuring expression of the MRN complex, monitoring
RAD51 foci formation and poly(ADP-ribosyl)ation as sur-
rogate markers for DSB repair proficiency [72]. As for
most cancer therapies, a major challenge of using PARPis
is the acquired resistance of initially PARPi-sensitive can-
cer cells due, for example, to the loss of 53BP1 (a p53
binding protein) or to overexpression of multidrug-resist-
ance efflux transporters [72, 73]. In addition, secondary
BRCA2 mutations have been identified, which restore the
full-length protein thereby re-establishing BRCA2 func-
tions and conferring PARPi resistance [74].
Thus, despite considerable efforts to develop PARPi for
clinical use, conventional DNA-damaging chemo- and
radio-therapy largely remains the mainstay of cancer treat-
ment. However, several onging preclinical and clinical
studies employ PARPi both as monotherapy and as chemo-
or radio-sensitisers, because an improvement of current
anti-cancer regimes is long-awaited.
Synthetic lethal strategies emerging from preclinical
research
As intensive basic research is leading towards a better un-
derstanding of cellular functions and their underlying ge-
netic networks, more and more genetic interactions become
apparent as potential targets for synthetic lethality in cancer
therapy. Beyond BRCA1 and BRCA2, their joint interac-
tion partner PALB2 is emerging as a breast cancer suscept-
ibility gene, thus providing another opportunity for PARPi-
based therapies [75].
PARP inhibition is not the only approach that takes advant-
age of synthetic lethal interactions between two DNA re-
pair pathways, as inhibition of apurinic/apyrimidinic (AP)
endonuclease 1, an essential component of BER, was re-
cently shown to eliminate cancer cells with HR defects
[76]. Moreover, synthetic lethality with components of the
cell-cycle checkpoint machinery could be exploited in can-
cers harbouring activated oncogenes, since oncogene-in-
duced replication stress activates the ATR-CHK1 sig-
nalling pathway. For example, exacerbated toxicity was
reported upon inhibition of CHK1 in lymphoma cells with
upregulated c-Myc expression [77]. This finding under-
scores the concept that cancers with elevated levels of rep-
lication stress rely on intact checkpoint signalling for cell
survival. Replicative stress induces pan-nuclear distribu-
tion of phosphorylated histone variant H2AX (γ-H2AX),
which is a useful biomarker for classification of tumour
biopsies in order to stratify patients [78].
Finally, disruption of the FA repair pathway was shown
to be synthetically lethal with abrogated checkpoint sig-
nalling. More precisely, inactivation of ATM or CHK1 res-
ulted in reduced viability of FA-deficient cells, illustrating
the concept that checkpoint signalling and FA are mutu-
ally compensatory pathways in the maintenance of gen-
ome integrity [79, 80]. These observations highlight the
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usefulness of SMIs, as currently tested for CHK1, to treat
tumours bearing a specific genetic background. Although
many of the strategies that are based on the concept of syn-
thetic lethality have so far only been investigated in pre-
clinical settings, some hold great promise of entering clin-
ical trials soon.
Haploinsufficiency of DDR factors
There is increasing evidence that haploinsufficiency of
DDR components promotes genome instability and drives
tumourigenesis. Dosage insufficiencies of DNA repair
genes might, however, only be unmasked once a cell is
challenged with an increased load of DNA damage such
as oncogene-induced replicative stress [81, 82]. Synthetic
lethal approaches might therefore be applicable not only
in cancer cells with deficiencies, but also in those bearing
haploinsufficiencies for DDR factors. Evidence from gene
targeting studies in mice revealed that, for example, the
loss of one allele of ATR or CtIP is sufficient to cause in-
creased chromosomal aberrations, genomic instability and
tumour susceptibility [83, 84]. This indicates that hetero-
zygous carriers of DDR defects are more prone to develop
tumours once the threshold of endogenous DNA damage
is increased as, for example, in precancerous lesions [85].
However, scientists are just beginning to unravel how hap-
loinsufficiency of DDR genes contributes to carcinogenesis
and how these may be exploited for novel synthetic lethal
approaches in cancer therapy.
Table 2: PARP inhibitors in preclinical or clinical development for cancer therapy*.
Inhibitor Mono- or combination
therapy
Preclinical and clinical study stage Clinical trial identifier/
reference
Single agent Phase II trials showing with promising response rates in patients with BRCA1/ or
BRCA2 mutated advanced breast and ovarian cancers
NCT01078662,
NCT00494234
[55, 56]
Single agent Phase II trial demonstrating efficacy for advanced high-grade serous ovarian cancer
without germline BRCA1/2 mutations, but not with TNBC
NCT00679783
[67]
Cediranib Phase I/II study for treatment of recurrent serous ovarian cancer and TNBC NCT01116648
Single agent and
combinations with other
drugs
Several ongoing Phase I/II trials for various cancers, dose-limiting adverse effects for
combination of olaparib and topotecan
NCT00516438,
NCT00819221,
NCT01296763,
NCT00912743, [101]
Olaparib
(AZD-2281, KU-59436)
AstraZeneca
Cisplatin, radiation Phase I trial to test olaparib as a radio- and/or chemo-sensitiser in combination with
high-dose radiotherapy with or without a daily cisplatin dose in locally advanced
NSCLC
NCT01562210
Single agent and
combinations with other
drugs
Ongoing Phase I/II trials in solid tumours such as sarcomas as well as breast, uterine
and ovarian cancers
NCT01455532,
NCT01033292,
NCT00687687
Gemcitabine/
carboplatin
Promising results from a Phase II trial failed to translate into survival benefit for TNBC
patients with unselected BRCA1/2 status in Phase III
NCT00938652,
NCT01130259,
[63]
Radiotherapy Ongoing Phase I trial of iniparib as radiosensitiser in nonoperable brain metastases NCT01551680
Temozolomide and
radiotherapy
Ongoing Phase I/II trials for newly diagnosed malignant glioblastoma NCT00687765
Iniparib**
(BSI-201)
Sanofi-Aventis
Gemcitabine/
carboplatin
Ongoing Phase III trial in advanced squamous NSCLC NCT01082549
Temozolomide,
carboplatin/paclitaxel
International randomised Phase II trial of veliparib combined with chemotherapy in
BRCA1/2-mutated, metastatic breast cancer
NCT01506609
Single agent Phase I trial for refractory BRCA 1/2-mutated solid cancers; platinum-refractory
ovarian, fallopian tube, or primary peritoneal cancer or basal-like breast cancer
Additional evaluation of BRCA1/2 expression and changes in PAR and γ-H2AX in
peripheral blood mononuclear cells as diagnostic biomarkers
NCT00892736
Veliparib
(ABT-888)
Abbott Laboratories
Single agent and
combinations with
chemo- and radio-
therapy
Phase I and II trials to identify efficient combinatorial regimens in various solid and
lymphoid tumours, promising results in combination with topotecan and
cyclophosphamide
NCT01154426,
NCT01282333,
NCT01386385 and more,
[102-104]
Single agent Phase I/II trials for BRCA1/2-mutated breast or ovarian cancer NCT01482715
Temozolomide Initial Phase I trial as enhancer for chemotherapy in unselected solid tumours; severe
myelosuppression of the combination in Phase II study for previously untreated
metastatic melanoma
[105]
Rucaparib
(AG-014699,
PF-01367338, CO-338)
Cancer Research UK
Clovis Oncology
Pfizer
Single agent and with
carboplatin
Phase I/II testing in advanced solid tumors with and without BRCA mutations
Several biomarkers for therapeutic response are being evaluated concurrently.
NCT01009190,
NCT00664781
Single agent Phase I trial in advanced solid tumours showing that MK-4827 is well tolerated, blocks
PARP and has promising antitumour activity in both BRCA-deficient and sporadic
cancer
[106]Niraparib
(MK-4827)
Merck
Tesaro Inc. Single agent and with
temozolomide
Phase I dose-escalation study for solid tumours and haematological malignancies NCT00749502,
NCT01294735
* For a complete overview of PARPi currently used in clinical trials, we direct the reader to [61, 107].
** Since the primary mechanism of action for iniparib is likely not via inhibition of PARP activity, it is no longer considered to be a bona fide PARPi [65].
ADP = adenosine diphosphate; γ-H2AX = phosphorylated histone variant H2AX; NSCLC = nonsmall cell lung cancer; PARP = poly(ADP-ribose) polymerase; PARPi =
PARP inhibitor; TNBC = triple negative breast cancer
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Conclusions and future perspectives
To date, DSB-inducing agents have been the core com-
ponents of conventional cancer therapy, confirming the ra-
tionale of inflicting excessive DNA damage in order to
kill cancer cells. However, most chemotherapeutic regi-
mens cause severe side effects that limit their therapeutic
potential. As summarised in this review, SMIs and synthet-
ic lethal approaches targeting the individual genetic pro-
file of the tumours are under clinical development, with
the aim to improve the patients' benefit by increasing the
efficacy while lowering the toxicity of cancer treatments.
A prerequisite for personalised therapy is the molecular
characterisation of tumours with reliable biomarkers to as-
sign patients the appropriate treatment. In order to stratify
cancer patients according to their DNA repair status, tu-
mour biopsies can be analysed with immunohistochem-
istry, fluorescence in-situ hybridisation (FISH), gene se-
quencing, expression profiling and other methods [86].
Relevant biomarker assays should ideally predict the func-
tionality of DNA repair pathways, rather than just provid-
ing information about mutations or expression levels of
proteins involved in the DDR. Certainly, such a detailed
molecular profiling of cancer versus normal tissue from a
given patient is critical to maximise the potential of person-
alised cancer drugs in terms of both therapeutic success and
cost-effectiveness.
Recent in-vitro and in-vivo research has deepened our
knowledge about synthetic genetic interactions and put for-
ward alternative ways to treat cancer. Furthermore, by util-
ising ribonucleic acid (RNA) interference technologies,
screens for synthetic lethal interactions of cancer-specific
defects in DNA repair pathways have augmented the dis-
covery of targets for cancer therapy. For example, studies
using MMR-deficient cells lacking human muts homo-
logue 2 (MSH2) revealed synthetic sickness with POLB,
a DNA polymerase acting in BER [87]. Since MSH2 is
mutated in 40% of patients with hereditary nonpolyposis
colorectal cancer, targeted inhibition of POLB potentially
opens new therapeutic applications. Moreover, gaining fur-
ther insights into the structure and mechanism of action of
DNA repair factors such as CtIP will aid the design of new
and more efficient SMIs of the DDR. Recently discovered
inhibitors of RPA and RAD51 are promising candidates,
which are in preclinical testing in order to be approved for
the use in clinical trials soon [48, 50].
Interestingly, the latest scientific progress in the field of mi-
croRNAs (miRNAs) has demonstrated an intensive inter-
play of these small regulatory RNAs with the DDR, includ-
ing DSB repair. Recent studies revealed that DNA dam-
age globally induces miRNA biogenesis and, vice versa,
that numerous miRNAs modulate the expression of DDR
factors [88–90]. Notably, BRCA1 expression was shown to
be downregulated by miR-182, conferring hypersensitivity
to PARPi [91]. Conversely, BRCA1 was demonstrated to
suppress expression of miR-155, an oncogenic miRNA that
is overexpressed in many cancers [92, 93]. These observa-
tions highlight the therapeutic potential of miRNA mimics
or inhibitors in future approaches for cancer therapy [94].
In summary, as the concept of personalised medicine
emerges, tumour-specific defects of DSB repair pathways
represent a promising therapeutic target to be exploited for
the selective elimination of cancer cells. Thus, there is an
air of optimism for targeted cancer therapy through exploit-
ing the DDR of tumour cells in the clinics.
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Figures (large format)
Figure 1
The DNA damage response.
Exogenous and endogenous DNA damaging agents generate various types of lesions including DNA single- and double-strand breaks (SSBs
and DSBs). The multifunctional MRN complex detects DSBs, while FANCM is required for the DNA interstrand crosslink (ICL)-induced
checkpoint response. PARP predominantly acts as a SSB sensor protein. RPA binds to regions of single-stranded DNA (ssDNA) that are
exposed at stalled replication forks or after DSB resection. MRN and RPA mediate the recruitment of ATM and ATR-ATRIP, respectively, and the
subsequent activation of the respective pathways, coordinating cell-cycle checkpoints, DNA repair and apoptotic responses to DNA damage.
The Ku70/Ku80 heterodimer (KU) competes with MRN for binding to DSBs. KU recruits DNA-PKcs to form the catalytically active DNA-PK
holoenzyme which is a major component of the canonical NHEJ machinery during DSB repair. MRN on the other hand initiates HR (see also fig.
2). Once activated, the DNA damage signalling cascade extends through multiple phosphorylation events primarily via the cell-cycle checkpoint
kinases CHK1 and CHK2. Their signals converge on downstream effectors such as the tumour suppressor protein p53 or the CDC25 protein
phosphatase and WEE1 tyrosine kinase. As a result, CDK activity is inhibited, delaying cell cycle progression from G1 to S (the G1/S
checkpoint) or from G2 to M phase (the G2/M checkpoint). The DNA damage response (DDR) thus orchestrates a variety of cellular outcomes:
the transcriptional programme of the damaged cell is altered and the cell cycle is transiently arrested, thereby facilitating repair of the DNA
lesions. In situations where DNA damage is too severe and cannot be repaired, the DDR triggers apoptosis or senescence.
ADP = adenosine diphosphate; ATM = ataxia telangiectasia mutated protein; ATR = ATM- and Rad3-related; ATRIP = ATR-interacting protein;
CDK = cyclin-dependant kinase; DNA = deoxyribonucleic acid; DNA-PK = DNA-dependant protein kinase; DNA-PKcs = DNA-PK catalytic
subunit; FANCM = Fanconi anaemia complementation group M; HR = homologous recombination; ICL = interstrand crosslink; MRN =
MRE11-RAD50-NBS1 complex; NEHJ = nonhomologous end joining; PARP = poly(ADP-ribose) polymerase; RPA = replication protein A
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Figure 2
DNA double-strand break (DSB) repair.
DSBs are predominantly repaired by two distinct pathways: NHEJ or HR. NHEJ operates throughout the cell cycle, but mainly during the G1 and
G2 phases, whereas HR peaks in S phase. Rapid association of the Ku70/80 heterodimer to DSBs promotes NHEJ by recruiting DNA-PKcs.
DNA ends are processed by the nucleolytic activity of Artemis, followed by religation catalysed by a complex of XLF, Ligase IV (Lig4) and
XRCC4. Alternatively, MRN, which is initially recruited to DSBs in competition with Ku70/80, initiates DSB resection together with CtIP thereby
promoting HR. 53BP1 antagonises BRCA1 in DSB resection. Extensive DSB resection by other nucleases and formation of RPA-coated ssDNA
stimulates the activation of ATR. Displacement of RPA by RAD51 is mediated by BRCA2 and PALB2, resulting in the formation of RAD51
nucleoprotein filaments. Subsequent strand invasion into the homologous DNA template and capturing of the second DNA end leads to the
formation of a double Holliday junction, which is processed by resolvases. Finally, the DNA is sealed by ligases to accomplish error-free repair
of the DSB.
53BP = p53 binding protein; ATM = ataxia telangiectasia mutated protein; CtBP = C-terminal binding protein; CtIP = CtBP-interacting protein;
DNA = deoxyribonucleic acid; DNA-PK = DNA-dependant protein kinase; DNA-PKcs = DNA-PK catalytic subunit; HR = homologous
recombination; MRN = MRE11-RAD50-NBS1 complex; NEHJ = nonhomologous end joining; PALB1/2 = partner and localiser of BRCA1/2; RPA
= replication protein A; ssDNA = single-stranded DNA; XLF = XRCC4-like factor; XRCC4 = X-ray repair cross-complementing protein 4
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Figure 3
Synthetic lethality.
Synthetic lethality is defined as a combination of mutations or perturbations in two or more genes that leads to cell death, whereas inactivation
of any one of the genes alone does not. Perturbation of genes can occur through genetic mutation or silencing, depletion by RNAi or inhibition
by SMIs and is depicted by a red cross. If genes that are essential for a certain DNA repair pathway (e.g. gene A) are inactivated in normal cells,
alternative pathways with functional genes (e.g. gene B) are utilised to respond to DNA damage. Conversely, cancer cells mutated or silenced
for a component of a DDR pathway are compromised in their ability to process DSBs. These cells then rely on alternative DNA repair pathways
to repair the breaks. Therefore, inhibition of the alternative pathway will cause cell death due to persisting DSBs. Please refer to main text for
details about the example given for synthetic lethality between BRCA1/2 mutation and PARP inhibition.
ADP = adenosine diphosphate; BER = base excision repair; DDR = DNA damage response; DNA = deoxyribonucleic acid; DSB = double-strand
break; HR = homologous recombination; PARP = poly(ADP-ribose) polymerase; RNA = ribonucleic acid; RNAi = RNA interference; SMI = small
molecule inhibitor
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FANCD2 and CtIP cooperate to repair DNA interstrand
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I examined whether CtIP can bind to ubiquitin. Specifically, I established and performed
pull-down assays using nitrilotriacetic acid (Ni-NTA) agarose beads, which were coupled
to recombinant His-tagged ubiquitin (rHis-Ub) as shown in Figure 3E.
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SUMMARY
The resolution of DNA interstrand crosslinks (ICLs)
requires a complex interplay between several pro-
cesses of DNA metabolism, including the Fanconi
anemia (FA) pathway and homologous recombina-
tion (HR). FANCD2 monoubiquitination and CtIP-
dependent DNA-end resection represent key events
in FA and HR activation, respectively, but very little
is known about their functional relationship. Here,
we show that CtIP physically interacts with both
FANCD2 and ubiquitin and that monoubiquitinated
FANCD2 tethers CtIP to damaged chromatin, which
helps channel DNA double-strand breaks generated
during ICL processing into the HR pathway. Conse-
quently, CtIP mutants defective in FANCD2 binding
fail to associate with damaged chromatin, which
leads to increased levels of nonhomologous end-
joining activity and ICL hypersensitivity. Interest-
ingly, we also observe that CtIP depletion aggravates
the genomic instability in FANCD2-deficient cells.
Thus, our data indicate that FANCD2 primes CtIP-
dependent resection during HR after ICL induction
but that CtIP helps prevent illegitimate recombina-
tion in FA cells.
INTRODUCTION
Fanconi anemia (FA) is a rare hereditary disorder characterized
by bone marrow failure, developmental abnormalities, and can-
cer predisposition (Moldovan and D’Andrea, 2009). Cells iso-
lated from FA patients display chromosomal instability and
hypersensitivity to DNA interstrand crosslink (ICL)-inducing
agents such as mitomycin C (MMC) and cisplatin. The high cyto-
toxicity of MMC, a property exploited in cancer therapy, is pri-
marily based on the strong inhibitory effect of unrepaired ICLs
on DNA replication (Deans andWest, 2011). Recent studies indi-
cate that the FA pathway orchestrates replication-coupled ICL
repair—involving nucleolytic incision, translesion DNA synthesis
(TLS), and homologous recombination (HR)—to maintain
genomic stability (Knipscheer et al., 2009). In response to ICL
damage, the FA core complex, consisting of eight proteins
(FANCA, B, C, E, F, G, L, and M), promotes monoubiquitination
of FANCD2 and FANCI (Garcia-Higuera et al., 2001; Smogor-
zewska et al., 2007). The ubiquitinated FANCD2/I complex reloc-
alizes to damaged chromatin, where it coordinates downstream
repair events (Kim and D’Andrea, 2012). ICL repair is initiated by
nucleolytic incisions on either side of the crosslink and carried
out by SLX4-associated XPF-ERCC1 and MUS81-EME1 nucle-
ases and FAN1 (Kottemann and Smogorzewska, 2013). ICL inci-
sion converts the stalled replication fork into a one-ended DNA
double-strand break (DSB), which is repaired by HR. Interest-
ingly, FA phenotypes can be partially rescued by inhibition of
nonhomologous end-joining (NHEJ), suggesting that the FA
pathway not only promotes error-free HR but also actively sup-
presses inappropriate repair of DSB intermediates by NHEJ in
order to prevent chromosomal instability (Adamo et al., 2010;
Pace et al., 2010).
Although FANCD2 is critically important for ICL repair, its
contribution to HR remains largely elusive (Nakanishi et al.,
2011; Smogorzewska et al., 2007). HR is initiated by DNA-end
resection, which occurs in human cells through the combined
action of CtIP and the MRE11-RAD50-NBS1 (MRN) complex,
together with DNA2 or EXO1 nucleases (Nimonkar et al., 2011;
Sartori et al., 2007). Importantly, DNA-end resection is a key
determinant of DSB repair pathway choice, as it commits cells
to HR, while, at the same time, suppresses NHEJ (Chapman
et al., 2012). A putative connection between the resection ma-
chinery and the FA pathway was recently proposed, based on
data showing that DNA2 and EXO1 depletion leads to cisplatin
hypersensitivity (Karanja et al., 2012). Additionally, CtIP was
shown to accumulate at sites of locally induced ICLs (Duquette
et al., 2012). However, the contribution of DNA-end resection
to ICL repair and the regulation of CtIP by the FA pathway
have not yet been thoroughly investigated.
RESULTS
FANCD2 Is Required forCtIP Localization to ICLDamage
Similar to FA cells, we observed that CtIP depletion results in hy-
persensitivity and increased chromosomal aberrations following
MMC treatment, implicating a key role for CtIP in ICL repair (Fig-
ures 1A, S1A, and S1B). Because FANCD2 monoubiquitination
constitutes a key step of the FA pathway, we investigated
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whether CtIP affects FANCD2 foci formation. However, silencing
of CtIP did not significantly change the assembly of FANCD2 foci
after MMC treatment (Figure 1B). Moreover, FANCD2 monoubi-
quitination and chromatin assembly still efficiently occurred in
CtIP-depleted cells (Figures S1C and S1D). Recently, it was
shown that the knockdown of CtIP leads to a 2-fold reduction
in FANCD2 accumulation at ICLs induced by 8-methoxypsoralen
plus UVA laser microirradiation (PUVA) (Duquette et al., 2012).
Therefore, we subjected CtIP-depleted cells to PUVA treatment
and noticed partially reduced levels of monoubiquitinated
FANCD2 on chromatin (Figures S1E and S1F). Taken together,
our data indicate that CtIP is not strictly required for FANCD2
monoubiquitination in response to ICL-inducing agents but that
its lossmay lead to a negative feedback loop limiting FA pathway
activation during ICL repair.
We also noticed that CtIP was highly enriched on chromatin
upon MMC or PUVA treatment (Figures S1C and S1F). Consis-
tent with this, ICL damage caused a strong increase in CtIP
foci that colocalized with FANCD2 (Figure 1C). Remarkably,
both spontaneous and damage-induced CtIP foci were abro-
gated in FANCD2-depleted cells (Figure 1C). Accordingly,
FANCD2 depletion impaired CtIP chromatin association in
Figure 1. FANCD2 Is Required for the Accumulation of CtIP at Sites of ICL Damage
(A) Metaphase spreads fromHEK293 cells transfectedwith the indicated small interfering RNAs (siRNAs) and treated for 20 hr withMMC (25 ng/ml) were analyzed
for chromosomal aberrations. A total of 100metaphase spreads from three independent experiments were analyzed for each condition. The percentages of cells
displaying chromatid breaks or radial chromosomes are shown (see also Figure S1B).
(B) After 48 hr of transfection with indicated siRNAs, U2OS cells grown on coverslips were treated for 24 hr with MMC (120 ng/ml), pre-extracted, fixed, and
immunostained for FANCD2. Nuclei were visualized by DAPI-staining. Graph shows the percentage of cells displaying more than ten FANCD2 foci/nuclei.
(C) U2OS cells stably expressing GFP-tagged CtIP were transfected with indicated siRNAs, and 48 hr later, cells grown on coverslips were treated as in (B) and
immunostained for FANCD2. Graph shows the percentage of cells displaying more than ten GFP-CtIP foci/nuclei.
(D and E) U2OS cells were transfected with indicated siRNAs, and 48 hr later, cells were treated as in (B) and extracts were analyzed by immunoblotting.
(F) FANCD2 mutant human fibroblasts (PD20F) and PD20F stably expressing wild-type FANCD2 (WT) or K561R mutant FANCD2 were treated as in (B) and
harvested for immunoblot analysis (see also Figure S1H).
(G) U2OS cells were transfected with FAN1 siRNA and processed as in (D).
In (B) and (C), for each condition, at least 100 cells were scored and the data are presented as the mean ± SD (n = 3). The scale bar represents 5 mm.
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MMC- and PUVA-treated cells (Figures 1D and S1G). In
response to ICL damage, FANCD2 becomes monoubiquitinated
at K561 by the FA core complex (Garcia-Higuera et al., 2001;
Meetei et al., 2003). Depletion of FANCA, a subunit of the FA
core complex, abolished both FANCD2 and CtIP association
with damaged chromatin (Figure 1E). Importantly, impaired
CtIP accumulation at ICLs in FANCD2-deficient fibroblasts
(PD20F) was restored by complementation with wild-type (WT)
FANCD2, but not with the K561R mutant (Figures 1F and S1H).
In addition, CtIP failed to form MMC-induced foci in cells pre-
treated with the proteasome inhibitor MG-132, which leads to
the sequestration of ubiquitin in the cytoplasm, further indicating
that FANCD2 monoubiquitination is a prerequisite for CtIP local-
ization to ICLs (Figure S1I).
During the initial processing of DSBs, CtIP acts together
with the MRE11-RAD50-NBS1 (MRN) complex. We therefore
explored whether efficient localization of CtIP to ICLs may
require theMRNcomplex. However, while NBS1 downregulation
resulted in defective chromatin association of MRE11, the levels
of chromatin-bound FANCD2 and CtIP remained unaltered (Fig-
ure S1J). On the other hand, monoubiquitinated FANCD2 was
reported to directly interact with and recruit FAN1 and SLX4 to
coordinate ICL incision (Kottemann and Smogorzewska, 2013;
Yamamoto et al., 2011). However, depletion of FAN1 or SLX4
did not significantly affect the binding of CtIP to damaged chro-
matin (Figures 1G and S1K). Collectively, our results suggest that
proper localization of CtIP to ICLs is controlled by FANCD2 but
occurs independently of bothMRN and structure-specific nucle-
ases involved in ICL incision.
FANCD2 Facilitates CtIP-Mediated DNA-End Resection
during ICL Repair
We observed that both MMC and PUVA treatment resulted in
robust RPA2-S4/S8 phosphorylation (Figures S2A and S1E).
RPA2 phosphorylation, particularly at S4 and S8, has been
widely used as a surrogate marker for single-stranded DNA
(ssDNA) that is generated by DNA-end resection (Kousholt
et al., 2012). Remarkably, knockdown of CtIP or FANCD2
strongly impaired RPA2 hyperphosphorylation in response to
ICL-inducing agents, which was particularly evident in the chro-
matin-bound fractions (Figures 2A and S2B). Likewise, the per-
centage of cells with RPA2-pS4/S8 foci was significantly
reduced in CtIP- or FANCD2-depleted cells (Figures 2B and
S2C). Moreover, by immunostaining of cells with anti-bromo-
deoxyuridine (anti-BrdU), we found thatMMC triggered substan-
tial ssDNA formation, which was reduced upon depletion of CtIP
or FANCD2 (Figures 2C and S2D). Impaired DNA-end resection
commits cells to error-prone repair of DSBs by NHEJ. Recently,
RIF1 was characterized as a key NHEJ-promoting factor by vir-
tue of its role in counteracting resection (Chapman et al., 2013; Di
Virgilio et al., 2013; Escribano-Dı´az et al., 2013; Zimmermann
et al., 2013). Indeed, MMC-induced RIF1 foci were elevated
in CtIP- or FANCD2-depleted cells, further supporting the idea
that both factors promote DNA-end resection and, thus, sup-
press NHEJ during ICL repair (Figures 2D and S2E).
To further substantiate the role of CtIP-dependent resection in
ICL repair, we monitored RIF1 foci in cells expressing GFP-
tagged CtIP-WT, CtIP-T847A, or CtIP-S327A (Figure S2F). The
mutated residues in CtIP represent CDK phosphorylation sites
required for resection (T847A) or for interaction with BRCA1
(S327A) (Figure S2G) (Huertas and Jackson, 2009; Yu and
Figure 2. FANCD2 and CtIP Promote DNA-End Resection during ICL
Repair
(A) U2OS cells were transfected with indicated small interfering RNAs
(siRNAs), and 48 hr after siRNA transfection, cells were either mock-treated
or treated for 24 hr with MMC (120 ng/ml) and extracts were analyzed
by immunoblotting. RPA2 and P-RPA2 represent nonmodified and hyper-
phosphorylated forms of RPA2, respectively.
(B) Same cells as in (A) were grown on coverslips, pre-extracted, fixed, and
coimmunostained for RPA2-pS4/S8 (pRPA2) and RPA2 (see also Figure S2C).
Graph shows the percentage of RPA2-foci-positive cells displaying more than
ten pRPA2 foci.
(C) Same cells as in (A) were coimmunostained for gH2AX and BrdU to visu-
alize single-stranded DNA under nondenaturing conditions (see also Fig-
ure S2D). Graph shows the percentage of gH2AX-foci-positive cells displaying
more than ten BrdU foci.
(D) Same cells as in (A) were immunostained for RIF1 (see also Figure S2E).
Graph shows the percentage of nuclei displaying more than ten RIF1 foci.
(E) U2OS cells were transfected with CtIP siRNA, and 24 hr post-siRNA
transfection, cells were transfected with siRNA-resistant GFP-tagged CtIP
wild-type (WT), T847A, or S327A mutant CtIP (see also Figure S2F). After 48 hr
of siRNA transfection, cells were treated as in (A) and immunostained for RIF1.
Graph shows the percentage of GFP-foci positive cells displaying more than
10 RIF1 foci. The scale bar represents 5 mm.
In (B)–(E), for each condition, at least 100 cells were scored and data are
presented as the mean ± SEM (n = 3).
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Chen, 2004). Our analysis revealed a strong increase in RIF1 foci
in MMC-treated T847A mutant cells, whereas the S327A muta-
tion had no significant impact on RIF1 foci formation (Figure 2E).
In agreement with this result, T847Amutant cells were hypersen-
sitive to MMC, whereas the viability of cells expressing CtIP-
S327A was similar to CtIP-WT cells, further supporting the idea
that BRCA1-CtIP interaction is not required for resection during
ICL repair (Figures S2H and S2I) (Reczek et al., 2013). Thus far,
our findings suggest a pivotal regulatory role for FANCD2 in
priming CtIP-mediated DNA-end resection to prevent aberrant
NHEJ activity following ICL damage.
CtIP Physically Interacts with FANCD2 and Ubiquitin
Given that CtIP localization to sites of ICL damage is facilitated
by FANCD2, we next addressed whether they exist in a complex
and found that FLAG-CtIP efficiently coimmunoprecipitated with
GFP-FANCD2, and vice versa (Figures 3A and S3A). Moreover,
we were able to specifically detect endogenous CtIP coimmuno-
precipitating with FLAG-FANCD2 but did not observe significant
changes in complex formation uponMMC treatment, suggesting
thatmonoubiquitination of FANCD2may not be essential for CtIP
binding (Figure 3B). In order to further address this issue, we
mixed recombinant CtIP purified from insect cells with GFP-
FANCD2 immunoprecipitated from human embryonic kidney
293T (HEK293T) cells. While CtIP efficiently bound to FANCD2-
WT, it only weakly interacted with the FANCD2-K561R mutant,
indicating that FANCD2 and CtIP physically interact and that
complex formationmight be reinforced by FANCD2monoubiqui-
tination (Figures 3C and S3B).
To verify the existence of endogenous CtIP-FANCD2 com-
plexes, we performed proximity ligation assays (in situ PLA). As
shown in Figure 3D, we could readily detect nuclear PLA signals
in undamaged cells, which significantly increased in numbers
upon MMC treatment, indicating that the FANCD2-CtIP interac-
tion is enhanced following ICL damage. Moreover, we observed
a strong reduction in CtIP-FANCD2 complex formation in
FANCA-depleted, but not SLX4- or FAN1-depleted, cells (Figures
3D,S3C, andS3D). These findings further support the importance
of FANCD2 monoubiquitination for the accumulation of CtIP
at damaged chromatin, presumably by facilitating FANCD2-
CtIP interaction. Although sequence analysis revealed that CtIP
does not contain any known ubiquitin-binding motifs (Hofmann,
Figure 3. CtIP Physically Interacts with
FANCD2 and Ubiquitin
(A) HEK293T cells were cotransfected with
FLAG-CtIP along with either empty vector or
GFP-FANCD2, and 48 hr after transfection, cells
were lysed in NP-40 buffer and whole cell ex-
tracts were analyzed before (input) or after
immunoprecipitation (IP) with anti-GFP (see also
Figure S3A).
(B) HEK293T cells were transfected with either
empty vector or FLAG-FANCD2, and 48 hr post-
transfection, cells were either mock-treated or
treated for 24 hr with MMC (120 ng/ml). Cells were
lysed in Triton-X buffer, and whole-cell extracts
were analyzed before (input) or after IP using anti-
FLAG M2 affinity resin.
(C) HEK293T cells were transfected with empty
vector, GFP-FANCD2 (WT), or GFP-FANCD2
K561R (KR). Then 48 hr after transfection, cells
were lysed in NP-40 buffer and whole-cell ex-
tracts were subjected to IP with anti-GFP. After
stringent washings, immunoprecipitated GFP-
tagged proteins were incubated with 0.5 mg of
recombinant FLAG-tagged CtIP (rFLAG-CtIP;
see also Figure S3B). Inputs and recovered
protein complexes were analyzed by immuno-
blotting.
(D) U2OS cells transfected with the indicated
siRNAs were left untreated or treated as in (B).
After pre-extraction, cells were fixed on coverslips
and incubated with antibodies against CtIP and
FANCD2 before the detection of protein-protein
interactions using a fluorescently labeled probe
(PLA-613). Nuclei were visualized by DAPI stain-
ing. Graph shows the quantification of the PLA
signals/nucleus. PLA signals from at least 100 cells were analyzed (n = 3) (see also Figures S3C and S3D). The scale bar represents 5 mm.
(E) His alone () or recombinant His-tagged ubiquitin (rHis-Ub) coupled to nickel nitrilotriacetic acid (Ni-NTA) agarose beads were incubated with HeLa nuclear
extracts (NE). Input and precipitated bead fractions from the pull-downs were subjected to immunoblotting. Ponceau staining is shown to indicate the amounts
of rHis-Ub used in the pull-down assay.
(F) Recombinant FLAG-tagged CtIP was incubated either alone or together with recombinant hemagglutinin (HA)-tagged ubiquitin and the samples were
subjected to IP with anti-HA. Inputs and recovered protein complexes were analyzed by immunoblotting.
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2009), our results prompted us to examine whether CtIP can bind
toubiquitin. Asshown inFigure3E,wediscovered thatCtIP is able
to interact with ubiquitin, although less efficiently compared to
Polh that contains a ubiquitin-binding domain (UBD) (Bienko
et al., 2005; Plosky et al., 2006). Furthermore, we observed com-
parable ubiquitin binding abilities of GFP-CtIP and UBZ-domain
containingGFP-SLX4 (Figure S3E) (Yamamoto et al., 2011). How-
ever, while the ubiquitin I44A mutant completely abolished UBZ-
mediated interactions of SLX4 and Polh with ubiquitin, it did not
affect the binding of CtIP, implicating a distinct type of ubiquitin
recognition (Figure S3F). We were also able to detect an interac-
tion between purified, recombinant proteins, implying that CtIP
can directly recognize ubiquitin (Figure 3F). Collectively, these
data demonstrate that CtIP interacts with FANCD2 and that
FANCD2 monoubiquitination enhances FANCD2-CtIP complex
formation, perhaps owing to the ability of CtIP to bind ubiquitin.
FANCD2-CtIP Interaction Promotes Crosslink
Resistance
To establish the functional significance of the FANCD2-CtIP
interaction for ICL repair, we sought to identify the FANCD2-
binding motif in CtIP. Whereas FANCD2 did not bind to a region
of CtIP containing putative coiled-coil motifs (45–160), it bound
efficiently to fragments of CtIP comprising amino acid (aa) resi-
dues 45–298 or 45–371 (Figure 4A), highlighting the region be-
tween aa residues 160–298 of CtIP to be important for FANCD2
binding. Detailed protein sequence analysis of this region re-
vealed four motifs with high sequence conservation between
vertebrates (Figure S4A). Remarkably, cells expressing RRK/
AAA or RYIE/AAIA mutant variants of CtIP were impaired in
MMC-induced GFP-CtIP foci formation and showed increased
RIF1 foci (Figures S4B and S4C). Consistent with a defect in
CtIP foci formation, RRK/AAA and RYIE/AAIA mutants exhibited
reduced FANCD2 binding in glutathione S-transferase (GST)
pull-down experiments (Figures 4B and 4C). Moreover, PLA sig-
nals were reduced in both CtIP mutants after MMC treatment,
further supporting the role of RRK and RYIE motifs in CtIP-
FANCD2 interaction (Figures 4D and 4E). MMC-induced CtIP
foci were also abrogated in U2OS cells stably expressing GFP-
tagged CtIP-RRK/AAA and -RYIE/AAIA mutants, whereas RIF1
foci were significantly increased in those cells (Figure 4F). How-
ever, both CtIP mutants were efficiently recruited to DSB-con-
taining tracks generated by laser microirradiation (Figure S4D).
Underscoring a differential regulation of CtIP in response to
ICL damage, CtIP recruitment to laser-induced DNA lesions
was FANCD2-independent (Figure S4E). Of note, a truncated
CtIP mutant lacking residues 153–322 was still proficient in ubiq-
uitin binding, indicating that neither RRK (aa 177–179) nor RYIE
(aa 185-188) sequence motifs are required for the interaction
between CtIP and ubiquitin (Figures S4F and S4G). Finally,
both RRK/AAA and RYIE/AAIA mutant cells were hypersensitive
to MMC, further supporting the idea that FANCD2 regulates CtIP
functionality during ICL repair (Figure 4G).
CtIP Counteracts ICL-Induced DNA Damage in the
Absence of FANCD2 Activation
To genetically determine the epistatic relationship between
CtIP and FANCD2 in ICL repair, we generated an MRC5 cell
line stably expressing doxycycline (DOX)-inducible small hairpin
RNA (shRNA) against CtIP (Figure 5A). Interestingly, depletion of
FANCD2 in DOX-treated MRC5 cells led to a further increase
in MMC hypersensitivity (Figures 5A and 5B). In agreement
with this, survival of PD20 cells uponMMC treatment was further
reduced after silencing of CtIP (Figure S5A). CtIP/FANCD2-defi-
cient MRC5 cells also showed elevated levels of MMC-induced
RIF1 foci and radial chromosomes compared to cells depleted
for either factor alone, indicative of potent, illegitimate repair of
DSBs by NHEJ (Figures 5C, 5D, S5B, and S5C). Previously,
BRCA1 has been reported to regulate the accumulation of
FANCD2 into repair foci and CtIP recruitment to PUVA-induced
ICLs (Garcia-Higuera et al., 2001; Duquette et al., 2012). Further
supporting a dual, nonredundant role for CtIP in ICL repair,
knockdown of BRCA1 in DOX-treated MRC5shCtIP cells resulted
in increased MMC sensitivity (Figure S5D). Thus, our data sug-
gest that CtIP-dependent DNA-end resection is essential to
counteract the toxic effects of ICL damage when the FA/BRCA
signaling pathway is compromised.
ATR kinase is a major regulator of the FA pathway and pro-
motes FANCD2/I monoubiquitination (Andreassen et al., 2004;
Smogorzewska et al., 2007). Recently, both ATM and ATR
kinases have been implicated in DNA-damage-induced CtIP
phosphorylation (Peterson et al., 2013; Wang et al., 2013). In
order to gain further mechanistic insight into the regulation of
CtIP during ICL repair, we applied selective ATR and/or ATM
inhibitors prior to MMC treatment (Reaper et al., 2011). CtIP
and RPA2 phosphorylation was strongly elevated after ATR
inhibition; meanwhile, FANCD2 monoubiquitination and CHK1
phosphorylation were reduced as expected (Figure 5E, lane 2).
Interestingly, MMC-induced hyperphosphorylation of CtIP and,
to a lesser extent, of RPA2 was reversed when both inhibitors
were combined (Figure 5E, lane 4). These data suggest that
ATM gets hyperactivated when ATR kinase is blocked, probably
as a result of prevalent cleavage of collapsed replication forks
into DSBs. The structure-specific endonuclease MUS81-EME1
has been implicated in the conversion of stalled replication forks
into DSBs, particularly in checkpoint-deficient cells (Hanada
et al., 2006; Murfuni et al., 2013). Indeed, inhibition of ATR
combined with MUS81 depletion significantly reduced the phos-
phorylation of H2AX and KAP1, both established ATM targets,
indicating that MUS81 is at least partially required for the
processing of ICL-stalled forks into DSBs (Figure 5F). Remark-
ably, phosphorylation levels of CtIP were also decreased, further
implying CtIP in promoting DNA-end resection and HR of repli-
cation-associated DSBs in the absence of a fully functional FA
pathway. Taken together, our results demonstrate that during
conventional ICL repair, CtIP-mediated DNA-end resection is
regulated by FANCD2 but that CtIP also helps prevent illegiti-
mate repair of stalled forks in FA-pathway-defective cells.
DISCUSSION
CtIP is an essential factor required for the initiation of DNA-end
resection during HR and, thus, for the suppression of DSB repair
byNHEJ.Given that FA-pathway-deficient cells exhibit increased
chromosomal instability in response to ICL damage, FA pro-
teins have also been implicated in NHEJ inhibition. Indeed, we
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observed that depletion ofCtIP or FANCD2 leads to an increase in
radial chromosome formation andRIF1 foci afterMMC treatment,
indicative of enhanced NHEJ activity. Accordingly, DNA-end
resection, as measured by phosphorylated RPA2 and BrdU
focus formation,was reduced inCtIP- or FANCD2-depleted cells.
Several mechanisms have been proposed how FA proteins pre-
vent NHEJ, including the restriction of NHEJ factors to access
DNA termini, cryptic exonuclease, or nucleosome-assembly
activity of FANCD2 (Adamo et al., 2010; Pace et al., 2010; Sato
et al., 2012). Based on our data, we propose that FANCD2 sup-
presses error-prone NHEJ through promoting CtIP-dependent
resection (Figure S6).
We observed that monoubiquitinated FANCD2 tethers CtIP to
damaged chromatin and identified two short, highly conserved
motifs within CtIP responsible for CtIP-FANCD2 interaction.
Consequently, CtIP mutants defective in FANCD2 binding are
Figure 4. Functional Characterization of CtIP Mutants Impaired in FANCD2 Binding
(A) GST or GST-CtIP proteins were coupled to glutathione Sepharose beads and incubated with HEK293T cell lysates transiently overexpressing GFP-FANCD2.
The recovered materials were analyzed by immunoblotting.
(B) Alignment of the putative FANCD2-interacting region in CtIP orthologs. RRK and RYxE motifs are highlighted in black boxes. Other, highly conserved amino
acid residues are marked in bold typeface (see also Figure S4A).
(C) GST or indicated GST-CtIP (45–298) proteins were coupled to glutathione Sepharose beads and incubated with HEK293T cell lysates transiently over-
expressing GFP-FANCD2. The recovered materials were analyzed by immunoblotting.
(D) U2OS cells stably expressing siRNA-resistant GFP-tagged wild-type (WT) and mutant (RRK/AAA and RYIE/AAIA) CtIP were transfected with CtIP siRNA for
72 hr, and whole-cell extracts were analyzed by immunoblotting. (S) and (L) indicate short and long exposures of the same immunoblot, respectively.
(E) Same cells as in (D) were transfected with CtIP siRNA. After 48 hr of siRNA transfection, cells grown on coverslips were treated for 24 hr withMMC (120 ng/ml),
fixed, and incubated with antibodies against CtIP and FANCD2 before the detection of protein-protein interactions using a fluorescently labeled probe (PLA-613).
Graph shows the quantification of the PLA signals/nucleus in GFP-positive cells. PLA signals from at least 100 cells were analyzed (n = 2).
(F) Same cells as in (E) were fixed and immunostained for RIF1. Graphs show the percentage of GFP-positive cells displayingmore than tenGFP-CtIP foci or more
than ten RIF1 foci, respectively. For each condition, at least 100 cells were scored. Data are presented as the mean ± SEM (n = 2).
(G) Same cells as in (D) were either mock-treated or continuously treated with the indicated doses of MMC, and the survival was determined after 5 days using the
CellTiter-Blue cell viability assay. Data are presented as the mean ± SD (n = 3).
In (E) and (F), the scale bar represents 5 mm.
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impaired in the formation of MMC-induced foci. Whereas
FANCD2monoubiquitinationmaynot beessential for thephysical
interactionwithCtIP, it is required to retainCtIPondamagedchro-
matin. Remarkably,weshow thatCtIPdirectly interactswithubiq-
uitin in vitro. Although bioinformatic analysis failed to predict
any motifs resembling known UBDs in CtIP, it is plausible that
the FANCD2-CtIP interaction is reinforced by the ability of CtIP
to recognize ubiquitin. However, a CtIP mutant lacking both
FANCD2-interacting motifs was proficient in ubiquitin binding.
Furthermore, a mutant form of ubiquitin (I44A) defective in most
UBD-mediated interactions was still able to interact with CtIP.
Therefore, one could hypothesize that CtIP may employ a dual
modeof recognizingmonoubiquitinatedFANCD2,but, if so, binds
ubiquitin by a uniquemechanism that involves a new type of UBD
(Bomar et al., 2007). Clearly, further investigations are needed to
establish the role of CtIP-ubiquitin interaction in the DNA damage
response. On the other hand, it was proposed that monoubiquiti-
nation of FANCD2 could alter FANCD2 conformation (Joo et al.,
2011). Thus, it is tempting to speculate that such structural
changes in FANCD2 stimulate CtIP-FANCD2 interaction. Finally,
the FANCD2/I complex may also facilitate CtIP recruitment
to damaged chromatin via its histone chaperone activity (Sato
et al., 2012). Increased MMC-induced sensitivity and RIF1 foci
formation in cells expressing CtIP mutants (RRK/AAA and RYIE/
AAIA) further strengthen thesignificanceofCtIP-FANCD2 interac-
tion in ICL repair. Notably, R177Q and Y186C, two cancer-asso-
ciated missense mutations in human CtIP, map exactly to the
region implicated in FANCD2 interaction (Figure S4A). Given
that RRK and RYIE motifs reside in a highly conserved stretch of
12 amino acids, it is also reasonable to think that they constitute
a single FANCD2 interaction ‘‘domain.’’ These data are similar
to those described in the accompanying paper by Unno et al.
(2014) published in this issue of Cell Reports.
Depletion of CtIP in FANCD2-deficient cells aggravates the
phenotypes of cells lacking either factor alone, indicating that
CtIP contributes to genome stability in FA-pathway-defective
Figure 5. CtIP Contributes to Genome Stability in FA-Pathway-Deficient Cells
(A) MRC5 cells stably expressing doxycycline (DOX)-inducible shRNA against CtIP (MRC5shCtIP) were transfected with indicated siRNAs. Then 24 hr after siRNA
transfection, cells were cultivated in the absence or presence of DOX (1 mg/ml) for 48 hr. Cells were treated with MMC (120 ng/ml) for 24 hr and subjected to
immunoblotting.
(B) Same cells as in (A) were treated for 24 hr with indicated doses of MMC, and survival was determined after 10 days by colony-formation assay. Data are
presented as the mean ± SD (n = 3).
(C) Same cells as in (A) were immunostained for RIF1. Graph shows the percentage of RIF1-foci-positive cells displaying more than ten RIF1 foci. For each
condition, at least 100 cells were scored. Data are presented as the mean ± SD (n = 3) (see also Figure S5B).
(D) Metaphase spreads from the same cells as in (A) treated for 20 hr with MMC (20 ng/ml) were analyzed for chromosomal aberrations. A total of 45 metaphase
spreads from three independent experiments were analyzed for each condition. The percentages of cells displaying radial chromosomes are shown (see also
Figure S5C).
(E) U2OS cells were pretreated for 15 min with DMSO, ATR inhibitor (VE-821, 1 mM), ATM inhibitor (KU-55933, 10 mM), or both inhibitors together. Cells were then
treated for 20 hr with MMC (120 ng/ml), and extracts were analyzed by immunoblotting.
(F) U2OS cells were transfected with MUS81 siRNA, and 48 hr after siRNA transfection, cells were pretreated for 15 min with DMSO or ATR inhibitor (VE-821,
1 mM). Cells were then treated as in (E) and harvested for immunoblot analysis.
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cells. Likewise, inactivation of FAN1 or SLX4 enhanced crosslink
sensitivity of cells compromised in FANCD2 activation, suggest-
ing that these proteins, though being recruited to ICLs by
FANCD2, can promote MMC resistance in a FA-pathway-inde-
pendent manner (Yamamoto et al., 2011; Zhou et al., 2012).
Furthermore, only partial epistasis of FANCD2 over CtIP could
be explained by an additional role of CtIP upstream of FANCD2
or by the proposed role of FANCD2 in protecting stalled forks
from degradation (Duquette et al., 2012; Schlacher et al.,
2012). There is increasing evidence that arrested and unpro-
tected replication forks frequently collapse and give rise to
DSBs, which can then undergo resection and repair by HR
(Couch et al., 2013). Accordingly, we observed enhanced
ATM-dependent phosphorylation of CtIP and RPA2 in cells co-
treated with MMC and ATR inhibitor, indicative of ongoing DSB
resection (Fugger et al., 2013). In line with this, CtIP phosphory-
lation was reduced upon depletion of MUS81, an endonuclease
implicated in the cleavage of stalled forks and DSB formation
(Ciccia et al., 2008). Furthermore, CtIP-dependent processing
of collapsed forks upon hydroxyurea treatment was recently re-
ported to be beneficial for genome integrity in the absence of
FANCM (Blackford et al., 2012). Therefore, we conclude that
CtIP can partially suppress genomic instability in the absence
of FANCD2, whereas, in FA-pathway-proficient cells, monoubi-
quitinated FANCD2 coordinates CtIP-mediated DNA-end resec-
tion during ICL repair.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfection
U2OS, HEK293T, and HEK293 cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal calf serum (FCS),
100 U/ml penicillin, and 100 mg/ml streptomycin. U2OS clones stably express-
ing siRNA-resistant forms of GFP-CtIP were described previously (Sartori
et al., 2007). FANCD2-deficient cells (PD20F) were obtained from Fanconi
Anemia Research Foundation (FARF) and cultured in DMEM supplemented
with 10% FCS and standard antibiotics. PD20F cells complemented with
FANCD2 wild-type (FARF) or K561R (kindly provided by Josef Jiricny) were
grown in standardmedium supplementedwith 1 mg/ml Puromycin.MRC5shCtIP
cells were grown in DMEM supplemented with 10% Tet system approved
FCS, 100 U/ml penicillin, 100 mg/ml streptomycin, Blasticidin (5 mg/ml), and
Zeocin (250 mg/ml). Plasmids were transfected either by using the standard
calcium phosphatemethod or FuGENE 6 (Roche) according to manufacturer’s
instructions. Transfection of all siRNA oligos was done with 40 nM final con-
centration using Lipofectamine RNAiMAX (Invitrogen). Data for survival curves
were generated by colony-formation assays as described previously (Sartori
et al., 2007).
Triton Extraction
Isolation of Triton-insoluble (chromatin-enriched) fractionwasperformedaspre-
viously described (Pen˜a-Diaz et al., 2012). In brief, cells were rinsed twice in cold
PBS and incubated for 5 min on ice in preextraction buffer (25 mM HEPES
[pH 7.4], 50 mMNaCl, 1 mMEDTA, 3 mMMgCl2, 300mM sucrose, 0.5% Triton
X-100, and protease inhibitors). After buffer removal, adherent cellular material
washarvestedbyscraping thecells intoLaemmlibuffer. Thechromatin-enriched
fraction was then heat denatured, sonicated, and analyzed by immunoblotting.
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Supplemental Experimental Procedures  
Plasmids. 
The pcDNA3.1-based expression vectors for FLAG-FANCD2, GFP-FANCD2 and 
GFP-FANCD2 K561R were kindly provided by Minoru Takata (Kyoto University, 
Japan). Expression constructs for epitope-tagged CtIP were described previously 
(Steger et al., 2013). The pGEX-4T1 plasmids for bacterial expression of CtIP 
fragments were described previously (Sartori et al., 2007). CtIP 45-298 fragment was 
generated by introducing two stop codons in pGEX-4T1 CtIP 45-371. The pcDNA5-
based GFP-SLX4 expression vector was a kind gift from Johan P. de Winter (VU 
University Medical Center, The Netherlands) (Stoepker et al., 2011). The pET23-
based 6xHis-ubiquitin vector for bacterial expression was kindly provided by 
Matthias Peter (ETH Zurich, Switzerland). All CtIP and ubiquitin mutations were 
introduced by site-directed mutagenesis using Expand Long Template PCR System 
(Roche) and confirmed by sequencing. To generate an entry vector harboring shCtIP 
(target sequence: CGTCAGCCTTACAACGCAA (You et al., 2009)), annealed 
double-stranded DNA oligos were ligated into pENTR/HI/TO (Invitrogen). The 
lentiviral destination construct encoding shCtIP (pLenti4-shCtIP) was generated in an 
in vitro recombination reaction after transformation of bacteria with pENTR-shCtIP 
and pLenti4/DEST (Invitrogen). 
 
siRNA sequences. 
All siRNA duplexes were purchased from Microsynth AG, the sequences were as 
follows: Luciferase (CNTL; CGUACGCGGAAUACUUCGA), CtIP (CtIP-1; 
GCUAAAACAGGAACGAAUC) and CtIP-2 (UCCACAACAUAAUCCUAAU) 
(Sartori et al., 2007), FANCD2 (CAGAGUUUGCUUCACUCUCUA) (Kratz et al., 
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2010), FANCA (CAGCGTTGAGATATCAAAGAT) (Kim et al., 2008), FAN1 
(GUAAGGCUCUUUCAACGUA) (Kratz et al., 2010), NBS1 
(GGAGGAAGAUGUCAAUGUUUU) (Yoo et al., 2009), SLX4 
(AAACGUGAAUGAAGCAGAAUU) (Svendsen et al., 2009), MUS81 
(CAGCCCUGGUGGAUCGAUA) (Neelsen et al., 2013), BRCA1 
(GGAACCUGUCUCCACAAAG) (Bruun et al., 2003). 
 
Lentivirus production. 
Lentiviruses encoding either the Tet-Repressor protein (TetR) or shCtIP were 
generated in human 293FT cell line as previously described (Tiscornia et al., 2006). 
Briefly, 293FT cells were transfected with a lentiviral vector (pLenti6/TR or pLenti4- 
shCtIP) in combination with ViraPowerTM Packaging Mix using LipofectamineTM 
2000 according to the manufacturers protocol (Invitrogen). Virus-containing 
supernatant was collected 72 h post-transfection and filtered through a sterile 0.45 µm 
low protein-binding filter (Millex-HV 0.45 µm PVDF, Millipore). The filtrated viral 
supernatant was aliquoted into 1.5 ml cryovials and stored at -80°C. 
 
Generation of a stable MRC5 cell line with inducible shCtIP expression. 
SV40-immortalized MRC5 cells were first transduced with viral supernatant 
harbouring pLenti6/TR and, 24 h later, infected with viral supernatant containing 
pLenti4/shCtIP. 48 h after the second transduction, cells were split at low confluency 
and grown in selection medium containing Blasticidin (5 µg/ml) and ZeocinTM (500 
µg/ml) for 11 days. Antibiotic-resistant colonies were isolated, expanded and 
individual clones screened for doxycycline (DOX) -inducible expression of shCtIP by 
immunoblotting. 
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Generation of the stable U2OS cell lines expressing GFP-CtIP-S327A, -
RRK/AAA or -RYIE/AAIA. 
U2OS cells (40% confluent) were transfected with the pEGFP-C1 plasmid containing 
siRNA-resistant CtIP cDNA, harbouring corresponding mutations in the coding 
sequence, using FuGENE 6 (Roche). 24 h after transfection, standard medium was 
replaced with selection medium containing Genetecin® (G418, GIBCO, 500 µg/ml). 
The medium was replaced every 2-3 days and antibiotic-resistant colonies were 
isolated and screened for GFP-CtIP expression by both immunofluorescence 
microscopy and western blotting. 
 
Immunofluorescence Microscopy 
U2OS or MRC5shCtIP cells grown on coverslips were either fixed directly in 
formaldehyde and permeabilized or pre-extracted for 5 min on ice before fixation in 
4% formaldehyde (w/v) in PBS for 12 min as described previously (Sartori et al., 
2007). After incubation with indicated primary and appropriate Alexa Fluor-488, -594 
and -647 conjugated secondary antibodies (1:1'000) (Life Technologies), coverslips 
were mounted with Vectrashield® (Vector Laboratories) containing DAPI and sealed. 
Images were acquired on a Leica DMRB fluorescence microscope. Laser micro-
irradiation was performed as described previously (Eid et al., 2010). 
 
Metaphase spread analysis. 
HEK293 cells were transfected with indicated siRNAs at a final concentration of 40 
nM using Lipofectamine RNAiMax transfection reagent (Invitrogen). 48 hours later 
cells were either mock-treated or treated with MMC (25 ng/ml) for 20 hours. Prior to 
harvesting, cells were treated with Colcemid (Gibco) at a final concentration of 0.1 
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µg/ml for 1 hour. Then, cells were collected in a 15 ml Falcon tube and centrifuged at 
200 g for 5 minutes. Cells were resuspended in 5 ml of a hypotonic KCl solution 
(0.075 M) and incubated for 10 minutes at 37°C. To fix the cells, 1 ml of fixing 
solution containing Methanol:Acetic acid (3:1) was added to the suspension, mixed 
and centrifuged at 200 g for 5 minutes. Then, cells were resuspended directly in fixing 
solution containing Methanol:Acetic acid (3:1), which was added dropwise, while 
gently vortexing, and spun down. This step was repeated twice. Finally, the cell pellet 
was resuspended in 0.5-1 ml Methanol:Acetic acid fixing solution depending on the 
density of the cell suspension. 20 µl (2 drops) of the cell suspension was dropped on a 
pre-wetted glass slide (45° tilted) from 30 cm distance. Slide was air-dried and DNA 
was stained with DAPI. Immunofluorescent images were acquired in the DAPI- 
channel using the Leica DMRB microscope with Leica DFC 360 FX camera and the 
Leica objective HCX PL AP0 100x. 
To prepare metaphase spreads from MRC5shCtIP cells, they were transfected with 
nontargeting or FANCD2 siRNA. 6 h after siRNA transfection, cells were cultivated 
in absence or presence of DOX (1 µg/ml) for 48 h. Cells were treated with MMC (20 
ng/ml) for 20 h and with Colcemid at a final concentration of 0.1 µg/ml in the last 3 
hours. Cells were harvested as described above. 
 
Antibodies. 
The primary antibodies used in this study are listed in a separate table below. 
Secondary HRP-conjugated anti-mouse and anti-rabbit antibodies were form GE- 
Healthcare and the HRP-conjugated anti-goat was from Santa Cruz Biotech. Alexa 
Fluor-488, -594, and -647-conjugated secondary antibodies were from Invitrogen. 
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Chemicals. 
Mitomycin C (MMC), 8-Methoxypsoralen (8-MOP) and MG132 were purchased 
from Sigma. ATM inhibitor (KU-55933) was purchased from Tocris Bioscience. 
ATR inhibitor (VE-821) was provided by Vertex Pharmaceuticals (Abingdon, UK). 
 
Immunoblotting, Immunoprecipitation, GST pulldown and Far-Western. 
If not specified otherwise, cell extracts were prepared in Laemmli buffer (4% SDS, 
20% glycerol, 120 mM Tris-HCl pH 6.8). Proteins were resolved by SDS–PAGE and 
transferred to nitrocellulose. Immunoblots were performed by using the appropriate 
antibodies and proteins visualized using the ECL detection system (Amersham). 
For GST pulldown assays and immunoprecipitation assays, cells were lysed in either 
NP-40 extraction buffer (50 mM Tris-HCl, pH 7.5, 120 mM NaCl, 1 mM EDTA, 15 
mM sodium pyrophosphate and 1 % NP-40 supplemented with phosphatase inhibitors 
(20 mM NaF, 1 mM sodium orthovanadate), protease inhibitors (1 mM benzamidine 
and 0.1 mM PMSF), deubiquitinase inhibitor (10 mM N-ethylmaleimide) and 10U 
Benzonase® (Roche)) or Triton X-100 buffer (50 mM Tris-HCl, pH 7.5, 200 mM 
NaCl, 1 mM EDTA, 0.2 % Triton X-100 supplemented with phosphatase, protease 
and deubiquitinase inhibitors) and clarified by centrifugation at 14000 rpm. GST pull-
downs and immunoprecipitations were performed as described previously (Sartori et 
al., 2007). Far-western blot analysis was performed as described (Wu et al., 2007). 
Anti-GFP immunoprecipitates from HEK293T cells transfected with GFP-CtIP-wt or 
GFP-CtIP-ΔN were subjected to far-western analysis using recombinant HA-
Ubiquitin (10 µg, Boston Biochem) as a probe followed by anti-HA immunoblotting.  
 
Purification of recombinant human CtIP. 
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Insect Sf9 cells infected with FLAG-GST-CtIP-6H recombinant baculovirus were 
harvested 50 h after infection. The cell pellet was resuspended in lysis buffer (50 mM 
Tris-HCl, pH 7.5, 0.5 M NaCl, 0.1% NP-40, 10 % glycerol, 10 mM imidazole) 
supplemented with protease inhibitors (Roche). Cells were disrupted by douncer 
homogenization and cell debris was removed by centrifugation at 45K for 45 min at 
4°C. Supernatant was filtered and loaded to Ni-NTA beads (Qiagen) overnight at 4°C. 
Beads were washed extensively with lysis buffer and lysis buffer supplemented with 
60 mM imidazole and then protein was eluted using lysis buffer supplemented with 
400 mM imidazole. Elution fractions were pooled, NaCl concentration was adjusted 
to 150 mM and loaded to heparin beads (GE Healthcare) for 90 min at 4°C. Heparin 
beads were washed with wash buffer (50 mM Tris-HCl, pH 7.5, 0.15 M NaCl, 0.1 % 
NP-40, 10 % glycerol) and proteins were eluted with elution buffer (50 mM Tris-HCl 
pH 7.5, 1 M NaCl, 0.1% NP-40, 10% glycerol). Elution fractions were pooled and 
dialyzed against dialysis buffer (50 mM Tris-HCl, pH 7.5, 0.15 M NaCl, 20% 
glycerol), aliquoted and stored at -80°C. 
 
In vitro protein interaction.  
To analyze in vitro protein interaction between CtIP and FANCD2, GFP-FANCD2 
wild-type or K561R mutant transiently expressed in HEK293T cells were 
immunoprecipitated with the anti-GFP antibody, coupled to Protein-A Sepharose 
beads (GE Healthcare) for 2 h at 4°C and immunocomplexes were stringently washed 
four times with NTEN buffer (0.5% NP- 40, 0.1 mM EDTA, 20 mM Tris-HCl, pH 
7.4, 1 M NaCl). 0.5 µg of recombinant human FLAG-GST-CtIP-6His purified from 
Sf9 insect cells were incubated either alone or with GFP-fusion FANCD2 
immunocomplexes bound to Protein-A Sepharose beads for 2 h at 4°C in 1 ml 
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TEN100 buffer (0.1 mM EDTA, 20 mM Tris-HCl, pH 7.4, 100 mM NaCl, 200 µg/ml 
BSA). Immunocomplexes were washed four times with NTEN350 buffer (0.5% NP-
40, 0.1 mM EDTA, 20 mM Tris-HCl, pH 7.4, 350 mM NaCl), boiled in SDS-sample 
buffer and analyzed by SDS-PAGE followed by immunoblotting. 
To analyze in vitro protein interaction between CtIP and ubiquitin, recombinant 
human FLAG-GST-CtIP-6His (0.2 µg) was incubated either alone or together with 
recombinant HA-Ubiquitin (5 µg, Boston Biochem) for 2 h at 4 C in the following 
buffer (20 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 25 nM 
NaF, 1% Triton-X-100, 10% glycerol, 10 µM ZnCl2, 200 µg/ml BSA supplemented 
with EDTA-free protease inhibitor cocktail). The samples were subjected to 
immunoprecipitation using anti-HA antibody. Immunocomplexes were washed four 
times with NTEN250 buffer (0.5% NP-40, 0.1 mM EDTA, 20 mM Tris-HCl, pH 7.4, 
250 mM NaCl), boiled in SDS-sample buffer and analyzed by immunoblotting. 
 
In vitro Ubiquitin-binding assay.  
pET23-6xHis-ubiquitin wt vector (His-Ub wt, kind gift from Matthias Peter), I44A 
mutant or empty vector were grown in BL21-CodonPlus(DE3)-RIL Escherichia coli 
(Invitrogen) and protein expression was induced upon addition of 1 mM IPTG for 4 h 
at 37 °C. Proteins were solubilized in the lysis buffer containing 50 mM Tris-HCl, pH 
7.5, 300 mM NaCl, 1 mM EDTA, 10 % glycerol, 1 % Triton X-100 and 20 mM 
imidazole supplemented with 1 mM DTT, 1 mM PMSF and EDTA-free protease 
inhibitor cocktail (Roche). His-Ub proteins were coupled to Ni-NTA Agarose 
(Qiagen), washed three times with lysis buffer supplemented with 500 mM NaCl and 
additional 20 mM imidazole, once with TEN100 buffer (20 mM Tris-HCl, pH 7.4, 0.1 
mM EDTA and 100 mM NaCl) and incubated in TEN100 buffer supplemented with 1 
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mg/ml BSA for 30 min at 4 °C. Next, His-Ub proteins bound to Ni-NTA Agarose 
were incubated either with 1 mg of HeLa nuclear extract or with 1 mg of HEK293T 
lysates transiently expressing GFP-CtIP or GFP-CtIP-ΔN for 2 h at 4 °C in 1 ml of 
cell lysis buffer (20 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 
25 nM NaF, 1% Triton-X-100, 10% glycerol, 10 µM ZnCl2, supplemented with 
phosphatase inhibitors (20 mM NaF) and EDTA-free protease inhibitor cocktail). 
Beads were then washed once with NTEN300 buffer (0.5% NP-40, 0.1 mM EDTA, 
20 mM Tris-HCl, pH 7.4, 300 mM NaCl), transferred to a new tube, washed another 
three times with NTEN300 and once with TEN100 buffer. Complexes were boiled in 
SDS sample buffer and analyzed by SDS–PAGE followed by immunoblotting. 
 
In Situ Proximity Ligation Assay. 
In situ proximity ligation assay (PLA) in combination with immunofluorescence 
confocal microscopy was performed using Duolink II Detection Kit with anti-Mouse 
PLUS and anti-Rabbit MINUS PLA Probes, according to the manufacturer’s 
instructions (Olink Bioscience) (Söderberg et al., 2006). 
 
CellTiter-Blue® Cell Viability assay. 
U2OS clones stably expressing siRNA-resistant forms of GFP-CtIP or MRC5shCtIP 
cells were transfected with indicated siRNA. 48 hours post-transfection cells were 
seeded in triplicates at a density of 500 cells/well in 96 well plate. 24 h later cells 
were continuously treated with indicated doses of MMC and grown for 5 days at 
37°C. To measure cell viability, CellTiter-Blue® reagent (Promega) was added on the 
last day, cells were incubated at 37°C for 4 h, and then fluorescence was measured at 
560/590 nm. 
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PUVA treatment. 
U2OS cells were incubated in PBS containing 10 µg/ml 8-MOP (Sigma) for 30 min. 
After incubation, cells were exposed to 10 kJ/m2 UV-A (365 nM, Vilber Lourmat 
Bio-Link BLX Crosslinker) in the presence of 8-MOP. Post-treatment PBS was 
removed and fresh media was added. At the indicated timepoints cells were harvested 
and proteins were analyzed by immunoblotting. 
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Supporting Table: Primary antibodies 
Antibody target Species Supplier/Reference Application* 
pATM S1981 rabbit 2152-1 (Epitomics) IB 
ATR (N-19) goat sc-1887 (Santa Cruz) IB 
BRCA1 (D-9) mouse sc-6954 (Santa Cruz) IB 
BrdU mouse RPN202 (GE Healthcare) IF 
CHK1 (G-4) mouse sc-8408 (Santa Cruz) IB 
pCHK1 S345 rabbit 2341(Cell Signaling) IB 
CtIP (14-1) mouse gift from Richard Baer IF  
CtIP rabbit A300-488A (Bethyl) IF (in situ PLA) 
CtIP (D-4) mouse sc-271339 (Santa Cruz) IB 
ERCC1 (FL-297) rabbit sc-10785 (Santa Cruz) IB 
FAN1 sheep gift from John Rouse  IB 
FANCA  rabbit A301-980A (Bethyl)  IB 
FANCD2 (FI17) mouse sc-20022 (Santa Cruz) IB and IF (in situ PLA) 
FANCD2 rabbit ab2187 (Abcam) IF 
FLAG mouse F3165 (Sigma) IB 
GFP rabbit ab290 (Abcam) IP  
GFP mouse sc-9996 (Santa Cruz) IB 
HA mouse sc-7392 (Santa Cruz) IB and IP 
γH2AX (20E3) rabbit 9718 (Cell Signaling) IB and IF 
KAP1 pS824  rabbit A300-767A (Bethyl) IB 
MRE11 (12D7) mouse GTX70212 (GeneTex) IB 
MUS81 mouse M1445 (Sigma) IB 
NBS1 (1D7) mouse GTX70224 (GeneTex) IB 
Pol η rabbit ab17725 (Abcam) IB 
RIF1 rabbit A300-569A (Bethyl) IF 
RPA2 (Ab-3) mouse NA19L (Calbiochem) IB and IF 
pRPA S4/S8 rabbit A300-245A (Bethyl) IB and IF 
SLX4 rabbit A302-270A (Bethyl) IB 
β-Tubulin (D-10) mouse sc-5274 (Santa Cruz) IB 
TFIIH p89 (S-19) rabbit  sc-293 (Santa Cruz) IB 
*IB: Immunoblot, IF: Immunofluorescence, IP: Immunoprecipitation 
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SUPPLEMENTARY FIGURE LEGENDS 
Figure S1 (related to Figure 1). CtIP localizes to ICL lesions in a FANCD2-dependent 
but NBS1- and SLX4-independent manner. 
(A) U2OS cells were transfected with non-targeting (CNTL), CtIP or FANCD2 siRNA. 48 h 
after transfection, cells were treated for 24 h with mitomycin C (MMC) and survival was 
determined after eight days by colony formation. Data are presented as the mean ± SD (N=3). 
(B) Representative images of metaphase spreads from cells described in (C) after treatment 
with MMC (25 ng/ml) for 20 h. Selected chromosomal aberrations are displayed in higher 
magnifications. (C) U2OS cells were transfected with indicated siRNAs. 48 h after 
transfection, cells were treated for 24 h with MMC (120 ng/ml) and total and chromatin-
bound proteins were analyzed by immunoblotting. (D) U2OS cells were transfected with 
different CtIP siRNAs. 48 h after transfection, cells were treated as in (C) and total proteins 
were analyzed by immunoblotting. Signal intensities of FANCD2 isoforms were quantified 
using Image J software and L/S indicates the ratio of monoubiquitinated (L) to non-
monoubiquitinated (S) FANCD2. (E) U2OS cells were grown in absence (-) or presence (+) 
of 10 µg/ml 8-MOP for 30 min prior to UVA exposure and harvested at the indicated time 
points after PUVA treatment. RPA2 and P-RPA2 represent non-modified and 
hyperphosphorylated forms of RPA2, respectively. (F,G) U2OS cells were transfected with 
the indicated siRNAs. 48 h after transfection, cells were either mock-treated (-) or treated with 
PUVA and released for 4 h. Total and chromatin-bound proteins were analyzed by 
immunoblotting using the indicated antibodies. (H) FANCD2-mutant human fibroblasts 
(PD20F) and PD20F cells stably expressing either wild-type FANCD2 (wt) or the K561R 
mutant were grown on coverslips, mock-treated or treated as in (C), pre-extracted, fixed and 
co-immunostained for CtIP and γH2AX. (I) U2OS cells grown on coverslips were pre-treated 
for 2 h with DMSO or MG-132 (20 µM) and then treated with MMC (500 ng/ml) for 4 h. 
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Cells were pre-extracted, fixed and co-immunostained for CtIP and γH2AX. (J,K) U2OS 
cells were transfected with indicated siRNAs. 48 h after transfection, cells were treated as in 
(C) and total and chromatin-bound proteins were analyzed by immunoblotting. The arrow 
indicates a non-specific band detected by the anti-SLX4 antibody. In (C, D, F, G, J and K), 
the asterisks indicate hyperphosphorylated CtIP. In (C, F, G and J), D2 and D2-Ub represent 
non-ubiquitinated and monoubiquitinated forms of FANCD2, respectively. In (C, F, G, J, and 
K), TFIIH and CHK1 were used as loading controls for chromatin-enriched and soluble 
proteins, respectively. In (H and I), graphs show the percentage of γH2AX-foci positive cells 
displaying more than 10 CtIP foci. For each condition at least 100 cells were scored. Data are 
presented as the mean ± SD (N=2). In (H and I) scale bar, 10 µm.  
 
Figure S2 (related to Figure 2). FANCD2 and CtIP promote resection during ICL 
repair. 
(A) U2OS cells were treated with MMC (120 ng/ml) for the indicated time points and whole 
cell lysates were analyzed by immunoblotting. (B) U2OS cells were transfected with the 
indicated siRNAs. 48 h after siRNA transfection, cells were either mock-treated (-) or treated 
with PUVA, released for 2 and 4 h and harvested for immunoblot analysis. (C-E) U2OS cells 
were transfected with indicated siRNAs. 48 h after siRNA transfection, cells grown on 
coverslips were treated for 24 h with MMC (120 ng/ml), pre-extracted, fixed and either co-
immunostained for RPA2 and RPA2-pS4/S8 (C), γH2AX and BrdU (D), or immunostained 
for RIF1 (E). Scale bar, 10 µm. (F) U2OS cells transfected with CtIP siRNA, were co-
transfected with siRNA-resistant GFP-tagged CtIP wild-type (wt), T847A or S327A mutant 
CtIP 24 h post-siRNA transfection. 48 h post-siRNA transfection, cells were analyzed by 
immunoblotting prior to MMC treatment. (G) HEK293T cells were transfected with the 
indicated pEGFP-C1 expression vectors. After 48 h, cells were lysed in NP-40 buffer and 
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whole cell extracts (4 mg) were analyzed by immunoblotting before (Input) and after 
immunoprecipitation (IP) using anti-GFP antibody. Ponceau staining is shown to indicate the 
amounts of immunoglobulins (IgG) used in the IPs. (H) U2OS cells stably expressing empty 
vector (e.v.) or siRNA-resistant GFP-tagged wild-type CtIP (wt), T847A, or S327A mutant 
CtIP were transfected with CtIP siRNA for 72 h and whole cell extracts were analyzed by 
western blotting. (I) Same cells as in (H) were either mock-treated or continuously treated 
with MMC and the survival was determined after 5 days using the CellTiter-Blue® Cell 
Viability assay. Data are presented as the mean ± SD (N≥3).  
 
Figure S3 (related to Figure 3). FANCD2-CtIP interaction requires FANCA but not 
SLX4 or FAN1. 
(A) HEK293T cells were co-transfected with GFP-FANCD2 together with either empty 
vector or FLAG-CtIP. 48 h after transfection, cells were lysed in NP40 buffer and whole cell 
extracts were analyzed by immunoblotting before (Input) and after immunoprecipitation (IP) 
using anti-FLAG M2 affinity resin. Ponceau staining is shown to indicate the amounts of 
immunoglobulins (IgG) used in the IPs. (B) Coomassie-stained gel of recombinant FLAG-
GST-CtIP-6His (0.5 µg) purified from Sf9 insect cells. (C) U2OS cells were transfected with 
indicated siRNAs. 48 h after siRNA transfection, cells were lysed and whole cell extracts 
were analyzed by immunoblotting. (D) Detection of endogenous CtIP-FANCD2 complexes 
by in situ PLA. Same cells as in (C) grown on coverslips were treated for 24 h with MMC 
(120 ng/ml) and pre-extracted prior to fixation. After incubation with antibodies against CtIP 
alone or against both CtIP and FANCD2, protein-protein interactions were detected using a 
fluorescently labeled probe (PLA-613). Scale bar, 20 µm. (E) Recombinant His-tagged 
ubiquitin (rHis-Ub) was immobilized on Ni-NTA agarose beads and incubated with whole 
cell extracts from HEK293T cells expressing GFP-SLX4 (left) or GFP-CtIP (right). Inputs 
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and precipitated bead fractions from the pull-downs were subjected to immunoblotting with 
anti-GFP antibody. Ponceau staining is shown to indicate the amounts of His-Ubiquitin used 
in the pull-down assays. (F) His alone (-) or recombinant wt and I44A mutant ubiquitin (rHis-
Ub) coupled to Ni-NTA agarose beads were incubated with HeLa nuclear extracts (NE). Input 
and precipitated bead fractions from the pull-downs were subjected to immunoblotting. 
Ponceau staining is shown to indicate the amounts of rHis-Ub used in the pull-down assay. 
 
Figure S4 (related to Figure 4). Identification and functional characterization of CtIP 
mutants impaired in FANCD2 interaction. 
(A) Multiple sequence alignment of the putative FANCD2-interacting region in CtIP 
orthologs (amino acids 160-298) was performed using Clustal W (www.ebi.ac.uk/Tools/msa). 
PDSP, RRK, RYxE and ILV motifs are highlighted in black boxes. Other, highly conserved 
amino acid residues are marked in bold typeface. R177Q and Y186C represent two cancer-
associated CtIP mutations recorded in the Catalogue of Somatic Mutations in Cancer 
(COSMIC) database (www.cancer.sanger.ac.uk). (B) U2OS cells were transfected with CtIP 
siRNA and after 24 h co-transfected with the indicated siRNA-resistant GFP-tagged CtIP 
constructs. 48 h post-siRNA transfection, cells grown on coverslips were treated for 24 h with 
MMC (120 ng/ml), fixed and immunostained for RIF1. Graphs show the percentage of GFP-
positive cells displaying more than 10 GFP-CtIP foci and the percentage of GFP-positive cells 
displaying more than 10 RIF1 foci, respectively. For each condition at least 100 cells were 
scored. Data are presented as the mean ± SEM (N=2). (C) Same cells as in (B) were analyzed 
by immunoblotting. (D) U2OS cells stably expressing siRNA-resistant GFP-CtIP-wt, GFP-
CtIP-RRK/AAA, or GFP-CtIP-RYIE/AAIA were transfected with CtIP siRNA and treated as 
in (D). 15 min after irradiation, cells were fixed, immunostained for γH2AX and analyzed by 
fluorescence microscopy. (E) U2OS cells stably expressing siRNA-resistant GFP-CtIP-wt 
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were transfected with indicated siRNAs. 24 h after siRNA transfection, cells grown on 
coverslips were sensitized with BrdU (10 µM) for 24 h prior to laser microirradiation. 30 min 
after irradiation, cells were fixed, co-immunostained for FANCD2 and γ-H2AX and analyzed 
by fluorescence microscopy. (F) Recombinant His-tagged ubiquitin (rHis-Ub) was 
immobilized on Ni-NTA agarose beads and incubated with whole cell extracts from 
HEK293T cells depleted of endogenous CtIP and expressing GFP-CtIP-wt or GFP-CtIP-ΔN 
(deleted of CtIP amino acids 153-322). Inputs and precipitated bead fractions from the pull-
downs were subjected to immunoblotting with anti-GFP antibody. Ponceau staining is shown 
to indicate the amounts of rHis-Ub used in the pull-down assays. (G) Anti-GFP 
immunoprecipitates from HEK293T cells transfected with GFP-CtIP-wt or GFP-CtIP-ΔN 
were subjected to far-western analysis using recombinant HA-Ubiquitin as a probe followed 
by anti-HA immunoblotting. Ponceau staining is shown to indicate the amounts of proteins 
transferred onto the nitrocellulose membrane. In (B, D and E) scale bar, 5 µm. 
 
Figure S5 (related to Figure 5). Analysis of CtIP/FANCD2 and CtIP/BRCA1 double-
deficient cells in response to MMC treatment. 
(A) FANCD2-deficient cells (PD20F) and PD20F stably expressing wild-type FANCD2 (D2) 
transfected with indicated siRNAs. 48 h post-siRNA transfection, cells were treated with the 
indicated doses of MMC for 24 h and survival was determined after eight days by colony 
formation. Data are presented as the mean ± SEM (N=3) (left). The same cells were analyzed 
by immunoblotting (right). (B) MRC5shCtIP cells were transfected with indicated siRNAs. 6 h 
post-siRNA transfection, cells were cultivated in the absence or presence of doxycycline 
(DOX, 1 µg/ml) for 48 h. Cells grown on coverslips were treated for 24 h with MMC (120 
ng/ml), pre-extracted, fixed and immunostained for RIF1. Scale bar, 10 µm. (C) 
Representative images of metaphase spreads from cells described in (B) after treatment with 
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MMC (20 ng/ml) for 20 h. Selected radial chromosomes are displayed in higher 
magnifications. (D) MRC5shCtIP cells were transfected with indicated siRNAs. 6 h post-siRNA 
transfection, cells were cultivated in the absence or presence of doxycycline (DOX, 1 µg/ml) 
for 48 h. Cells were continuously treated with the indicated doses of MMC and the survival 
was determined after 5 days using the CellTiter-Blue® Cell Viability assay. Data are 
presented as the mean ± SD (N=3) (left). The same cells were analyzed by immunoblotting 
(right). 
 
Figure S6. CtIP-mediated resection counteracts ICL-induced DNA damage in a 
FANCD2-dependent and -independent manner. 
Replication fork stalling at ICLs triggers activation of the ATR kinase resulting in 
monoubiquitination and stable association of the FANCD2-FANCI complex on chromatin. 
Monoubiquitinated FANCD2 recruits FAN1 and SLX4-associated nucleases to coordinate 
ICL incision giving rise to DSB intermediates. Translesion synthesis (TLS) polymerases 
bypass the unhooked crosslink and nucleotide excision repair (NER) removes the remaining 
adducts. Monoubiquitinated FANCD2 interacts with CtIP, thereby tethering it to damaged 
chromatin to ensure proper coordination of ICL processing and DNA-end resection. Once the 
DSB is formed, CtIP is phosphorylated by ATM kinase and promotes resection, thus initiating 
homologous recombination (HR), and, concomitantly antagonizing non-homologous end 
joining (NHEJ). In the absence of FANCD2, or in case of impaired activation of the FA-
pathway, persistent ICLs trigger the conversion of stalled replication forks into DSBs, a 
process that is at least partially dependent on the endonucleolytic activity of MUS81. Also in 
this case, CtIP-dependent resection commits cells to error-free repair of DSBs, thus 
preserving genome stability in response to ICL damage. 
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